Original Article
A Comparison of Multimodal Therapy and Surgery for Esophageal Adenocarcinoma
N Engl J Med 1996; 335:462-467August 15, 1996
- Abstract
Background
Uncontrolled studies suggest that a combination of chemotherapy and radiotherapy improves the survival of patients with esophageal adenocarcinoma. We conducted a prospective, randomized trial comparing surgery alone with combined chemotherapy, radiotherapy, and surgery.
Methods
Patients assigned to multimodal therapy received two courses of chemotherapy in weeks 1 and 6 (fluorouracil, 15 mg per kilogram of body weight daily for five days, and cisplatin, 75 mg per square meter of body-surface area on day 7) and a course of radiotherapy (40 Gy, administered in 15 fractions over a three-week period, beginning concurrently with the first course of chemotherapy), followed by surgery. The patients assigned to surgery had no preoperative therapy.
Results
Of the 58 patients assigned to multimodal therapy and the 55 assigned to surgery, 10 and 1, respectively, were withdrawn for protocol violations. At the time of surgery, 23 of 55 patients (42 percent) treated with preoperative multimodal therapy who could be evaluated had positive nodes or metastases, as compared with 45 of the 55 patients (82 percent) who underwent surgery alone (P<0.001). Thirteen of the 52 patients (25 percent) who underwent surgery after multimodal therapy had complete responses, as determined pathologically. The median survival of patients assigned to multimodal therapy was 16 months, as compared with 11 months for those assigned to surgery alone (P = 0.01). At one, two, and three years, 52, 37, and 32 percent, respectively, of patients assigned to multimodal therapy were alive, as compared with 44, 26, and 6 percent of those assigned to surgery, with the survival advantage favoring multimodal therapy reaching significance at three years (P = 0.01).
Conclusions
Multimodal treatment is superior to surgery alone for patients with resectable adenocarcinoma of the esophagus.
Media in This Article
Figure 1
Kaplan–Meier Plot of Survival of Patients with Esophageal Adenocarcinoma, According to the Intention-to-Treat Analysis.Figure 2
Kaplan–Meier Plot of Survival of Patients with Esophageal Adenocarcinoma, According to the Treatment Actually Received.Article Activity
- Article
During the past 20 years the rate of increase in the incidence of adenocarcinoma of the esophagus has outstripped that of all other tumors.1-4 This dramatic change has been accompanied by a shift in the biologic behavior of esophageal cancer toward poorer differentiation and greater nodal involvement.5 At the time of resection 85 to 95 percent of patients have lymph-node involvement, and after standard surgical resection fewer than 10 percent survive five years.5,6 The role of more radical surgery is controversial, and no randomized trials have been reported. Since most patients have systemic disease at presentation,7,8 systemic therapy may improve the outcome.
Single-drug or multidrug chemotherapy rarely induces a complete response, as determined pathologically, and does not enhance survival.9 When patients with potentially curable cancer were treated with radiotherapy alone, the two-year survival was only 10 percent.10 Neoadjuvant therapy given before surgery may reduce the incidence of micrometastases, increase resectability, control systemic disease, and allow accurate assessment of the completeness of the pathological response, all of which might influence decisions on postoperative treatment. A number of studies have compared the response of patients to neoadjuvant therapy with the outcome in historical control patients11-20 and have shown that esophageal adenocarcinoma responds to treatment based on fluorouracil and radiotherapy. We report a trial in which a combination of preoperative chemotherapy and radiotherapy was compared with surgery alone.
Methods
Patients
In May 1990, we undertook a randomized, controlled trial to compare the outcome of multimodal treatment, consisting of two courses of fluorouracil and cisplatin and 40 Gy of radiotherapy followed by surgery, with the outcome of surgery alone for esophageal adenocarcinoma. Patients who met any of the following criteria were excluded from the study: age greater than 76 years, distant metastases, carcinoma of the cervical esophagus requiring laryngectomy, leukocyte count of less than 3500 per cubic millimeter, platelet count of less than 100,000 per cubic millimeter, serum creatinine concentration above 1.4 mg per deciliter (124 μmol per liter), an Eastern Cooperative Oncology Group (ECOG) performance status of 3 or 4, previous chemotherapy or radiotherapy, previous malignant condition (apart from skin cancer), coexisting disease contraindicating surgery, and social circumstances not conducive to compliance with the full treatment protocol. The study was approved by the St. James's Hospital Ethics Committee, and informed consent was obtained from all patients.
Preoperative Tumor Staging
The extent of the tumor was evaluated in each patient by physical examination, chest radiography, abdominal ultrasonography, and upper gastrointestinal endoscopy. Bronchoscopy was performed when indicated by symptoms, the location of the tumor, or chest radiography. Computed tomography was performed in selected patients with equivocal findings on chest radiographs or liver ultrasonograms. Isotope bone scans were occasionally performed if indicated.
Patient Monitoring
Initially the patients were hospitalized for the duration of treatment, but later in the study they were routinely admitted only for chemotherapy. Many who could commute to the radiotherapy facility received radiotherapy as outpatients. Patients were interviewed and examined daily during chemotherapy. The following hematologic and biochemical studies were performed at least twice weekly: platelet and leukocyte counts and measurements of hemoglobin and serum electrolytes, creatinine, bilirubin, alkaline phosphatase, and γ-glutamyltransferase. Arterial-blood gas analysis and pulmonary-function tests were performed at the outset and repeated when indicated.
Chemotherapy
Chemotherapy consisted of two courses of fluorouracil and cisplatin. Fluorouracil (15 mg per kilogram of body weight per day) was infused over a period of 16 hours on days 1 through 5. After one day of hydration with 2 liters of 0.9 percent saline, cisplatin (75 mg per square meter of body-surface area) was infused over a period of eight hours on day 7. This cycle was repeated in week 6.
Radiotherapy
Radiotherapy was begun on the first day of the first course of chemotherapy and given for a total of 15 days (days 1 to 5, 8 to 12, and 15 to 19). All patients were treated with megavoltage-therapy units with either 4-MV photons (Cobalt model SEM100, Fairy Engineering, or Phillips model SL75-5) or 8-MV photons (Dynaray model 10, Radiation Dynamics). The treated area extended 5 cm beyond the longitudinal margins of the tumor, as defined by endoscopic and radiologic examination, and 2 to 3 cm beyond the radial margins. Initially, all patients were treated with parallel opposed fields (anteroposterior and posteroanterior). The technique was modified in 1994 to a three-field arrangement (anterior, right-posterior, and left-posterior oblique fields) to diminish the amount of radiation to the spinal cord. With the parallel opposed fields, a midline dose of 40 Gy in 15 fractions was prescribed (2.67 Gy per fraction). With the three-field technique, a dose of 40 Gy ±10 percent in 15 fractions was delivered to the entire treatment volume (2.67 Gy per fraction) with a computerized treatment-planning system (AECL/Theratronics Therplan). There was no correction for transmission of radiation to the lungs during either treatment technique.
Surgery
Surgery was carried out eight weeks after the beginning of treatment but was delayed if the leukocyte count was less than 2500 per cubic millimeter or the platelet count was less than 100,000 per cubic millimeter. Five operative approaches were used. Tumors of the cardia were resected through an approach involving the abdomen and the left side of the chest. In selected patients total gastrectomy and distal esophagectomy were performed through an abdominal approach. Tumors of the lower third of the esophagus were resected by the Lewis–Tanner operation, and tumors of the middle third by a three-stage operation in which the esophagus was mobilized in the right side of the chest and the anastomosis performed in the neck. In patients with poor respiratory reserve the transhiatal approach was used. Intestinal continuity was restored by placing the stomach in the posterior mediastinum. A single layer of interrupted linen sutures was used for the anastomosis. Patients were extubated in the operating room or the recovery room, returned to the intensive care unit for four days on average, and were usually discharged less than three weeks after surgery.
Treatment-Induced Toxicity
A toxic reaction was defined according to the criteria of the World Health Organization (WHO).21 With the introduction of ondansetron early in the study for the treatment of cisplatin-induced nausea, all patients were treated prophylactically before and during the cisplatin infusion. If the leukocyte count fell below 2500 per cubic millimeter or the platelet count fell below 100,000 per cubic millimeter, chemotherapy was withheld or radiotherapy or surgery was delayed until the count recovered. An interruption in the treatment regimen of more than two weeks was considered a major deviation from the protocol.
Pathological Stage
The tumor stage was defined according to the classification of the American Joint Committee on Cancer.22 The stage of the cancer was defined in each patient according to the location and extent of any residual disease after chemotherapy and radiotherapy. The absence of residual tumor in the resected specimen, including the lymph nodes, was defined as a complete pathological response (stage 0). The tumor was classified as stage 1 if there was residual tumor in the mucosa or submucosa and the lymph nodes were free of tumor. If residual deposits involved the muscularis propria or adventitia but the lymph nodes were free of tumor, the disease was classified as stage 2a. If there was no residual tumor in the esophagus but a tumor deposit was found in the nodes, it was classified as stage 2b. If tumor breached the esophageal wall and the lymph nodes also contained tumor, it was defined as stage 3. Stage 4 disease was defined as metastases extending beyond the regional nodes.
Statistical Analysis
Survival was measured from the date of randomization to the date of death or most recent follow-up visit. Estimates of median survival are based on the Kaplan–Meier method; group comparisons of survival involving individual variables were based on the log-rank test. For categorical data, group comparisons were based on the chi-square or Fisher's exact test. Freedman's method23 was used to estimate the sample size required to detect an improvement in two-year survival of 20 percentage points after chemotherapy and radiotherapy over a base-line survival rate of 23 percent for surgery alone — the survival rate for adenocarcinoma in the facility at the commencement of the study. With an alpha error of 5 percent and a power of 80 percent, the number of patients required in the study was estimated to be 190. Early indications of a clinically relevant difference between treatments suggested that an interim analysis should be undertaken. The trial was closed six years after it began because a statistically significant difference between the groups was found.
Results
Demographic Data
Between May 1990 and September 1995, 113 patients with adenocarcinoma of the esophagus were recruited. Fifty-eight patients were randomly assigned to receive chemotherapy and radiotherapy before surgery, and 55 were assigned to receive surgery alone. The characteristics of the patients in the two groups were similar before treatment (Table 1Table 1
Characteristics of the Two Treatment Groups at Base Line.). While the trial was in progress an additional 45 patients underwent resection but did not undergo randomization for the following reasons: 14 were older than 76 years, 6 had distant metastases, 3 had uncertain histologic findings, 2 had complete dysphagia, 2 had previously undergone complex esophageal surgery, 1 required laryngectomy, 1 had recurrent tumor, and 10 chose surgery or chemoradiotherapy; in 6 the reason for not undergoing randomization was not documented.The median length of follow-up for all patients was 10 months (range, 0.1 to 59). The median follow-up for patients who died was 7.5 months (range, 0.1 to 37), whereas for patients who were still alive as of the most recent follow-up visit it was 18 months (range, 1 to 59). The median follow-up was 10 months (range, 0.1 to 59) for patients assigned to multimodal therapy and 8 months (range, 0.1 to 38) for patients assigned to surgery.
Protocol Violations
The chemoradiotherapy protocol was violated in 10 instances, and the surgery protocol in 1. Table 2Table 2
Protocol Violations Leading to the Withdrawal of 11 Patients from the Study. lists the protocol violations.Treatment-Related Morbidity
Treatment-related toxicity was low, and the regimen was well tolerated. Six patients in the multimodal group (10 percent) had grade III toxic reactions, as defined by WHO criteria (three gastrointestinal, two hematologic, and one cardiac); two patients had grade IV toxic reactions (one cardiac and one gastrointestinal); and one patient had a fatal hemorrhage from the tumor bed during treatment.
Treatment was delayed in two patients because of leukopenia, which resolved within two weeks. Two patients whose ECOG performance status deteriorated did not undergo surgery and were included in the group with grade III gastrointestinal toxic reactions.
Postoperative Complications
Respiratory complications occurred in 28 patients in the multimodal group and 32 patients in the surgery group. Fourteen cardiac events occurred in the chemoradiotherapy group, as compared with 13 in the surgery group. There were two anastomotic leaks, one recurrent nerve palsy, and one chylothorax in each group; one patient in the multimodal group had severe postoperative pancreatitis, and one patient in the surgery group had a postoperative hemorrhage requiring a second operation.
Mortality during Hospitalization
Seven patients died in the hospital, for a 90-day in-hospital mortality rate of 6 percent. Of the five patients in the multimodal group who died during hospitalization, three had completed the protocol. One died of postoperative hemorrhage, one of chylothorax, and one of an anastomotic leak. Two patients did not complete the multimodal protocol. One died preoperatively of a hemorrhage from the tumor bed, and one with complete dysphagia who had surgery before completing chemoradiotherapy died postoperatively of sepsis.
Two patients assigned to surgery died of sepsis in the hospital. A chylothorax developed in one patient within three weeks after surgery, and an iatrogenic perforation occurred in the second after attempted dilatation of the tumor.
Response to Chemoradiotherapy
At the time of surgery, only 42 percent (23 of 55) of the patients in the multimodal group who could be evaluated had positive lymph nodes or metastases, as compared with 82 percent (45 of 55) of the patients in the surgery group (P<0.001) (Table 3Table 3
Pathological Stage of the Tumor at the End of Treatment Actually Received.). A complete pathological response occurred in 13 of the 52 patients in the multimodal group (25 percent) who underwent resection, including 1 patient who died and had no viable tumor at autopsy and 1 patient who only had high-grade dysplasia in the tumor bed. In two patients overt metastases developed during treatment.Survival
A comparison of the two treatment groups based on the intention-to-treat principle showed a survival advantage for the multimodal group (median survival, 16 months, as compared with 11 months in the group treated with surgery alone; P = 0.01) (Figure 1Figure 1
Kaplan–Meier Plot of Survival of Patients with Esophageal Adenocarcinoma, According to the Intention-to-Treat Analysis.). When the two groups were compared on the basis of the treatment actually received, the median survival was 32 months in the multimodal group and 11 months in the surgery group (P =0.001) (Figure 2Figure 2Kaplan–Meier Plot of Survival of Patients with Esophageal Adenocarcinoma, According to the Treatment Actually Received.). When survival at one, two, and three years was calculated on the basis of the intention to treat, 52, 37, and 32 percent of the patients assigned to multimodal therapy were alive, as compared with 44, 26, and 6 percent of those assigned to surgery alone; the difference reached statistical significance at three years (P =0.01). The survival rates at three years according to the treatment actually received were 37 percent (10 of 27 patients) in the multimodal group and 7 percent (2 of 30) in the surgery group (P =0.006) (Table 4Table 4
Survival Three Years after Treatment According to the Intention to Treat and According to the Treatment Actually Received.).Thirteen patients in the multimodal group had a complete pathological response. One died during treatment. A 72-year-old woman died five months after surgery; there was no autopsy, but her family physician attributed her death to tumor. The remaining 11 were alive and tumor-free 43, 36, 27, 21, 21, 16, 16, 5, 4, 4, and 2 months after resection.
Nineteen patients in the multimodal group had residual disease confined to the esophagus. As of this writing the median survival for this subgroup had not been reached: 11 were alive, none with overt disease, after a median follow-up of 37 months (range, 10 to 59). Eight had died, five of proven and one of suspected recurrence, after a median survival of 8 months (range, 3 to 32). Thirteen had stage 3 disease, four of whom were alive at 54, 43, 18, and 4 months, whereas nine had died after a median of 7 months (range, 2 to 11), all but one of recurrent disease.
Ten patients assigned to surgery had disease confined to the esophagus and had a median survival of 14 months (range, 0.3 to 38). Three of these patients were alive at 25, 29, and 38 months, whereas seven patients had died after a median of 11 months (range, 0.3 to 23). Thirty-eight patients had stage 3 disease; 9 of them were alive after a median follow-up of 5 months (range, 1 to 24), whereas 29 had died after a median of 10 months (range, 0.1 to 37).
Discussion
In this prospective, randomized trial we compared multimodal therapy with surgery alone for esophageal adenocarcinoma. We found that 25 percent of the patients assigned to multimodal therapy had a complete pathological response after resection and 32 percent were alive at three years, whereas only 6 percent of patients treated with surgery alone lived for three years. These results support the findings of nonrandomized studies that have shown a complete pathological response in approximately 20 percent of patients treated with multimodal therapy13,14,17-20 and a survival advantage over historical control patients who had surgery only.
Many trials of multimodal therapy have pooled adenocarcinomas and squamous-cell tumors on the assumption that the two have a similar response to treatment. This assumption is unwarranted, because patients with adenocarcinomas have a higher incidence of lymph-node involvement (85 to 95 percent, as compared with 50 to 60 percent for those with squamous-cell carcinomas) and appear to be less sensitive to chemoradiotherapy.13 In one randomized trial24 of 100 patients, the 75 with adenocarcinoma were randomly assigned to chemotherapy, radiotherapy, and transhiatal resection or to resection alone. There was no difference in the estimated two-year survival between the two groups. This result may reflect the administration of a lower dose of fluorouracil than we used and a difference in attrition rates between the groups, since the survival difference in our study did not become significant until the third year.
The relative contributions of chemotherapy, radiotherapy, and surgery to the survival advantage in the multimodal group are unclear. Herskovic et al. compared chemotherapy and radiotherapy with radiotherapy alone in 121 patients, all but 15 of whom had squamous-cell carcinoma.10 Thirty-eight percent of the patients in the multimodal group survived two years. Perhaps only patients with residual disease in the esophageal wall or local nodes benefit from resection. Unfortunately, current imaging methods cannot distinguish these patients from those with a complete pathological response.25 In our study the omission of surgery would have left 75 percent of the patients in the multimodal group with residual disease, which in 19 cases (33 percent) appeared to be confined to the esophagus. In these patients, the residual tumor would probably have progressed. A molecular marker that reliably predicts response would greatly facilitate the process of selecting suitable candidates for surgery. The expression of epidermal growth factor receptor and that of proliferating-cell nuclear antigen have shown potential as markers in patients with squamous-cell carcinoma,26 and the expression of c-erb B-2 may have a role in patients with adenocarcinoma.27
It is unclear whether the survival advantage in the multimodal group at three years will persist. Leichman et al. reported on a trial using cisplatin, fluorouracil, and 30 Gy of concurrently administered radiotherapy.28 Fifteen of 21 treated patients with squamous-cell carcinoma subsequently underwent resection, of whom 5 had complete pathological responses. All those with responses subsequently died of distant metastases at 30 to 60 months.
The chemoradiotherapy regimen was well tolerated, and there were few toxic reactions. Ten patients were withdrawn from multimodal therapy because of protocol violations. Two of these patients had a deterioration in ECOG performance status that was attributed to severe cisplatin-induced nausea, but the introduction of ondansetron virtually eliminated such nausea. One patient in whom complete dysphagia developed was withdrawn from the trial, but the current approach to such patients includes insertion of a stent and continuation of treatment. There were only two instances, both due to leukopenia, in which treatment or surgery had to be postponed because of side effects. The administration of colony-stimulating factor should help minimize the delay in such cases. The side effects of the preoperative treatment were severe in six patients (10 percent), life-threatening in two patients (3 percent), and fatal in one patient (2 percent); these results compare favorably with those in other recent reports.11-20
In conclusion, multimodal therapy followed by surgery provides a significant survival advantage over surgery alone at three years for patients with adenocarcinoma of the esophagus. Although 17 percent of the patients in the multimodal group were withdrawn because of protocol violations, direct treatment-related toxic effects were minimal. The evidence suggests that multimodal therapy should be considered in all patients with tumor confined to the esophagus and draining lymph nodes.
Source Information
From the Departments of Surgery (T.N.W., T.P.J.H.) and Gastroenterology (N.N., N.K.), St. James's Hospital; the Department of Radiotherapy, St. Luke's Hospital (D.H.); and the Departments of Community Health and Statistics, Trinity College (A.K.) — all in Dublin, Ireland.
Address reprint requests to Dr. Walsh at the Department of Surgery, Beaumont Hospital, Dublin 9, Ireland.
- References
References
1
Hesketh PJ ,Clapp RW ,Doos WG ,Spechler SJ . The increasing frequency of adenocarcinoma of the esophagus. Cancer 1989;64:526-530
CrossRef | Web of Science | Medline2
Husemann B . Cardia carcinoma considered as a distinct clinical entity. Br J Surg 1989;76:136-139
CrossRef | Web of Science | Medline3
Powell J ,McConkey CC . The rising trend in oesophageal adenocarcinoma and gastric cardia. Eur J Cancer Prev 1992;1:265-269
CrossRef | Medline4
Blot WJ ,Devesa SS ,Kneller RW ,Fraumeni JF Jr . Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991;265:1287-1289
CrossRef | Web of Science | Medline5
Lund O ,Hasenkam JM ,Aagaard MT ,Kimose HH . Time-related changes in characteristics of prognostic significance in carcinomas of the oesophagus and cardia. Br J Surg 1989;76:1301-1307
CrossRef | Web of Science | Medline6
Papachristou DN ,Fortner JG . Adenocarcinoma of the gastric cardia: the choice of gastrectomy. Ann Surg 1980;192:58-64
CrossRef | Web of Science | Medline7
Bosch A ,Frias Z ,Caldwell W ,Jaeschke WH . Autopsy findings in carcinoma of the esophagus. Acta Radiol Oncol Radiat Phys Biol 1979;18:103-112
Medline8
Anderson LL ,Lad TE . Autopsy findings in squamous-cell carcinoma of the esophagus. Cancer 1982;50:1587-1590
CrossRef | Web of Science | Medline9
Whittington R ,Coia LR ,Haller DG ,Rubenstein JH ,Rosato EF . Adenocarcinoma of the esophagus and esophago-gastric junction: the effects of single and combined modalities on the survival and patterns of failure following treatment. Int J Radiat Oncol Biol Phys 1990;19:593-603
CrossRef | Web of Science | Medline10
Herskovic A ,Martz K ,Al-Sarraf M , et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992;326:1593-1598
Full Text | Web of Science | Medline11
Adelstein DJ ,Rice TW ,Boyce GA , et al. Adenocarcinoma of the esophagus and gastroesophageal junction: clinical and pathologic assessment of response to induction chemotherapy. Am J Clin Oncol 1994;17:14-18
CrossRef | Web of Science | Medline12
Ajani JA ,Roth JA ,Ryan B , et al. Evaluation of pre- and postoperative chemotherapy for resectable adenocarcinoma of the esophagus or gastroesophageal junction. J Clin Oncol 1990;8:1231-1238
Web of Science | Medline13
Wolfe WG ,Vaughn AL ,Seigler HF ,Hathorn JW ,Leopold KA ,Duhaylongsod FG . Survival of patients with carcinoma of the esophagus treated with combined-modality therapy. J Thorac Cardiovasc Surg 1993;105:749-755
Web of Science | Medline14
Stewart JR ,Hoff SJ ,Johnson DH , et al. Improved survival with neoadjuvant therapy and resection for adenocarcinoma of the esophagus. Ann Surg 1993;218:571-576
CrossRef | Web of Science | Medline15
Hoff SJ ,Stewart JR ,Sawyers JL , et al. Preliminary results with neoadjuvant therapy and resection for esophageal carcinoma. Ann Thorac Surg 1993;56:282-286
CrossRef | Web of Science | Medline16
Gill PG ,Jamieson GG ,Denham J , et al. Treatment of adenocarcinoma of the cardia with synchronous chemotherapy and radiotherapy. Br J Surg 1990;77:1020-1023
CrossRef | Web of Science | Medline17
Coia LR ,Paul AR ,Engstrom PF . Combined radiation and chemotherapy as primary management of adenocarcinoma of the esophagus and gastroesophageal junction. Cancer 1988;61:643-649
CrossRef | Web of Science | Medline18
Ajani JA ,Roth JA ,Ryan MB , et al. Intensive preoperative chemotherapy with colony-stimulating factor for resectable adenocarcinoma of the esophagus or gastroesophageal junction. J Clin Oncol 1993;11:22-28
Web of Science | Medline19
Urba SG ,Orringer MB ,Perez-Tamayo C ,Bromberg J ,Forastiere A . Concurrent preoperative chemotherapy and radiation therapy in localized esophageal adenocarcinoma. Cancer 1992;69:285-291
CrossRef | Web of Science | Medline20
Carey RW ,Hilgenberg AD ,Choi NC , et al. A pilot study of neoadjuvant chemotherapy with 5-fluorouracil and cisplatin with surgical resection and postoperative radiation therapy and/or chemotherapy in adenocarcinoma of the esophagus. Cancer 1991;68:489-492
CrossRef | Web of Science | Medline21
Miller AB ,Hoogstraten B ,Staquet M ,Winkler A . Reporting results of cancer treatment. Cancer 1981;47:207-214
CrossRef | Web of Science | Medline22
Esophagus. In: Beahrs OH, Henson DE, Hutter RVP, Myers MH, eds. Manual for staging of cancer. 3rd ed. Philadelphia: J.B. Lippincott, 1988:63-7.
23
Freedman LS . Tables of the number of patients required in clinical trials using the logrank test. Stat Med 1982;1:121-129
CrossRef | Medline24
Urba SG ,Orringer MB ,Turrist A , et al. A randomized trial comparing transhiatal esophagectomy (THE) to preoperative concurrent chemoradiation [CT/XRT] followed by esophagectomy in locoregional esophageal carcinoma [CA]. Proc Am Soc Clin Oncol 1995;14:199-199 abstract.25
Esophageal carcinoma. In: Rösch T, Classen M. Gastroenterologic endosonography. Stuttgart, Germany: Georg Thieme Verlag, 1992:45-62.
26
Hickey K ,Grehan D ,Reid IM ,O'Briain S ,Walsh TN ,Hennessy TPJ . Expression of epidermal growth factor receptor and proliferating cell nuclear antigen predicts response of esophageal squamous cell carcinoma to chemoradiotherapy. Cancer 1994;74:1693-1698
CrossRef | Web of Science | Medline27
Duhaylongsod FG ,Gottfried MR ,Iglehart JD ,Vaughn AL ,Wolfe WG . The significance of c-erb B-2 and p53 immunoreactivity inpatients with adenocarcinoma of the esophagus. Ann Surg 1995;221:677-683
CrossRef | Web of Science | Medline28
Leichman L ,Steiger Z ,Seydel HG , et al. Preoperative chemotherapy and radiation therapy for patients with cancer of the esophagus: a potentially curative approach. J Clin Oncol 1984;2:75-79
Web of Science | Medline
- Citing Articles (619)
Citing Articles
1
Gaurav Kumar, Sheh Rawat, Abhishek Puri, Manoj Kumar Sharma, Pranav Chadha, Anand Giri Babu, Girigesh Yadav. (2011) Analysis of dose–volume parameters predicting radiation pneumonitis in patients with esophageal cancer treated with 3D-conformal radiation therapy or IMRT. Japanese Journal of Radiology
CrossRef2
M. van Heijl, S.S.K.S. Phoa, M.I. van Berge Henegouwen, J.M.T. Omloo, B.M. Mearadji, G.W. Sloof, P.M.M. Bossuyt, M.C.C.M. Hulshof, D.J. Richel, J.J.G.H.M. Bergman, F.J.W. ten Kate, J. Stoker, J.J.B. van Lanschot. (2011) Accuracy and reproducibility of 3D-CT measurements for early response assessment of chemoradiotherapy in patients with oesophageal cancer. European Journal of Surgical Oncology (EJSO) 37:12, 1064-1071
CrossRef3
M. Hingorani, T. Crosby, A. Maraveyas, S. Dixit, A. Bateman, R. Roy. (2011) Neoadjuvant Chemoradiotherapy for Resectable Oesophageal and Gastro-oesophageal Junction Cancer—Do We Need Another Randomised Trial?. Clinical Oncology 23:10, 696-705
CrossRef4
Sarahgene Gillianne DeFoe, Arjun Pennathur, John C. Flickinger, Dwight E. Heron, Michael K. Gibson, James D. Luketich, Joel S. Greenberger. (2011) Retrospective Review of Patients With Locally Advanced Esophageal Cancer Treated at the University of Pittsburgh. American Journal of Clinical Oncology 34:6, 587-592
CrossRef5
Elfriede Bollschweiler, Arnulf H. Hölscher, Ralf Metzger, Sarah Besch, Stefan P. Mönig, Stephan E. Baldus, Uta Drebber. (2011) Prognostic Significance of a New Grading System of Lymph Node Morphology After Neoadjuvant Radiochemotherapy for Esophageal Cancer. The Annals of Thoracic Surgery 92:6, 2020-2027
CrossRef6
Hiroshi Miyata, Masahiko Yano, Takushi Yasuda, Rie Hamano, Makoto Yamasaki, Eihou Hou, Masaaki Motoori, Osamu Shiraishi, Koji Tanaka, Masaki Mori, Yuichiro Doki. (2011) Randomized study of clinical effect of enteral nutrition support during neoadjuvant chemotherapy on chemotherapy-related toxicity in patients with esophageal cancer. Clinical Nutrition
CrossRef7
John A. Harvin, Guy Lahat, Arlene M. Correa, Jared Lee, Dipen Maru, Jaffer Ajani, Edith M. Marom, James Welsh, Manoop S. Bhutani, Garret Walsh, Jack Roth, Reza Mehran, Ara Vaporciyan, David Rice, Stephen Swisher, Wayne Hofstetter. (2011) Neoadjuvant chemoradiotherapy followed by surgery for esophageal adenocarcinoma: Significance of microscopically positive circumferential radial margins. The Journal of Thoracic and Cardiovascular Surgery
CrossRef8
George W. Dittrick, Jill M Weber, Ravi Shridhar, Sarah Hoffe, Marcovalerio Melis, Khaldoun Almhanna, James Barthel, James McLoughlin, Richard C. Karl, Kenneth L. Meredith. (2011) Pathologic Nonresponders after Neoadjuvant Chemoradiation for Esophageal Cancer Demonstrate no Survival Benefit Compared with Patients Treated with Primary Esophagectomy. Annals of Surgical Oncology
CrossRef9
Stephen G. Maher, Dermot T. McDowell, Ben C. Collins, Cian Muldoon, William M. Gallagher, John V. Reynolds. (2011) Serum Proteomic Profiling Reveals That Pretreatment Complement Protein Levels are Predictive of Esophageal Cancer Patient Response to Neoadjuvant Chemoradiation. Annals of Surgery 254:5, 809-817
CrossRef10
Jae Won Park, Jong Hoon Kim, Eun Kyung Choi, Sang-wook Lee, Sang Min Yoon, Si Yeol Song, Yu Sun Lee, Sung Bae Kim, Seung il Park, Seung Do Ahn. (2011) Prognosis of Esophageal Cancer Patients With Pathologic Complete Response After Preoperative Concurrent Chemoradiotherapy. International Journal of Radiation Oncology*Biology*Physics 81:3, 691-697
CrossRef11
Kfir Ben-David, George Rossidis, Robert A. Zlotecki, Stephen R. Grobmyer, Juan C. Cendan, George A. Sarosi, Steven N. Hochwald. (2011) Minimally Invasive Esophagectomy is Safe and Effective Following Neoadjuvant Chemoradiation Therapy. Annals of Surgical Oncology 18:12, 3324-3329
CrossRef12
Ahmed Ba-Ssalamah, Wolfgang Matzek, Susanne Baroud, Nina Bastati, Johannes Zacherl, Sebastian F. Schoppmann, Michael Hejna, Fritz Wrba, Michael Weber, Christian J. Herold, Richard M. Gore. (2011) Accuracy of hydro-multidetector row CT in the local T staging of oesophageal cancer compared to postoperative histopathological results. European Radiology 21:11, 2326-2335
CrossRef13
Hiroshi Miyata, Makoto Yamasaki, Yukinori Kurokawa, Shuji Takiguchi, Kiyokazu Nakajima, Yoshiyuki Fujiwara, Koji Konishi, Masaki Mori, Yuichiro Doki. (2011) Survival Factors in Patients with Recurrence After Curative Resection of Esophageal Squamous Cell Carcinomas. Annals of Surgical Oncology 18:12, 3353-3361
CrossRef14
Chaitan K. Narsule, Marissa M. Montgomery, Hiran C. Fernando. (2011) Evidence-Based Review of the Management of Cancers of the Gastroesophageal Junction. Thoracic Surgery Clinics
CrossRef15
A. Herskovic, W. Russell, M. Liptay, M. J. Fidler, M. Al-Sarraf. (2011) Esophageal carcinoma advances in treatment results for locally advanced disease: review. Annals of Oncology
CrossRef16
Zachary Torgersen, Abhishek Sundaram, Masato Hoshino, Brittany Willer, Xiang Fang, Tsewang Tashi, Tommy Lee, Sumeet K. Mittal. (2011) Prognostic Implications of Lymphadenectomy in Esophageal Cancer After Neo-adjuvant Therapy: a Single Center Experience. Journal of Gastrointestinal Surgery 15:10, 1769-1776
CrossRef17
Vikram K. Jain, David Cunningham, Ian Chau. (2011) Preoperative and Postoperative Chemotherapy for Gastric Cancer. Surgical Oncology Clinics of North America
CrossRef18
Jae Y. Kim, Arlene M. Correa, Ara A. Vaporciyan, Jack A. Roth, Reza J. Mehran, Garrett L. Walsh, David C. Rice, Jaffer A. Ajani, Dipen M. Maru, Manoop S. Bhutani, James Welsh, Edith M. Marom, Stephen G. Swisher, Wayne L. Hofstetter. (2011) Does the Timing of Esophagectomy After Chemoradiation Affect Outcome?. The Annals of Thoracic Surgery
CrossRef19
Jan Brabender, Ralf Metzger, Daniel Vallböhmer, Frederike Ling, Susanne Neiss, Elfriede Bollschweiler, Paul M. Schneider, Arnulf H. Hölscher, Peter P. Grimminger. (2011) Roles of thymidylate synthase and dihydropyrimidine dehydrogenase expression in blood as predictors of response to multimodal therapy in esophageal cancer. Surgery
CrossRef20
William S. Twaddell, Peter C. Wu, Roy J.J. Verhage, Marcus Feith, David H. Ilson, Christoph P. Schuhmacher, James D. Luketich, Björn Brücher, Daniel Vallböhmer, Wayne L. Hofstetter, Mark Jonathan Krasna, Daniela Kandioler, Paul M. Schneider, Bas P.L. Wijnhoven, Stephen J. Sontag. (2011) Barrett's esophagus: treatments of adenocarcinomas II. Annals of the New York Academy of Sciences 1232:1, 265-291
CrossRef21
B. Kayani, E. Zacharakis, K. Ahmed, G.B. Hanna. (2011) Lymph node metastases and prognosis in oesophageal carcinoma – A systematic review. European Journal of Surgical Oncology (EJSO) 37:9, 747-753
CrossRef22
Ryohei Kawabata, Hiroshi Imamura, Tomono Kishimoto, Shinji Kitamura, Yoshimi Hachino, Yukako Yasui, Misako Fujino, Chika Fujii, Hiroshi Furukawa. (2011) Second-line combination chemotherapy with docetaxel and nedaplatin for metastatic or recurrent squamous cell carcinoma of the esophagus refractory to chemotherapy with 5-fluorouracil plus cisplatin. Esophagus 8:3, 179-185
CrossRef23
Robert E. Merritt, Richard I. Whyte, Nicole T. D'Arcy, Chuong D. Hoang, Joseph B. Shrager. (2011) Morbidity and Mortality After Esophagectomy Following Neoadjuvant Chemoradiation. The Annals of Thoracic Surgery
CrossRef24
Adil Sadiq, Kamal A. Mansour. (2011) Esophageal Cancer: Recent advances. Thoracic Cancer 2:3, 75-83
CrossRef25
M. Orditura, G. Galizia, F. Morgillo, E. Martinelli, E. Lieto, F. Vitiello, N. Di Martino, R. Pacelli, A. Renda, F. Ciardiello, F. De Vita. (2011) Complete response to preoperative chemoradiation and survival in esophageal cancer: a pooled analysis of three single-institution phase II trials. Diseases of the Esophagusno-no
CrossRef26
Shannon E. Fogh, Anthony Yu, Gregory J. Kubicek, Walter Scott, Edith Mitchell, Ernest L. Rosato, Adam C. Berger. (2011) Do Elderly Patients Experience Increased Perioperative or Postoperative Morbidity or Mortality When Given Neoadjuvant Chemoradiation Before Esophagectomy?. International Journal of Radiation Oncology*Biology*Physics 80:5, 1372-1376
CrossRef27
Ewout F. W. Courrech Staal, Berthe M. P. Aleman, Marie-Louise F. van Velthuysen, Annemieke Cats, Henk Boot, Edwin P. M. Jansen, Frits van Coevorden, Johanna W. van Sandick. (2011) Chemoradiation for Esophageal Cancer. American Journal of Clinical Oncology 34:4, 343-349
CrossRef28
Chunhui Han, Daniel C. Schiffner, Timothy E. Schultheiss, Yi-Jen Chen, An Liu, Jeffrey Y.C. Wong. (2011) Residual setup errors and dose variations with less-than-daily image guided patient setup in external beam radiotherapy for esophageal cancer. Radiotherapy and Oncology
CrossRef29
Ryan P. Merkow, Karl Y. Bilimoria, Martin D. McCarter, Warren B. Chow, Clifford Y. Ko, David J. Bentrem. (2011) Use of Multimodality Neoadjuvant Therapy for Esophageal Cancer in the United States: Assessment of 987 Hospitals. Annals of Surgical Oncology
CrossRef30
Ryu Ishihara, Sachiko Yamamoto, Hiroyasu Iishi, Kengo Nagai, Fumi Matui, Natsuko Kawada, Takashi Ohta, Hiromitsu Kanzaki, Masao Hanafusa, Noboru Hanaoka, Yoji Takeuchi, Koji Higashino, Noriya Uedo, Naotoshi Sugimoto, Yoshifumi Kawaguchi, Kinji Nishiyama, Masaaki Motoori, Masahiko Yano, Takuya Hosoki. (2011) Predicting the effects of chemoradiotherapy for squamous cell carcinoma of the esophagus by induction chemotherapy response assessed by positron emission tomography: toward PET-response-guided selection of chemoradiotherapy or esophagectomy. International Journal of Clinical Oncology
CrossRef31
Hiroshi Miyata, Makoto Yamasaki, Yukinori Kurokawa, Shuji Takiguchi, Kiyokazu Nakajima, Yoshiyuki Fujiwara, Masaki Mori, Yuichiro Doki. (2011) Multimodal treatment for resectable esophageal cancer. General Thoracic and Cardiovascular Surgery 59:7, 461-466
CrossRef32
Juan A. Díaz-González, Javier Rodríguez, José L. Hernández-Lizoain, Raquel Ciérvide, Miren Gaztañaga, Iñigo San Miguel, Leire Arbea, J. Javier Aristu, Ana Chopitea, Fernando Martínez-Regueira, Víctor Valentí, Jesús García-Foncillas, Rafael Martínez-Monge, Jesús J. Sola. (2011) Patterns of Response After Preoperative Treatment in Gastric Cancer. International Journal of Radiation Oncology*Biology*Physics 80:3, 698-704
CrossRef33
Jang-Ming Lee, Shi-Yi Yang, Pei-Wen Yang, Chia-Tung Shun, Ming-Tsang Wu, Chih-Hung Hsu, Chia-Chi Lin, Jason Chia-Hsien Cheng, Ying-Hao Wang, Tzu-Hsuen Chuang, Jin-Shing Chen, Hsao-Hsun Hsu, Pei-Ming Huang, Shuenn-Wen Kuo, Yung-Chie Lee. (2011) Polymorphism in Epidermal Growth Factor Receptor Intron 1 Predicts Prognosis of Patients with Esophageal Cancer after Chemoradiation and Surgery. Annals of Surgical Oncology 18:7, 2066-2073
CrossRef34
Katrin M Sjoquist, Bryan H Burmeister, B Mark Smithers, John R Zalcberg, R John Simes, Andrew Barbour, Val Gebski. (2011) Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. The Lancet Oncology 12:7, 681-692
CrossRef35
A. Thukral, J. Metz, W.-T. Hwang, P. O'Dwyer, J. Plastaras, S. Both, V. Bar Ad. (2011) Toxicity data for preoperative concurrent chemoradiotherapy with oxaliplatin and continuous infusion 5-fluorouracil for locally advanced esophageal cancer. Diseases of the Esophagus 24:5, 330-336
CrossRef36
M. Pera, R. Gallego, C. Montagut, M. Martin-Richard, M. Iglesias, C. Conill, A. Reig, C. Balague, L. Petriz, D. Momblan, J. Bellmunt, J. Maurel. (2011) Phase II trial of preoperative chemoradiotherapy with oxaliplatin, cisplatin, and 5-FU in locally advanced esophageal and gastric cancer. Annals of Oncology
CrossRef37
Sachiko Yamamoto, Ryu Ishihara, Masaaki Motoori, Yoshifumi Kawaguchi, Noriya Uedo, Yoji Takeuchi, Koji Higashino, Masahiko Yano, Satoaki Nakamura, Hiroyasu Iishi. (2011) Comparison Between Definitive Chemoradiotherapy and Esophagectomy in Patients With Clinical Stage I Esophageal Squamous Cell Carcinoma. The American Journal of Gastroenterology 106:6, 1048-1054
CrossRef38
D. Tougeron, J.-P. Richer, C. Silvain. (2011) Management of esophageal adenocarcinoma. Journal of Visceral Surgery 148:3, e161-e170
CrossRef39
D. Tougeron, J.-P. Richer, C. Silvain. (2011) Traitement des adénocarcinomes de l’œsophage. Journal de Chirurgie Viscérale 148:3, 184-195
CrossRef40
Matthew Koshy, Bruce D. Greenwald, Petr Hausner, Mark J. Krasna, Naomi Horiba, Richard J. Battafarano, Whitney Burrows, Mohan Suntharalingam. (2011) Outcomes After Trimodality Therapy for Esophageal Cancer. American Journal of Clinical Oncology 34:3, 259-264
CrossRef41
James Welsh, Arya Amini, Anna Likhacheva, Jeremy Erasmus J., Daniel Gomez, Marta Davila, Reza J. Mehran, Ritsuko Komaki, Zhongxing Liao, Wayne L. Hofstetter, Jeffrey Lee H., Manoop S. Bhutani, Jaffer A. Ajani. (2011) Update: Modern Approaches to the Treatment of Localized Esophageal Cancer. Current Oncology Reports 13:3, 157-167
CrossRef42
Tsutomu Nakamura, Masaho Ota, Takeshi Ohki, Takuya Sato, Yuji Shirai, Masakazu Yamamoto, Norio Mitsuhashi. (2011) Induction chemoradiotherapy followed by esophagectomy for advanced squamous cell carcinoma of the esophagus. Esophagus 8:2, 89-95
CrossRef43
David Grosshans, Nicholas S. Boehling, Matthew Palmer, Chris Spicer, Rolly Erice, James D. Cox, Ritsuko Komaki, Joe Y. Chang. (2011) Improving cardiac dosimetry: Alternative beam arrangements for intensity modulated radiation therapy planning in patients with carcinoma of the distal esophagus. Practical Radiation Oncology
CrossRef44
Tetsuhiro Owaki, Masataka Matsumoto, Hiroshi Okumura, Yasuto Uchicado, Yoshiaki Kita, Tetsuro Setoyama, Ken Sasaki, Toshihide Sakurai, Itaru Omoto, Mario Shimada, Fuminori Sakamoto, Heiji Yoshinaka, Sumiya Ishigami, Shinichi Ueno, Shoji Natsugoe. (2011) Endoscopic ultrasonography is useful for monitoring the tumor response of neoadjuvant chemoradiation therapy in esophageal squamous cell carcinoma. The American Journal of Surgery
CrossRef45
Pei-Chun Chen, Yen-Ching Chen, Liang-Chuan Lai, Mong-Hsun Tsai, Shin-Kuang Chen, Pei-Wen Yang, Yung-Chie Lee, Chuhsing K. Hsiao, Jang-Ming Lee, Eric Y. Chuang. (2011) Use of Germline Polymorphisms in Predicting Concurrent Chemoradiotherapy Response in Esophageal Cancer. International Journal of Radiation Oncology*Biology*Physics
CrossRef46
Baldassarre Stea, Lisa J. Hazard, Victor J. Gonzalez, Russell Hamilton. (2011) The role of radiation therapy in the control of locoregional and metastatic cancer. Journal of Surgical Oncology 103:6, 627-638
CrossRef47
Joshua D. Lawson, Jason K. Sicklick, Paul T. Fanta. (2011) Gastric Cancer. Current Problems in Cancer 35:3, 97-127
CrossRef48
Hui Liu, LiXia Lu, Qi Zhu, YuanTao Hao, YunXian Mo, Mengzhong Liu, YongHong Hu, NianJi Cui, TieHua Rong. (2011) Cervical nodal metastases of unresectable thoracic esophageal squamous cell carcinoma: Characteristics of long-term survivors after concurrent chemoradiotherapy. Radiotherapy and Oncology 99:2, 181-186
CrossRef49
Alicia Okines, David Cunningham, Ian Chau. (2011) Targeting the human EGFR family in esophagogastric cancer. Nature Reviews Clinical Oncology 8:8, 492-503
CrossRef50
N. Solomon, D. Mezentsev, I. Reis, M. Lima, J. Rios, E. Avisar, D. Franceschi, A. Livingstone, L. Podolsky, B. Ardalan. (2011) A Phase II Study of Neoadjuvant and Adjuvant Chemotherapy with 5-Fluorodeoxyuridine, Leucovorin, Oxaliplatin and Docetaxel in the Treatment of Previously Untreated Advanced Esophageal Adenocarcinoma. Japanese Journal of Clinical Oncology 41:4, 469-476
CrossRef51
James Welsh, Daniel Gomez, Matthew B. Palmer, Beverly A. Riley, Amin V. Mayankkumar, Ritsuko Komaki, Lei Dong, X. Ronald Zhu, Anna Likhacheva, Zhongxing Liao, Wayne L. Hofstetter, Jaffer A. Ajani, James D. Cox. (2011) Intensity-Modulated Proton Therapy Further Reduces Normal Tissue Exposure During Definitive Therapy for Locally Advanced Distal Esophageal Tumors: A Dosimetric Study. International Journal of Radiation Oncology*Biology*Physics
CrossRef52
Kilian S. May, Gary Y. Yang, Nikhil I. Khushalani. (2011) The Role of Radiation in the Perioperative Treatment of Esophagogastric Cancer. Current Treatment Options in Oncology 12:1, 61-71
CrossRef53
Branislav Bystricky, Alicia F.C. Okines, David Cunningham. (2011) Optimal Therapeutic Strategies for Resectable Oesophageal or Oesophagogastric Junction Cancer. Drugs 71:5, 541-555
CrossRef54
Christophe Mariette, Guillaume Piessen, Nicolas Briez, Caroline Gronnier, Jean Pierre Triboulet. (2011) Oesophagogastric junction adenocarcinoma: which therapeutic approach?. The Lancet Oncology 12:3, 296-305
CrossRef55
J. M. Watkins, A. J. Zauls, P. L. Kearney, K. Shirai, B. N. Ruppert, J. L. Harper, C. A. Sherman, E. G. Aguero, C. E. Reed, A. K. Sharma. (2011) Toxicity, Response Rates and Survival Outcomes of Induction Cisplatin and Irinotecan Followed by Concurrent Cisplatin, Irinotecan and Radiotherapy for Locally Advanced Esophageal Cancer. Japanese Journal of Clinical Oncology 41:3, 334-342
CrossRef56
Autumn J McRee, Stacy Cowherd, Andrew Z Wang, Richard M Goldberg. (2011) Chemoradiation therapy in the management of gastrointestinal malignancies. Future Oncology 7:3, 409-426
CrossRef57
Deepa Reddy, Zev A. Wainberg. (2011) Targeted Therapies for Metastatic Esophagogastric Cancer. Current Treatment Options in Oncology 12:1, 46-60
CrossRef58
Kosuke Narumiya, Ralf Metzger, Elfriede Bollschweiler, Hakan Alakus, Jan Brabender, Uta Drebber, Arnulf H Hölscher, Ute Warnecke-Eberz. (2011) Impact of ABCB1 C3435T polymorphism on lymph node regression in multimodality treatment of locally advanced esophageal cancer. Pharmacogenomics 12:2, 205-214
CrossRef59
Hiroshi Miyata, Makoto Yamasaki, Shuji Takiguchi, Kiyokazu Nakajima, Yoshiyuki Fujiwara, Koji Konishi, Eiichi Morii, Masaki Mori, Yuichiro Doki. (2011) Prognostic Value of Endoscopic Biopsy Findings After Induction Chemoradiotherapy With and Without Surgery for Esophageal Cancer. Annals of Surgery 253:2, 279-284
CrossRef60
Shaun McKenzie, Brian Mailey, Avo Artinyan, Michelle Metchikian, Stephen Shibata, Kemp Kernstine, Joseph Kim. (2011) Improved Outcomes in the Management of Esophageal Cancer with the Addition of Surgical Resection to Chemoradiation Therapy. Annals of Surgical Oncology 18:2, 551-558
CrossRef61
F De Vita, M Orditura, E Martinelli, L Vecchione, R Innocenti, V C Sileni, C Pinto, M Di Maio, A Farella, T Troiani, F Morgillo, V Napolitano, E Ancona, N Di Martino, A Ruol, G Galizia, A Del Genio, F Ciardiello. (2011) A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancer. British Journal of Cancer 104:3, 427-432
CrossRef62
Thomas Dipetrillo, Mohan Suntharalingam, Thomas Ng, Jacques Fontaine, Naomi Horiba, Nicklas Oldenburg, Kimberly Perez, Ari Birnbaum, Richard Battafarano, Whitney Burrows, Howard Safran. (2011) Neoadjuvant Paclitaxel Poliglumex, Cisplatin, and Radiation for Esophageal Cancer. American Journal of Clinical Oncology1
CrossRef63
Pius Maliakal, Maen Abdelrahim, Umesh T. Sankpal, Cima Maliakal, Cheryl H. Baker, Stephen Safe, Luis J. Herrera, Ala Abudayyeh, Sumanth Kaja, Riyaz Basha. (2011) Chemopreventive effects of tolfenamic acid against esophageal tumorigenesis in rats. Investigational New Drugs
CrossRef64
James Welsh, Stephen H. Settle, Arya Amini, Lianchun Xiao, Akihiro Suzuki, Yuki Hayashi, Wayne Hofstetter, Ritsuko Komaki, Zhongxing Liao, Jaffer A. Ajani. (2011) Failure patterns in patients with esophageal cancer treated with definitive chemoradiation. Cancern/a-n/a
CrossRef65
N. Waraich, F. Rashid, A. Jan, D. Semararo, R. Deb, P.C. Leeder, S.Y. Iftikhar. (2011) Vascular invasion is not a risk factor in oesophageal cancer recurrence. International Journal of Surgery 9:3, 237-240
CrossRef66
Mark van Heijl, Jikke M. Omloo, Mark I. van Berge Henegouwen, Otto S. Hoekstra, Ronald Boellaard, Patrick M. Bossuyt, Olivier R. Busch, Hugo W. Tilanus, Maarten C. Hulshof, Ate van der Gaast, Grard A. Nieuwenhuijzen, Han J. Bonenkamp, John Th. Plukker, Miguel A. Cuesta, Fiebo J. ten Kate, Jan Pruim, Herman van Dekken, Jacques J. Bergman, Gerrit W. Sloof, J. Jan van Lanschot. (2011) Fluorodeoxyglucose Positron Emission Tomography for Evaluating Early Response During Neoadjuvant Chemoradiotherapy in Patients With Potentially Curable Esophageal Cancer. Annals of Surgery 253:1, 56-63
CrossRef67
Maria C Wolf, Michael Stahl, Bernd J Krause, Luigi Bonavina, Christiane Bruns, Claus Belka, Franz Zehentmayr. (2011) Curative treatment of oesophageal carcinoma: current options and future developments. Radiation Oncology 6:1, 55
CrossRef68
D. Tougeron, M. Scotté, H. Hamidou, F. Di Fiore, B. Paillot, F. Michot, P. Michel. (2011) Definitive chemoradiotherapy in patients with esophageal adenocarcinoma: An alternative to surgery?. Journal of Surgical Oncologyn/a-n/a
CrossRef69
Amedeo Amedei, Marisa Benagiano, Chiara della Bella, Elena Niccolai, Mario M. D'Elios. (2011) Novel Immunotherapeutic Strategies of Gastric Cancer Treatment. Journal of Biomedicine and Biotechnology 2011, 1-17
CrossRef70
C Matuschek, E Bölke, M Peiper, WT Knoefel, W Budach, A Erhardt, A Scherer, PA Gerber, BA Buhren, N Gattermann, SE Baldus, E Rusnak, V Shukla, K Orth. (2011) The role of neoadjuvant and adjuvant treatment for adenocarcinoma of the upper gastrointestinal tract. European Journal of Medical Research 16:6, 265
CrossRef71
Nils Homann, Claudia Pauligk, Kim Luley, Thomas Werner Kraus, Hans-Peter Bruch, Akin Atmaca, Frank Noack, Hans-Michael Altmannsberger, Elke Jäger, Salah-Eddin Al-Batran. (2011) Pathological complete remission in patients with oesophagogastric cancer receiving preoperative 5-fluorouracil, oxaliplatin and docetaxel. International Journal of Cancern/a-n/a
CrossRef72
Niamh Lynam-Lennon, John V. Reynolds, Graham P. Pidgeon, Joanne Lysaght, Laure Marignol, Stephen G. Maher. (2010) Alterations in DNA Repair Efficiency are Involved in the Radioresistance of Esophageal Adenocarcinoma. Radiation Research 174:6a, 703-711
CrossRef73
Aminah Jatoi, Gamini Soori, Nathan R. Foster, Bradley K. Hiatt, James A. Knost, Tom R. Fitch, Matthew D. Callister, Francis C. Nichols, Tim M. Husted, Steven R. Alberts. (2010) Phase II Study of Preoperative Pemetrexed, Carboplatin, and Radiation Followed by Surgery for Locally Advanced Esophageal Cancer and Gastroesophageal Junction Tumors. Journal of Thoracic Oncology 5:12, 1994-1998
CrossRef74
Kaushik Mukherjee, A. Bapsi Chakravarthy, Laura W. Goff, Wael El-Rifai. (2010) Esophageal Adenocarcinoma: Treatment Modalities in the Era of Targeted Therapy. Digestive Diseases and Sciences 55:12, 3304-3314
CrossRef75
K. H. Chang, O. J. McAnena, M. J. Smith, R. R. Salman, M. F. Khan, D. Lowe. (2010) Surgery for oesophageal cancer at Galway University Hospital 1993–2008. Irish Journal of Medical Science 179:4, 521-527
CrossRef76
Gang Li, Wei Hu, Jianhua Wang, Xia Deng, Ping Zhang, Xuebang Zhang, Congyin Xie, Shixiu Wu. (2010) Phase II Study of Concurrent Chemoradiation in Combination With Erlotinib for Locally Advanced Esophageal Carcinoma. International Journal of Radiation Oncology*Biology*Physics 78:5, 1407-1412
CrossRef77
Elfriede Bollschweiler, Sarah Besch, Uta Drebber, Wolfgang Schröder, Stefan P. Mönig, Daniel Vallböhmer, Stephan E. Baldus, Ralf Metzger, Arnulf H. Hölscher. (2010) Influence of Neoadjuvant Chemoradiation on the Number and Size of Analyzed Lymph Nodes in Esophageal Cancer. Annals of Surgical Oncology 17:12, 3187-3194
CrossRef78
James Welsh, Matthew B. Palmer, Jaffer A. Ajani, Zhongxing Liao, Steven G. Swisher, Wayne L. Hofstetter, Pamela K. Allen, Steven H. Settle, Daniel Gomez, Anna Likhacheva. (2010) Esophageal Cancer Dose Escalation using a Simultaneous Integrated Boost Technique. International Journal of Radiation OncologyBiologyPhysics
CrossRef79
Matthew J. Schuchert, James D. Luketich, Rodney J. Landreneau. (2010) Management of Esophageal Cancer. Current Problems in Surgery 47:11, 845-946
CrossRef80
E.F.W. Courrech Staal, M.W.J.M. Wouters, H. Boot, R.A.E.M. Tollenaar, J.W. van Sandick. (2010) Quality-of-care indicators for oesophageal cancer surgery: A review. European Journal of Surgical Oncology (EJSO) 36:11, 1035-1043
CrossRef81
A. F. C. Okines, D. Cunningham. (2010) Multimodality treatment for localized gastro-oesophageal cancer. Annals of Oncology 21:Supplement 7, vii286-vii293
CrossRef82
Meysan Hurmuzlu, Kjell Øvrebø, Tore Wentzel-Larsen, Ludvig Paul Muren, Asgaut Viste, Rune Smaaland. (2010) High-dose preoperative chemoradiotherapy in esophageal cancer patients does not increase postoperative pulmonary complications: Correlation with dose–volume histogram parameters. Radiotherapy and Oncology 97:1, 60-64
CrossRef83
M. Stahl. (2010) Is there any role for surgery in the multidisciplinary treatment of esophageal cancer?. Annals of Oncology 21:Supplement 7, vii283-vii285
CrossRef84
E. F. W. Courrech Staal, B. M. P. Aleman, H. Boot, M.-L. F. van Velthuysen, H. van Tinteren, J. W. van Sandick. (2010) Systematic review of the benefits and risks of neoadjuvant chemoradiation for oesophageal cancer. British Journal of Surgery 97:10, 1482-1496
CrossRef85
Srikrishna V. Patnana, Santosh B. Murthy, Lianchun Xiao, Eric Rohren, Wayne L. Hofstetter, Stephen G. Swisher, Zhongxing Liao, Jeffrey H. Lee, Manoop S. Bhutani, Homer A. Macapinlac, Xuemei Wang, Jaffer A. Ajani. (2010) Critical role of surgery in patients with gastroesophageal carcinoma with a poor prognosis after chemoradiation as defined by positron emission tomography. Cancer 116:19, 4487-4494
CrossRef86
S. Dighe, S. Purkayastha, I. Swift, P.P. Tekkis, A. Darzi, R. A’Hern, G. Brown. (2010) Diagnostic precision of CT in local staging of colon cancers: a meta-analysis. Clinical Radiology 65:9, 708-719
CrossRef87
Min P. Kim, Arlene M. Correa, Jared Lee, David C. Rice, Jack A. Roth, Reza J. Mehran, Garrett L. Walsh, Jaffer A. Ajani, Dipen M. Maru, Joe Y. Chang, Edith M. Marom, Homer A. Macapinlac, Jeff H. Lee, Ara A. Vaporciyan, Thomas Rice, Stephen G. Swisher, Wayne L. Hofstetter. (2010) Pathologic T0N1 Esophageal Cancer After Neoadjuvant Therapy and Surgery: An Orphan Status. The Annals of Thoracic Surgery 90:3, 884-891
CrossRef88
Jennifer J. Knox, Rebecca Wong, Antonio L. Visbal, Anne M. Horgan, Maha Guindi, Jennifer Hornby, Wei Xu, Jolie Ringash, Shaf Keshavjee, Eric Chen, Masoom Haider, Gail Darling. (2010) Phase 2 trial of preoperative irinotecan plus cisplatin and conformal radiotherapy, followed by surgery for esophageal cancer. Cancer 116:17, 4023-4032
CrossRef89
A. Baraniskin, A. Tannapfel, A. Reinacher-Schick. (2010) Neoadjuvante Therapie von Tumoren des oberen Gastrointestinaltrakts. Der Gastroenterologe 5:5, 412-422
CrossRef90
Nicholas W. Choong, Ann M. Mauer, Daniel C. Haraf, Mark K. Ferguson, Alan B. Sandler, Kenneth A. Kesler, Paul A. S. Fishkin, Rafat H. Ansari, James Wade, Stuart A. Krauss, David F. Sciortino, Mitchell C. Posner, Masha Kocherginsky, Philip C. Hoffman, Livia Szeto, Everett E. Vokes. (2010) Long-term outcome of a phase II study of docetaxel-based multimodality chemoradiotherapy for locally advanced carcinoma of the esophagus or gastroesophageal junction. Medical Oncology
CrossRef91
R. J. Cohen, K. Paskalev, S. Litwin, R. A. Price Jr., S. J. Feigenberg, A. A. Konski. (2010) Original article: Esophageal motion during radiotherapy: quantification and margin implications. Diseases of the Esophagus 23:6, 473-479
CrossRef92
D.G. Power, J.V. Reynolds. (2010) Localized adenocarcinoma of the esophagogastric junction – Is there a standard of care?. Cancer Treatment Reviews 36:5, 400-409
CrossRef93
Daniel King Hung Tong, Simon Law, Dora Lai Wan Kwong, Kwok Wah Chan, Alfred King Yin Lam, Kam Ho Wong. (2010) Histological Regression of Squamous Esophageal Carcinoma Assessed by Percentage of Residual Viable Cells after Neoadjuvant Chemoradiation is an Important Prognostic Factor. Annals of Surgical Oncology 17:8, 2184-2192
CrossRef94
J. M. Howard, P. Beddy, D. Ennis, M. Keogan, G. P. Pidgeon, J. V. Reynolds. (2010) Associations between leptin and adiponectin receptor upregulation, visceral obesity and tumour stage in oesophageal and junctional adenocarcinoma. British Journal of Surgery 97:7, 1020-1027
CrossRef95
Thomas Ng, Michael P. Vezeridis. (2010) Advances in the surgical treatment of esophageal cancer. Journal of Surgical Oncology 101:8, 725-729
CrossRef96
Takahiro Yoshida, Junichi Seike, Takanori Miyoshi, Hiromichi Yamai, Hirokazu Takechi, Yasuhiro Yuasa, Yoshihito Furukita, Yota Yamamoto, Atsushi Umemoto, Akira Tangoku. (2010) Preoperative chemotherapy with weekly docetaxel plus low-dose cisplatin and 5-fluorouracil for stage II/III squamous cell carcinoma of the esophagus. Esophagus 7:2, 95-100
CrossRef97
M. Stahl. (2010) Multimodale Therapie beim Adenokarzinom des Ösophagus und des ösophagogastralen Übergangs. Der Onkologe 16:5, 504-509
CrossRef98
R. Malthaner, R.K.S. Wong, K. Spithoff. (2010) Preoperative or Postoperative Therapy for Resectable Oesophageal Cancer: an Updated Practice Guideline. Clinical Oncology 22:4, 250-256
CrossRef99
R. H. Mak, H. J. Mamon, D. P. Ryan, D. T. Miyamoto, M. Ancukiewicz, W. K. Kobayashi, C. G. Willett, N. C. Choi, L. S. Blaszkowsky, T. S. Hong. (2010) Toxicity and outcomes after chemoradiation for esophageal cancer in patients age 75 or older. Diseases of the Esophagus 23:4, 316-323
CrossRef100
Geoffrey Y. Ku, David H. Ilson. (2010) Esophagogastric cancer: Targeted agents. Cancer Treatment Reviews 36:3, 235-248
CrossRef101
T. H. La, A. Y. Minn, Z. Su, G. A. Fisher, J. M. Ford, P. Kunz, K. A. Goodman, A. C. Koong, D. T. Chang. (2010) Multimodality treatment with intensity modulated radiation therapy for esophageal cancer. Diseases of the Esophagus 23:4, 300-308
CrossRef102
T. L. Lopes, M. A. Eloubeidi. (2010) A pilot study of fully covered self-expandable metal stents prior to neoadjuvant therapy for locally advanced esophageal cancer. Diseases of the Esophagus 23:4, 309-315
CrossRef103
T.D.L. Crosby, M. Evans. (2010) Resectable Oesophageal Cancer: a Practice Guideline Update. Practice Changing or Supporting the Status Quo?. Clinical Oncology 22:4, 247-249
CrossRef104
Doreen Dähn, Joachim Martell, Hilke Vorwerk, Clemens F. Hess, Heinz Becker, Klaus Jung, Reinhard Hilgers, Hendrik Andreas Wolff, Robert Michael Hermann, Hans Christiansen. (2010) Influence of Irradiated Lung Volumes on Perioperative Morbidity and Mortality in Patients After Neoadjuvant Radiochemotherapy for Esophageal Cancer. International Journal of Radiation Oncology*Biology*Physics 77:1, 44-52
CrossRef105
G. Verlato, A. Zanoni, A. Tomezzoli, A. Minicozzi, S. Giacopuzzi, M. Di Cosmo, I. Franceschetti, G. de Manzoni. (2010) Response to induction therapy in oesophageal and cardia carcinoma using Mandard tumour regression grade or size of residual foci. British Journal of Surgery 97:5, 719-725
CrossRef106
David A. Schomas, J. Fernando Quevedo, James M. Donahue, Francis C. Nichols III, Yvonne Romero, Robert C. Miller. (2010) The prognostic importance of pathologically involved celiac node metastases in node-positive patients with carcinoma of the distal esophagus or gastroesophageal junction: a surgical series from the Mayo Clinic. Diseases of the Esophagus 23:3, 232-239
CrossRef107
Alicia Okines, Bhupinder Sharma, David Cunningham. (2010) Perioperative management of esophageal cancer. Nature Reviews Clinical Oncology 7:4, 231-238
CrossRef108
Jaffer A. Ajani, Arlene M. Correa, Garrett L. Walsh, Ritsuko Komaki, Jeffrey H. Lee, Ara A. Vaporciyan, David C. Rice, James C. Yao, Dipen M. Maru, Wayne L. Hofstetter, Alexandria T. Phan, Stephen G. Swisher. (2010) Trimodality therapy without a platinum compound for localized carcinoma of the esophagus and gastroesophageal junction. Cancer 116:7, 1656-1663
CrossRef109
John R. Hyngstrom, Mitchell C. Posner. (2010) Neoadjuvant strategies for the treatment of locally advanced esophageal cancer. Journal of Surgical Oncology 101:4, 299-304
CrossRef110
Arlene A. Forastiere. (2010) Multimodality treatment of esophagus cancer: current status and future perspectives in the United States. Esophagus 7:1, 1-6
CrossRef111
Naveenraj Solomon, Ying Zhuge, Michael Cheung, Dido Franceschi, Leonidas G. Koniaris. (2010) The Roles of Neoadjuvant Radiotherapy and Lymphadenectomy in the Treatment of Esophageal Adenocarcinoma. Annals of Surgical Oncology 17:3, 791-803
CrossRef112
David Schreiber, Justin Rineer, Dan Vongtama, Angela Wortham, Peter Han, David Schwartz, Kwang Choi, Marvin Rotman. (2010) Impact of Postoperative Radiation after Esophagectomy for Esophageal Cancer. Journal of Thoracic Oncology 5:2, 244-250
CrossRef113
Jeffrey Bradley, Issam El Naqa. (2010) Treatment for M1a Cancer of the Esophagus May Not Be Largely Palliative. Journal of Thoracic Oncology 5:2, 284-285
CrossRef114
Cecilie D. Amdal, Anne-Birgitte Jacobsen, Johan E. Tausjø, Johan N. Wiig, Trond Warloe, Karl O. Karlsen, Berit Sandstad, Kristin Bjordal. (2010) Radical treatment for oesophageal cancer patients unfit for surgery and chemotherapy. A 10-year experience from the Norwegian Radium Hospital. Acta Oncologica 49:2, 209-218
CrossRef115
M. Zemanova, L. Petruzelka, A. Pazdro, D. Kralova, M. Smejkal, G. Pazdrova, H. Honova. (2010) Prospective non-randomized study of preoperative concurrent platinum plus 5-fluorouracil-based chemoradiotherapy with or without paclitaxel in esophageal cancer patients: long-term follow-up. Diseases of the Esophagus 23:2, 160-167
CrossRef116
Melanie Goldfarb, Steven Brower, S. D. Schwaitzberg. (2010) Minimally invasive surgery and cancer: controversies part 1. Surgical Endoscopy 24:2, 304-334
CrossRef117
Stephen A. Barnett, Nabil P. Rizk. (2010) Randomized Clinical Trials in Esophageal Carcinoma. Surgical Oncology Clinics of North America 19:1, 59-80
CrossRef118
David Tom Cooke, Allan Pickens. 2010. Carcinoma of the Esophagus. , 503-510.
CrossRef119
Naveenraj L. Solomon, Michael C. Cheung, Margaret M. Byrne, Ying Zhuge, Dido Franceschi, Alan S. Livingstone, Leonidas G. Koniaris. (2010) Does Chemoradiotherapy Improve Outcomes for Surgically Resected Adenocarcinoma of the Stomach or Esophagus?. Annals of Surgical Oncology 17:1, 98-108
CrossRef120
Ute Warnecke-Eberz, Ralf Metzger, Elfriede Bollschweiler, Stephan E Baldus, Rolf P Mueller, Hans P Dienes, Arnulf H Hoelscher, Paul M Schneider. (2010) TaqMan ® low-density arrays and analysis by artificial neuronal networks predict response to neoadjuvant chemoradiation in esophageal cancer. Pharmacogenomics 11:1, 55-64
CrossRef121
Hironobu Sato, Hiroshi Miyake, Moritaka Ohhara, Kei Kimizuka, Woodae Kang, Takeshi Kikuchi, Manabu Hanada, Toshiro Takimoto, Tohru Furusaka, Masaki Takeuchi. (2010) A Case of Complete Response of Primary Cervical Esophageal Carcinoma with Preoperative Chemoradiotherapy. Journal of Nihon University Medical Association 69:6, 370-373
CrossRef122
Takeshi MATSUTANI, Eiji UCHIDA, Hiroshi MARUYAMA, Seiji SUZUKI, Akihisa MATSUDA, Koji SASAJIMA. (2010) CASE REPORT OF MIDDLE THORACIC ESOPHAGEAL ADENOCARCINOMA AT THE ORAL MARGIN OF BARRETT'S EPITHELIUM. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association) 71:1, 72-76
CrossRef123
Elfriede Bollschweiler, Arnulf H Hölscher, Ralf Metzger. (2010) Histologic tumor type and the rate of complete response after neoadjuvant therapy for esophageal cancer. Future Oncology 6:1, 25-35
CrossRef124
Ewout F. W. Courrech Staal, Frits Coevorden, Annemieke Cats, Berthe M. P. Aleman, Marie-Louise F. Velthuysen, Henk Boot, Marie-Jeanne T. F. D. Vrancken Peeters, Johanna W. Sandick. (2009) Outcome of Low-Volume Surgery for Esophageal Cancer in a High-Volume Referral Center. Annals of Surgical Oncology 16:12, 3219-3226
CrossRef125
Robert Diaz, Gaspar Reynes, Alejandro Tormo, Manuel Juan, Regina Gironés, Ángel Segura, Jorge Aparicio, Paula Richart, Helena Cueva, José García. (2009) Long-term results of neoadjuvant chemotherapy and combined chemoradiotherapy before surgery in the management of locally advanced oesophageal cancer: a single-centre experience. Clinical and Translational Oncology 11:12, 835-841
CrossRef126
Bas P. L. Wijnhoven, Jan J. B. Lanschot, Hugo W. Tilanus, Ewout W. Steyerberg, Ate Gaast. (2009) Neoadjuvant Chemoradiotherapy for Esophageal Cancer: A Review of Meta-Analyses. World Journal of Surgery 33:12, 2606-2614
CrossRef127
Suzan Cheng, Mark Iannettoni, Matthew Koshy, Mohan Suntharalingam, Susan Urba. (2009) Squamous Cell Carcinoma of the Esophagus: Treat With How Many Modalities?. Seminars in Oncology 36:6, 493-497
CrossRef128
Heta Javeri, Lianchun Xiao, Eric Rohren, Jeffrey H. Lee, Zhongxing Liao, Wayne Hofstetter, Dipen Maru, Manoop S. Bhutani, Stephen G. Swisher, Homer Macapinlac, Xuemei Wang, Jaffer A. Ajani. (2009) The higher the decrease in the standardized uptake value of positron emission tomography after chemoradiation, the better the survival of patients with gastroesophageal adenocarcinoma. Cancer 115:22, 5184-5192
CrossRef129
Hiroshi Miyata, Makoto Yamasaki, Shuji Takiguchi, Kiyokazu Nakajima, Yoshiyuki Fujiwara, Toshiro Nishida, Masaki Mori, Yuichiro Doki. (2009) Salvage esophagectomy after definitive chemoradiotherapy for thoracic esophageal cancer. Journal of Surgical Oncology 100:6, 442-446
CrossRef130
Julian A. Abrams, Donna L. Buono, Joshua Strauss, Russell B. McBride, Dawn L. Hershman, Alfred I. Neugut. (2009) Esophagectomy compared with chemoradiation for early stage esophageal cancer in the elderly. Cancer 115:21, 4924-4933
CrossRef131
R. Semrau, D. Vallböhmer, A.H. Hölscher, R.-P. Müller. (2009) Neoadjuvante Therapie der Adenokarzinome des oberen Gastrointestinaltraktes. Der Chirurg 80:11, 1035-1041
CrossRef132
Peter Grimminger, Daniel Vallböhmer, Andreas Hoffmann, Christian Schulte, Elfriede Bollschweiler, Paul M. Schneider, Arnulf H. Hölscher, Ralf Metzger, Jan Brabender. (2009) Quantitative analysis of Survivin RNA expression in blood as a non-invasive predictor of response to neoadjuvant radiochemotherapy in esophageal cancer. Journal of Surgical Oncology 100:6, 447-451
CrossRef133
Stephen G. Maher, Charles M. Gillham, Shane P. Duggan, Paul C. Smyth, Nicola Miller, Cian Muldoon, Kenneth J. OʼByrne, Orla M. Sheils, Donal Hollywood, John V. Reynolds. (2009) Gene Expression Analysis of Diagnostic Biopsies Predicts Pathological Response to Neoadjuvant Chemoradiotherapy of Esophageal Cancer. Annals of Surgery 250:5, 729-737
CrossRef134
David J. Adelstein, Thomas W. Rice, Lisa A. Rybicki, Jerrold P. Saxton, Gregory M. M. Videtic, Sudish C. Murthy, David P. Mason, Cristina P. Rodriguez, Denise I. Ives. (2009) Mature Results from a Phase II Trial of Postoperative Concurrent Chemoradiotherapy for Poor Prognosis Cancer of the Esophagus and Gastroesophageal Junction. Journal of Thoracic Oncology 4:10, 1264-1269
CrossRef135
Atsushi Takeno, Shuji Takiguchi, Makoto Yamasaki, Hiroshi Miyata, Ryohei Kawabata, Yoichiro Nushijima, Tomoki Makino, Yoshiyuki Fujiwara, Kiyokazu Nakajima, Toshiro Nishida, Masaki Mori, Yuichiro Doki. (2009) A suspected [18F]fluorodeoxyglucose positron emission tomography-negative metastatic lymph node successfully diagnosed by laparoscopic staging in esophageal cancer: Report of two cases. Surgery Today 39:10, 888-891
CrossRef136
Ying Zhuge, Michael C. Cheung, Relin Yang, Dalal Eldick, Leonidas G. Koniaris, Juan E. Sola. (2009) Pediatric Intestinal Foregut and Small Bowel Solid Tumors: A Review of 105 Cases. Journal of Surgical Research 156:1, 95-102
CrossRef137
Keisuke Kubota, Ken-ichi Mafune, Kazuhiko Yamada, Hideomi Yamashita, Junko Kuroda, Susumu Aikou, Michio Kaminishi. (2009) Complete regression of advanced esophageal cancer with abdominal bulky lymph node metastasis treated by concurrent chemoradiotherapy using docetaxel, cisplatin, and 5-fluorouracil. Esophagus 6:3, 183-187
CrossRef138
Min Kyoung Kim, Kyung-Ja Cho, Seung-Il Park, Yong Hee Kim, Jong Hoon Kim, Ho-Young Song, Ji Hoon Shin, Hwoon Yong Jung, Gin Hyug Lee, Kee Don Choi, Ho June Song, Jin-Sook Ryu, Sung-Bae Kim. (2009) Initial Stage Affects Survival Even After Complete Pathologic Remission is Achieved in Locally Advanced Esophageal Cancer: Analysis of 70 Patients With Pathologic Major Response After Preoperative Chemoradiotherapy. International Journal of Radiation Oncology*Biology*Physics 75:1, 115-121
CrossRef139
T. Ruhstaller, L. Widmer, J. C. Schuller, A. Roth, V. Hess, W. Mingrone, R. von Moos, M. Borner, B. C. Pestalozzi, S. BalmerMajno, D. Koberle, L. Terraciano, A. Schnider, S. Bodis, R. Popescu, . (2009) Multicenter phase II trial of preoperative induction chemotherapy followed by chemoradiation with docetaxel and cisplatin for locally advanced esophageal carcinoma (SAKK 75/02). Annals of Oncology 20:9, 1522-1528
CrossRef140
C.G. Willett, B.G. Czito. (2009) Chemoradiotherapy in Gastrointestinal Malignancies. Clinical Oncology 21:7, 543-556
CrossRef141
X.-F. Cao, X.-T. He, L. Ji, J. Xiao, J. Lv. (2009) Effects of neoadjuvant radiochemotherapy on pathological staging and prognosis for locally advanced esophageal squamous cell carcinoma. Diseases of the Esophagus 22:6, 477-481
CrossRef142
Cathy E. Fleming, Gary Bass, Thomas N. Walsh. (2009) Roedl JB et al., Adenocarcinomas of the esophagus: response to chemoradiotherapy is associated with decrease of metabolic tumor volume as measured on PET–CT comparison to histopathologic and clinical response evaluation, Radiother Oncol 2008; 89: 278–86.. Radiotherapy and Oncology 92:2, 291
CrossRef143
R R Weichselbaum, D Kufe. (2009) Translation of the radio- and chemo-inducible TNFerade vector to the treatment of human cancers. Cancer Gene Therapy 16:8, 609-619
CrossRef144
Daniel T. Chang, Christopher Chapman, John Shen, Zheng Su, Albert C. Koong. (2009) Treatment of Esophageal Cancer Based on Histology. American Journal of Clinical Oncology 32:4, 405-410
CrossRef145
Penelope A. Bradbury, Matthew H. Kulke, Rebecca S. Heist, Wei Zhou, Clement Ma, Wei Xu, Ariela L. Marshall, Rihong Zhai, Susanne M. Hooshmand, Kofi Asomaning, Li Su, Frances A. Shepherd, Thomas J. Lynch, John C. Wain, David C. Christiani, Geoffrey Liu. (2009) Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomes. Pharmacogenetics and Genomics 19:8, 613-625
CrossRef146
Bernhard Berger, Claus Belka. (2009) Evidence-based radiation oncology: Oesophagus. Radiotherapy and Oncology 92:2, 276-290
CrossRef147
Karin Ribi, Dieter Koeberle, Jan C. Schuller, Hanspeter Honegger, Arnaud Roth, Viviane Hess, Peter Moosmann, Roger Moos, Markus Borner, Norbert Lombriser, Bernhard Pestalozzi, Thomas Ruhstaller. (2009) Is a change in patient-reported dysphagia after induction chemotherapy in locally advanced esophageal cancer a predictive factor for pathological response to neoadjuvant chemoradiation?. Supportive Care in Cancer 17:8, 1109-1116
CrossRef148
Hiroshi Miyata, Akiko Yoshioka, Makoto Yamasaki, Yoichiro Nushijima, Shuji Takiguchi, Yoshiyuki Fujiwara, Toshiro Nishida, Masayuki Mano, Masaki Mori, Yuichiro Doki. (2009) Tumor budding in tumor invasive front predicts prognosis and survival of patients with esophageal squamous cell carcinomas receiving neoadjuvant chemotherapy. Cancer 115:14, 3324-3334
CrossRef149
E. van Meerten, A. van der Gaast, H.W. Tilanus, J.W. Poley, K. Muller, H. van Dekken. (2009) Pathological analysis after neoadjuvant chemoradiotherapy for esophageal carcinoma: The rotterdam experience. Journal of Surgical Oncology 100:1, 32-37
CrossRef150
Zhen Zhang, Yuan Chen, Yanzhi Chen, Melenda Jeter, Wayne L. Hofstetter, Jaffer Ajani, Stephen G. Swisher, Joe Y. Chang, Pamela K. Allen, James D. Cox, Ritsuko Komaki, Zhongxing X. Liao. (2009) Outcomes with Esophageal Cancer Radiation Therapy. Journal of Thoracic Oncology 4:7, 880-888
CrossRef151
Geoffrey Y. Ku, David H. Ilson. (2009) Role of Neoadjuvant Therapy for Esophageal Adenocarcinoma. Surgical Oncology Clinics of North America 18:3, 533-546
CrossRef152
David T. Cooke, Giant C. Lin, Christine L. Lau, Linda Zhang, Ming-Sing Si, Julia Lee, Andrew C. Chang, Allan Pickens, Mark B. Orringer. (2009) Analysis of Cervical Esophagogastric Anastomotic Leaks After Transhiatal Esophagectomy: Risk Factors, Presentation, and Detection. The Annals of Thoracic Surgery 88:1, 177-185
CrossRef153
N Starling, A Okines, D Cunningham, W Allum, A Wotherspoon, M Benson, J Thompson, J Thomas, G Brown, A Riddell, F Stavridi, S Ashley, J Oates, I Chau. (2009) A phase II trial of preoperative chemotherapy with epirubicin, cisplatin and capecitabine for patients with localised gastro-oesophageal junctional adenocarcinoma. British Journal of Cancer 100:11, 1725-1730
CrossRef154
H Alakus, U Warnecke-Eberz, E Bollschweiler, S P Mönig, D Vallböhmer, J Brabender, U Drebber, S E Baldus, K Riemann, W Siffert, A H Hölscher, R Metzger. (2009) GNAS1 T393C polymorphism is associated with histopathological response to neoadjuvant radiochemotherapy in esophageal cancer. The Pharmacogenomics Journal 9:3, 202-207
CrossRef155
Grace L. Smith, Benjamin D. Smith, Thomas A. Buchholz, Zhongxing Liao, Melenda Jeter, Stephen G. Swisher, Wayne L. Hofstetter, Jaffer A. Ajani, Mary F. McAleer, Ritsuko Komaki, James D. Cox. (2009) Patterns of Care and Locoregional Treatment Outcomes in Older Esophageal Cancer Patients: The SEER-Medicare Cohort. International Journal of Radiation Oncology*Biology*Physics 74:2, 482-489
CrossRef156
Matthias Schmidt, Elfriede Bollschweiler, Markus Dietlein, Stefan P. Mönig, Carsten Kobe, Daniel Vallboehmer, Wolfgang Eschner, Arnulf Hölscher, Harald Schicha. (2009) Mean and maximum standardized uptake values in [18F]FDG-PET for assessment of histopathological response in oesophageal squamous cell carcinoma or adenocarcinoma after radiochemotherapy. European Journal of Nuclear Medicine and Molecular Imaging 36:5, 735-744
CrossRef157
A. A. Siddiqui, C. Glynn, D. Loren, T. Kowalski. (2009) Self-expanding plastic esophageal stents versus jejunostomy tubes for the maintenance of nutrition during neoadjuvant chemoradiation therapy in patients with esophageal cancer: a retrospective study. Diseases of the Esophagus 22:3, 216-222
CrossRef158
Abhijit A. Patel, John A. Wolfgang, Andrzej Niemierko, Theodore S. Hong, Torunn Yock, Noah C. Choi. (2009) Implications of Respiratory Motion as Measured by Four-Dimensional Computed Tomography for Radiation Treatment Planning of Esophageal Cancer. International Journal of Radiation Oncology*Biology*Physics 74:1, 290-296
CrossRef159
Jan Brabender, Dariusch Arbab, Xi Huan, Daniel Vallböhmer, Peter Grimminger, Frederike Ling, Susanne Neiss, Elfriede Bollschweiler, Paul M. Schneider, Arnulf H. Hölscher, Ralf Metzger. (2009) Death-Associated Protein Kinase (DAPK) Promoter Methylation and Response to Neoadjuvant Radiochemotherapy in Esophageal Cancer. Annals of Surgical Oncology 16:5, 1378-1383
CrossRef160
Marcovalerio Melis, James M. McLoughlin, E. Michelle Dean, Erin M. Siegel, Jill M. Weber, Nilay Shah, Scott T. Kelley, Richard C. Karl. (2009) Correlations Between Neoadjuvant Treatment, Anemia, and Perioperative Complications in Patients Undergoing Esophagectomy for Cancer. Journal of Surgical Research 153:1, 114-120
CrossRef161
Toshiyuki Sakaeda, Motohiro Yamamori, Akiko Kuwahara, Kohshi Nishiguchi. (2009) Pharmacokinetics and pharmacogenomics in esophageal cancer chemoradiotherapy. Advanced Drug Delivery Reviews 61:5, 388-401
CrossRef162
Inderpal S. Sarkaria, Nabil P. Rizk, Manjit S. Bains, Laura H. Tang, David H. Ilson, Bruce I. Minsky, Valerie W. Rusch. (2009) Post-treatment Endoscopic Biopsy Is a Poor-Predictor of Pathologic Response in Patients Undergoing Chemoradiation Therapy for Esophageal Cancer. Annals of Surgery 249:5, 764-767
CrossRef163
Dipen M. Maru, Rajyalakshmi Luthra, Arlene M. Correa, Jill White-Cross, Sharmila Anandasabapathy, Sunil Krishnan, Sushovan Guha, Ritsuko Komaki, Stephen G. Swisher, Jaffer A. Ajani, Wayne L. Hofstetter, Asif Rashid. (2009) Frequent loss of heterozygosity of chromosome 1q in esophageal adenocarcinoma. Cancer 115:7, 1576-1585
CrossRef164
Norikatsu Miyoshi, Masahiko Yano, Ko Takachi, Kentaro Kishi, Shingo Noura, Hidetoshi Eguchi, Terumasa Yamada, Isao Miyashiro, Masayuki Ohue, Hiroaki Ohigashi, Yo Sasaki, Osamu Ishikawa, Yuichiro Doki, Shingi Imaoka. (2009) Myelotoxicity of preoperative chemoradiotherapy is a significant determinant of poor prognosis in patients with T4 esophageal cancer. Journal of Surgical Oncology 99:5, 302-306
CrossRef165
J. G. Izzo, X. Wu, T.-T. Wu, P. Huang, J.-S. Lee, Z. Liao, J. H. Lee, M. S. Bhutani, W. Hofstetter, D. Maru, M.-C. Hung, J. A. Ajani. (2009) Therapy-induced expression of NF-κB portends poor prognosis in patients with localized esophageal cancer undergoing preoperative chemoradiation. Diseases of the Esophagus 22:2, 127-132
CrossRef166
Sudish C. Murthy, Maria Solovera Rozas, David J. Adelstein, David P. Mason, Royce Calhoun, Lisa A. Rybicki, Jingyuan Feng, Eugene H. Blackstone, Thomas W. Rice. (2009) Induction Chemoradiotherapy Increases Pleural and Pericardial Complications after Esophagectomy for Cancer. Journal of Thoracic Oncology 4:3, 395-403
CrossRef167
Yixing Jiang, Eric Kimchi, Jaffer A Ajani. (2009) Localized squamous cell carcinoma of the esophagus: bimodality or trimodality approach?. Future Oncology 5:2, 157-161
CrossRef168
Jaffer A. Ajani. (2009) Future Developments in Esophageal Cancer Research. Gastroenterology Clinics of North America 38:1, 183-188
CrossRef169
Geoffrey Y. Ku, David H. Ilson. (2009) Preoperative Therapy for Esophageal Cancer. Gastroenterology Clinics of North America 38:1, 135-152
CrossRef170
P. Cen, A. M. Correa, J. H. Le, D. Maru, S. Anandasabapathy, Z. Liao, W. L. Hofstetter, S. G. Swisher, R. Komaki, W. A. Ross, A. Vaporciyan, J. A. Ajani. (2009) Adenocarcinoma of the lower esophagus with Barrett's esophagus or without Barrett's esophagus: differences in patients' survival after preoperative chemoradiation. Diseases of the Esophagus 22:1, 32-41
CrossRef171
Amanda L. Schwer, Ari Ballonoff, Robert McCammon, Kyle Rusthoven, Ralph B. D'Agostino, Tracey E. Schefter. (2009) Survival Effect of Neoadjuvant Radiotherapy Before Esophagectomy for Patients With Esophageal Cancer: A Surveillance, Epidemiology, and End-Results Study. International Journal of Radiation Oncology*Biology*Physics 73:2, 449-455
CrossRef172
Yuji Tachimori. (2009) Role of salvage esophagectomy after definitive chemoradiotherapy. General Thoracic and Cardiovascular Surgery 57:2, 71-78
CrossRef173
James M. Donahue, Francis C. Nichols, Zhuo Li, David A. Schomas, Mark S. Allen, Stephen D. Cassivi, Aminah Jatoi, Robert C. Miller, Dennis A. Wigle, K. Robert Shen, Claude Deschamps. (2009) Complete Pathologic Response After Neoadjuvant Chemoradiotherapy for Esophageal Cancer Is Associated With Enhanced Survival. The Annals of Thoracic Surgery 87:2, 392-399
CrossRef174
Roderick M. Quiros, Courtney L. Bui. (2009) Multidisciplinary Approach to Esophageal and Gastric Cancer. Surgical Clinics of North America 89:1, 79-96
CrossRef175
J. J. G. Scheepers, D. L. van der Peet, A. A. F. A. Veenhof, M. A. Cuesta. (2009) Influence of circumferential resection margin on prognosis in distal esophageal and gastroesophageal cancer approached through the transhiatal route. Diseases of the Esophagus 22:1, 42-48
CrossRef176
Heta Javeri, Lianchun Xiao, Eric Rohren, Ritsuko Komaki, Wayne Hofstetter, Jeffrey H. Lee, Dipen Maru, Manoop S. Bhutani, Stephen G. Swisher, Xuemei Wang, Jaffer A. Ajani. (2009) Influence of the baseline 18F-fluoro-2-deoxy-D-glucose positron emission tomography results on survival and pathologic response in patients with gastroesophageal cancer undergoing chemoradiation. Cancer 115:3, 624-630
CrossRef177
Ali Salavati, Sandip Basu, Pedram Heidari, Abass Alavi. (2009) Impact of fluorodeoxyglucose PET on the management of esophageal cancer. Nuclear Medicine Communications 30:2, 95-116
CrossRef178
Mark J. Krasna. (2009) Stage-Specific Therapy for Cancer of the Oesophagus. Drugs & Aging 26:3, 185-194
CrossRef179
Najib Safieddine, Wei Xu, Sayed Mohammed Quadri, Jennifer J. Knox, Jennifer Hornby, Joanne Sulman, Rebecca Wong, Maha Guindi, Shaf Keshavjee, Gail Darling. (2009) Health-related quality of life in esophageal cancer: Effect of neoadjuvant chemoradiotherapy followed by surgical intervention. The Journal of Thoracic and Cardiovascular Surgery 137:1, 36-42
CrossRef180
Eduardo B. da Silveira, Everson L. Artifon. (2008) Cost-Effectiveness of Palliation of Unresectable Esophageal Cancer. Digestive Diseases and Sciences 53:12, 3103-3111
CrossRef181
Johannes B. Roedl, Rivka R. Colen, Nagaraj S. Holalkere, Alan J. Fischman, Noah C. Choi, Michael A. Blake. (2008) Adenocarcinomas of the esophagus: Response to chemoradiotherapy is associated with decrease of metabolic tumor volume as measured on PET–CT. Radiotherapy and Oncology 89:3, 278-286
CrossRef182
Wei Liu, Xiaodong Zhang, Weijing Sun. (2008) Developments in Treatment of Esophageal/Gastric Cancer. Current Treatment Options in Oncology 9:4-6, 375-387
CrossRef183
Johannes B. Roedl, Dushyant V. Sahani, Rivka R. Colen, Alan J. Fischman, Peter R. Mueller, Michael A. Blake. (2008) Tumour length measured on PET-CT predicts the most appropriate stage-dependent therapeutic approach in oesophageal cancer. European Radiology 18:12, 2833-2840
CrossRef184
Thomas J Murphy, Narayamasamy Ravi, John V Reynolds. (2008) Treatment options for esophageal cancer. Expert Opinion on Pharmacotherapy 9:18, 3197-3210
CrossRef185
Christian G. Peyre, Jeffrey A. Hagen, Steven R. DeMeester, Jan J. B. Van Lanschot, Arnulf Hölscher, Simon Law, Alberto Ruol, Ermanno Ancona, S Michael Griffin, Nasser K. Altorki, Thomas W. Rice, John Wong, Toni Lerut, Tom R. DeMeester. (2008) Predicting Systemic Disease in Patients With Esophageal Cancer After Esophagectomy. Annals of Surgery 248:6, 979-985
CrossRef186
Theodore S. Hong, Joseph H. Killoran, Marcelo Mamede, Harvey J. Mamon. (2008) Impact of Manual and Automated Interpretation of Fused PET/CT Data on Esophageal Target Definitions in Radiation Planning. International Journal of Radiation Oncology*Biology*Physics 72:5, 1612-1618
CrossRef187
Hisahiro Matsubara. (2008) Neoadjuvant chemoradiation therapy for the treatment of esophageal carcinoma. International Journal of Clinical Oncology 13:6, 474-478
CrossRef188
Geoffrey Y Ku, David H Ilson. (2008) Multimodality therapy for the curative treatment of cancer of the esophagus and gastroesophageal junction. Expert Review of Anticancer Therapy 8:12, 1953-1964
CrossRef189
Takashi Kobayashi, Masanori Teruya, Tomokazu Kishiki, Daisuke Endo, Yoshiharu Takenaka, Hozumi Tanaka, Kenji Miki, Kaoru Kobayashi, Koji Morita. (2008) Inflammation-based prognostic score, prior to neoadjuvant chemoradiotherapy, predicts postoperative outcome in patients with esophageal squamous cell carcinoma. Surgery 144:5, 729-735
CrossRef190
Jan Brabender, Daniel Vallböhmer, Peter Grimminger, Andreas C. Hoffmann, Frederike Ling, Georg Lurje, Elfriede Bollschweiler, Paul M. Schneider, Arnulf H. Hölscher, Ralf Metzger. (2008) ERCC1 RNA Expression in Peripheral Blood Predicts Minor Histopathological Response to Neoadjuvant Radio-chemotherapy in Patients with Locally Advanced Cancer of the Esophagus. Journal of Gastrointestinal Surgery 12:11, 1815-1821
CrossRef191
Tomoki Makino, Yuichiro Doki, Hiroshi Miyata, Takushi Yasuda, Makoto Yamasaki, Yoshiyuki Fujiwara, Shuji Takiguchi, Ichiro Higuchi, Jun Hatazawa, Morito Monden. (2008) Use of 18F-fluorodeoxyglucose-positron emission tomography to evaluate responses to neo-adjuvant chemotherapy for primary tumor and lymph node metastasis in esophageal squamous cell carcinoma. Surgery 144:5, 793-802
CrossRef192
S Lorenzen, B Brücher, F Zimmermann, H Geinitz, J Riera, T Schuster, N Roethling, H Höfler, K Ott, C Peschel, J R Siewert, M Molls, F Lordick. (2008) Neoadjuvant continuous infusion of weekly 5-fluorouracil and escalating doses of oxaliplatin plus concurrent radiation in locally advanced oesophageal squamous cell carcinoma: results of a phase I/II trial. British Journal of Cancer 99:7, 1020-1026
CrossRef193
E. Bollschweiler, R. Metzger, U. Drebber, S. Baldus, D. Vallbohmer, M. Kocher, A. H. Holscher. (2008) Histological type of esophageal cancer might affect response to neo-adjuvant radiochemotherapy and subsequent prognosis. Annals of Oncology 20:2, 231-238
CrossRef194
K. Tanaka, Y. Mohri, M. Ohi, T. Yokoe, Y. Koike, Y. Morimoto, C. Miki, H. Tonouchi, M. Kusunoki. (2008) Mitotic Checkpoint Genes, hsMAD2 and BubR1, in Oesophageal Squamous Cancer Cells and their Association with 5-fluorouracil and Cisplatin-based Radiochemotherapy. Clinical Oncology 20:8, 639-646
CrossRef195
Andrew P. Barbour, Mark Jones, Mithat Gonen, David C. Gotley, Janine Thomas, Damien B. Thomson, Bryan Burmeister, B. Mark Smithers. (2008) Refining Esophageal Cancer Staging After Neoadjuvant Therapy: Importance of Treatment Response. Annals of Surgical Oncology 15:10, 2894-2902
CrossRef196
S. K. Seung, J. W. Smith, H. J. Ross. (2008) Selective dose escalation of chemoradiotherapy for locally advanced esophageal cancer. Diseases of the Esophagus 21:7, 589-595
CrossRef197
Francesca Milano, Kausilia K. Krishnadath. (2008) Novel therapeutic strategies for treating esophageal adenocarcinoma: The potential of dendritic cell immunotherapy and combinatorial regimens. Human Immunology 69:10, 614-624
CrossRef198
A. Takashima, K. Shirao, Y. Hirashima, D. Takahari, N. Okita, S. Akatsuka, T. Eguchi Nakajima, J. Matsubara, H. Yasui, T. Asakawa, K. Kato, T. Hamguchi, K. Muro, Y. Yamada, Y. Shimada. (2008) Chemosensitivity of patients with recurrent esophageal cancer receiving perioperative chemotherapy. Diseases of the Esophagus 21:7, 607-611
CrossRef199
J. Theisen, K. Danenberg, K. Ott, K. Becker, P. Danenberg, H. J. Stein, J.-R. Siewert. (2008) Predictors of response and survival for neoadjuvant treated patients with esophageal adenocarcinoma. Diseases of the Esophagus 21:7, 601-606
CrossRef200
Robert A. Wolff, Gauri R. Varadhachary, Douglas B. Evans. (2008) Adjuvant Therapy for Adenocarcinoma of the Pancreas: Analysis of Reported Trials and Recommendations for Future Progress. Annals of Surgical Oncology 15:10, 2773-2786
CrossRef201
S. J. Crane, G. R. Locke, W. S. Harmsen, A. R. Zinsmeister, Y. Romero, N. J. Talley. (2008) Survival Trends in Patients With Gastric and Esophageal Adenocarcinomas: A Population-Based Study. Mayo Clinic Proceedings 83:10, 1087-1094
CrossRef202
Heta Javeri, Rohan Arora, Arlene M. Correa, Wayne L. Hofstetter, Jeffrey H. Lee, Zhongxing Liao, Mary F. McAleer, Dipen Maru, Manoop S. Bhutani, Stephen G. Swisher, Julie G. Izzo, Jaffer A. Ajani. (2008) Influence of induction chemotherapy and class of cytotoxics on pathologic response and survival after preoperative chemoradiation in patients with carcinoma of the esophagus. Cancer 113:6, 1302-1308
CrossRef203
Simon Ekman, Martin Dreilich, Johan Lennartsson, Bengt Wallner, Daniel Brattström, Magnus Sundbom, Michael Bergqvist. (2008) Esophageal cancer: current and emerging therapy modalities. Expert Review of Anticancer Therapy 8:9, 1433-1448
CrossRef204
R. N. Keswani, A. Chumsangsri, R. Mustafi, J. Delgado, E. E. W. Cohen, M. Bissonnette. (2008) Sorafenib inhibits MAPK-mediated proliferation in a Barrett's esophageal adenocarcinoma cell line. Diseases of the Esophagus 21:6, 514-521
CrossRef205
L. A. Healy, A. M. Ryan, J. Moore, S. Rowley, N. Ravi, P. J. Byrne, J. V. Reynolds. (2008) Health-related quality of life assessment at presentation may predict complications and early relapse in patients with localized cancer of the esophagus. Diseases of the Esophagus 21:6, 522-528
CrossRef206
G. F. Tillman, T. Pawlicki, A. C. Koong, K. A. Goodman. (2008) Preoperative versus postoperative radiotherapy for locally advanced gastroesophageal junction and proximal gastric cancers: a comparison of normal tissue radiation doses. Diseases of the Esophagus 21:5, 437-444
CrossRef207
Min Kyoung Kim, Sung- Bae Kim, Jin Hee Ahn, Yong Hee Kim, Jong Hoon Kim, Hwoon Yong Jung, Gin Hyug Lee, Kee Don Choi, Ho-Young Song, Ji Hoon Shin, Kyung-Ja Cho, Jin-Sook Ryu, Seung-Il Park. (2008) Treatment Outcome and Recursive Partitioning Analysis-Based Prognostic Factors in Patients With Esophageal Squamous Cell Carcinoma Receiving Preoperative Chemoradiotherapy. International Journal of Radiation Oncology*Biology*Physics 71:3, 725-734
CrossRef208
Ichirou Higuchi, Takushi Yasuda, Masahiko Yano, Yuichirou Doki, Hiroshi Miyata, Mitsuaki Tatsumi, Hironori Fukunaga, Shuji Takiguchi, Yoshiyuki Fujiwara, Jun Hatazawa, Morito Monden. (2008) Lack of fludeoxyglucose F 18 uptake in posttreatment positron emission tomography as a significant predictor of survival after subsequent surgery in multimodality treatment for patients with locally advanced esophageal squamous cell carcinoma. The Journal of Thoracic and Cardiovascular Surgery 136:1, 205-212.e3
CrossRef209
Toni Lerut, Johnny Moons, Willy Coosemans, Herbert Decaluwé, Georges Decker, Paul De Leyn, Philippe Nafteux, Dirk Van Raemdonck. (2008) Multidisciplinary Treatment of Advanced Cancer of the Esophagus and Gastroesophageal Junction: A European Center's Approach. Surgical Oncology Clinics of North America 17:3, 485-502
CrossRef210
N. A. Jennings, S. M. Griffin, P. J. Lamb, S. Preston, D. Richardson, D. Karat, N. Hayes. (2008) Prospective study of bone scintigraphy as a staging investigation for oesophageal carcinoma. British Journal of Surgery 95:7, 840-844
CrossRef211
R. Ogawa, H. Ishiguro, Y. Kuwabara, M. Kimura, A. Mitsui, Y. Mori, R. Mori, K. Tomoda, T. Katada, K. Harada, Y. Fujii. (2008) Identification of candidate genes involved in the radiosensitivity of esophageal cancer cells by microarray analysis. Diseases of the Esophagus 21:4, 288-297
CrossRef212
Arjun Pennathur, James D. Luketich, Rodney J. Landreneau, Julie Ward, Neil A. Christie, Michael K. Gibson, Matthew Schuchert, Kristi Cooper, Stephanie R. Land, Chandra P. Belani. (2008) Long-Term Results of a Phase II Trial of Neoadjuvant Chemotherapy Followed by Esophagectomy for Locally Advanced Esophageal Neoplasm. The Annals of Thoracic Surgery 85:6, 1930-1937
CrossRef213
Neal W. Wilkinson, James Howe, Greer Gay, Lina Patel-Parekh, Carol Scott-Conner, John Donohue. (2008) Differences in the Pattern of Presentation and Treatment of Proximal and Distal Gastric Cancer: Results of the 2001 Gastric Patient Care Evaluation. Annals of Surgical Oncology 15:6, 1644-1650
CrossRef214
Yixing Jiang, Eric T Kimchi, Alberto J Montero, Kevin F Staveley-O’Carroll, Jaffer A Ajani. (2008) Upper gastrointestinal tumors: current status and future perspectives. Expert Review of Anticancer Therapy 8:6, 975-991
CrossRef215
C. Rizzetto, S.R. DeMeester, J.A. Hagen, C.G. Peyre, J.C. Lipham, T.R. DeMeester. (2008) En bloc esophagectomy reduces local recurrence and improves survival compared with transhiatal resection after neoadjuvant therapy for esophageal adenocarcinoma. The Journal of Thoracic and Cardiovascular Surgery 135:6, 1228-1236
CrossRef216
Daniel Vallböhmer, Elmar Kuhn, Ute Warnecke-Eberz, Jan Brabender, Andreas C Hoffmann, Ralf Metzger, Stephan E Baldus, Uta Drebber, Arnulf H Hoelscher, Paul M Schneider. (2008) Failure in downregulation of intratumoral survivin expression following neoadjuvant chemoradiation in esophageal cancer. Pharmacogenomics 9:6, 681-690
CrossRef217
Katsuhiko Higuchi, Wasaburo Koizumi, Satoshi Tanabe, Tohru Sasaki, Chikatoshi Katada, Hiromichi Ishiyama, Kazushige Hayakawa. (2008) A phase I trial of definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced esophageal carcinoma: Kitasato digestive disease & oncology group trial (KDOG 0501). Radiotherapy and Oncology 87:3, 398-404
CrossRef218
Nikhil I. Khushalani. (2008) Cancer of the Esophagus and Stomach. Mayo Clinic Proceedings 83:6, 712-722
CrossRef219
N. I. Khushalani. (2008) Cancer of the Esophagus and Stomach. Mayo Clinic Proceedings 83:6, 712-722
CrossRef220
Matthew Wilson, Ernest L. Rosato, Karen A. Chojnacki, Inna Chervoneva, John C. Kairys, Herbert E. Cohn, Francis E. Rosato, Adam C. Berger. (2008) Prognostic Significance of Lymph Node Metastases and Ratio in Esophageal Cancer. Journal of Surgical Research 146:1, 11-15
CrossRef221
A. Gines, S. D. Cassivi, J. A. Martenson, C. Schleck, C. Deschamps, F. A. Sinicrope, S. R. Alberts, J. A. Murray, Alan R. Zinsmeister, Enrique Vazquez-Sequeiros, F. C. Nichols, R. C. Miller, J. F. Quevedo, M. S. Allen, J. A. Alexander, T. Zais, M. G. Haddock, Y. Romero. (2008) Impact of endoscopic ultrasonography and physician specialty on the management of patients with esophagus cancer. Diseases of the Esophagus 21:3, 241-250
CrossRef222
Esther van Meerten, Ate van der Gaast, Caspar W.N. Looman, Hugo W.G. Tilanus, Karin Muller, Marie-Louise Essink-Bot. (2008) Quality of Life During Neoadjuvant Treatment and After Surgery for Resectable Esophageal Carcinoma. International Journal of Radiation Oncology*Biology*Physics 71:1, 160-166
CrossRef223
S. Abd-Aziz, L.G.A. Ong, M.A. Hassan, M.I.A. Karim. (2008) Process Parameters Optimisation of Mannanase Production from Aspergillus niger FTCC 5003 Using Palm Kernel Cake as Carbon Source. Asian Journal of Biochemistry 3:5, 297-307
CrossRef224
James M. McLoughlin, Marcovalerio Melis, Erin M. Siegel, E. Michelle Dean, Jill M. Weber, Jeannie Chern, Melanie Elliott, Scott T. Kelley, Richard C. Karl. (2008) Are Patients with Esophageal Cancer Who Become PET Negative after Neoadjuvant Chemoradiation Free of Cancer?. Journal of the American College of Surgeons 206:5, 879-886
CrossRef225
C.M. Gillham, N. Aherne, S. Rowley, J. Moore, D. Hollywood, K. O'Byrne, J.V. Reynolds. (2008) Quality of Life and Survival in Patients Treated with Radical Chemoradiation Alone for Oesophageal Cancer. Clinical Oncology 20:3, 227-233
CrossRef226
H. Wilke, N. Willich, H.-J. Meyer, M. Stahl. (2008) Neoadjuvante und perioperative Therapie des Magenkarzinoms. Der Onkologe 14:4, 370-380
CrossRef227
Theresa D. Luu, Puja Gaur, Seth D. Force, Charles A. Staley, Kamal A. Mansour, Joseph I. Miller, Daniel L. Miller. (2008) Neoadjuvant Chemoradiation Versus Chemotherapy for Patients Undergoing Esophagectomy for Esophageal Cancer. The Annals of Thoracic Surgery 85:4, 1217-1224
CrossRef228
B. M. Smithers, G. C. Couper, J. M. Thomas, D. Wong, D. C. Gotley, I. Martin, J. A. Harvey, D. B. Thomson, E. T. Walpole, N. Watts, B. H. Burmeister. (2008) Positron emission tomography and pathological evidence of response to neoadjuvant therapy in adenocarcinoma of the esophagus. Diseases of the Esophagus 21:2, 151-158
CrossRef229
Brian G. Czito, Darrel P. Cohen, Chris R. Kelsey, A. Craig Lockhart, Johanna C. Bendell, Christopher G. Willett, William P. Petros, Thomas A. D'Amico, Roxanne Truax, Herbert I. Hurwitz. (2008) A Phase I Study of UFT/Leucovorin, Carboplatin, and Paclitaxel in Combination With External Beam Radiation Therapy for Advanced Esophageal Carcinoma. International Journal of Radiation Oncology*Biology*Physics 70:4, 1066-1072
CrossRef230
Vahide I. Ugur, Sakire P. Kara, Bulent Kucukplakci, Taciser Demirkasimoglu, Cem Misirlioglu, Aytul Ozgen, Yesim Elgin, Ergun Sanri, Kadri Altundag, Nadi Ozdamar. (2008) Clinical characteristics and outcome of patients with stage III esophageal carcinoma: a single-center experience from Turkey. Medical Oncology 25:1, 63-68
CrossRef231
John S. Moody, Stephen M. Sawrie, Kevin R. Kozak, John P. Plastaras, George Howard, James A. Bonner. (2008) Stage-Specific Survival Differences Associated with Postoperative Radiotherapy for Gastrointestinal Cancers. Journal of Gastrointestinal Cancer 39:1-4, 86-99
CrossRef232
Patrick B. McDonough, David R. Jones, K. R. Shen, Patrick G. Northup, Roman L. Galysh, Alfredo Hernandez, Grace E. White, Michel Kahaleh, Vanessa M. Shami. (2008) Does FDG-PET Add Information to EUS and CT in the Initial Management of Esophageal Cancer? A Prospective Single Center Study. The American Journal of Gastroenterology 103:3, 570-574
CrossRef233
Masaki Nakamura, Makoto Iwahashi, Mikihito Nakamori, Koichiro Ishida, Teiji Naka, Takeshi Iida, Masahiro Katsuda, Toshiaki Tsuji, Yoshihiro Nakatani, Hiroki Yamaue. (2008) An analysis of the factors contributing to a reduction in the incidence of pulmonary complications following an esophagectomy for esophageal cancer. Langenbeck's Archives of Surgery 393:2, 127-133
CrossRef234
Heath B. Mackley, Jonathan S. Adelstein, Chandana A. Reddy, David J. Adelstein, Thomas W. Rice, Jerrold P. Saxton, Gregory M. M. Videtic. (2008) Choice of Radiotherapy Planning Modality Influences Toxicity in the Treatment of Locally Advanced Esophageal Cancer. Journal of Gastrointestinal Cancer 39:1-4, 130-137
CrossRef235
Silvia Gómez Senent, César Gómez Raposo, José María Segura Cabral. (2008) Cáncer de esófago. Medicina Clínica 130:11, 423-428
CrossRef236
E. Samalin, M. Ychou. (2008) Le point sur les traitements adjuvants et néoadjuvants des adénocarcinomes œsogastriques. Oncologie 10:3, 175-181
CrossRef237
Arjun Pennathur, James D. Luketich. (2008) Resection for Esophageal Cancer: Strategies for Optimal Management. The Annals of Thoracic Surgery 85:2, S751-S756
CrossRef238
Ji Young Jang. (2008) The Outcome of Conventional External Beam Radiotherapy for Patients with Squamous Cell Carcinoma of the Esophagus. The Journal of the Korean Society for Therapeutic Radiology and Oncology 26:1, 17
CrossRef239
A. Adenis, C. Mariette, X. Mirabel, T. Sarrazin, E. Lartigau, J.P. Triboulet. (2008) Acute respiratory disease syndrome with preoperative chronomodulated chemoradiotherapy in patients with esophageal cancer. Early termination of a phase I trial. European Journal of Surgical Oncology (EJSO) 34:1, 30-35
CrossRef240
Min Kyoung Kim, Kyung-Ja Cho, Gui Young Kwon, Seung-Il Park, Yong Hee Kim, Jong Hoon Kim, Ho-Young Song, Ji Hoon Shin, Hwoon Yong Jung, Gin Hyug Lee, Kee Don Choi, Sung-Bae Kim. (2008) ERCC1 predicting chemoradiation resistance and poor outcome in oesophageal cancer. European Journal of Cancer 44:1, 54-60
CrossRef241
Víctor Valentí, Rally Fares, Neal Reynolds, Patricia Cohen, Nick Theodoro, Alberto Martínez-Isla. (2008) Esofagectomía transhiatal por vía abierta y vía laparoscópica para el cáncer de esófago: análisis de los márgenes de resección y ganglios linfáticos. Cirugía Española 83:1, 24-27
CrossRef242
O Kyu Noh, Hyoung Uk Je, Sung Bae Kim, Gin Hyug Lee, Seung Il Park, Si Yeol Song, Sang-wook Lee, Seung Do Ahn, Eun Kyung Choi, Jong Hoon Kim. (2008) Results of Definitive Chemoradiotherapy for Unresectable Esophageal Cancer. The Journal of the Korean Society for Therapeutic Radiology and Oncology 26:4, 195
CrossRef243
L. Schoot, E. A. P. M. Romme, M. J. Sangen, G. J. Creemers, G. Lijnschoten, O. J. Repelaer Driel, H. J. T. Rutten, G. A. P. Nieuwenhuijzen. (2008) A Highly Active and Tolerable Neoadjuvant Regimen Combining Paclitaxel, Carboplatin, 5-FU, and Radiation Therapy in Patients with Stage II and III Esophageal Cancer. Annals of Surgical Oncology 15:1, 88-95
CrossRef244
Eugene Y. Chang, Xin Li, Michael Jerosch-Herold, Ryan A. Priest, C. Kristian Enestvedt, Jingang Xu, Charles S. Springer, Blair A. Jobe. (2008) The Evaluation of Esophageal Adenocarcinoma Using Dynamic Contrast-Enhanced Magnetic Resonance Imaging. Journal of Gastrointestinal Surgery 12:1, 166-175
CrossRef245
Michael W. Wouters, Bas P. Wijnhoven, Henrieke E. Karim-Kos, Harriet G. Blaauwgeers, Laurents P. Stassen, Willem-Hans Steup, Huug W. Tilanus, Rob A. Tollenaar. (2008) High-Volume versus Low-Volume for Esophageal Resections for Cancer: The Essential Role of Case-Mix Adjustments based on Clinical Data. Annals of Surgical Oncology 15:1, 80-87
CrossRef246
Jurjen J Boonstra, Winand NM Dinjens, Hugo W Tilanus, Linetta B Koppert. (2007) Molecular biological challenges in he treatment of esophageal adenocarcinoma. Expert Review of Gastroenterology & Hepatology 1:2, 275-286
CrossRef247
M. A. Morgan, W. G. Lewis, T. D. L. Crosby, X. Escofet, S. A. Roberts, A. E. Brewster, T. J. Harvard, G. W. B. Clark. (2007) Prospective cohort comparison of neoadjuvant chemoradiotherapyversus chemotherapy in patients with oesophageal cancer. British Journal of Surgery 94:12, 1509-1514
CrossRef248
Nabil P. Rizk, Venkatraman E. Seshan, Manjit S. Bains, David H. Ilson, Bruce D. Minsky, Laura Tang, Valerie W. Rusch. (2007) Prognostic Factors After Combined Modality Treatment of Squamous Cell Carcinoma of the Esophagus. Journal of Thoracic Oncology 2:12, 1117-1123
CrossRef249
Markus Moehler, P.R. Galle, I. Gockel, T. Junginger, H. Schmidberger. (2007) Multimodal treatment of gastric cancer. Best Practice & Research Clinical Gastroenterology 21:6, 965-981
CrossRef250
Kiichi Maezato, Tadashi Nishimaki, Mariko Oshiro, Toshimitu Yamashiro, Hideaki Sasaki, Yasunori Sashida. (2007) Signet-Ring Cell Carcinoma of the Esophagus Associated with Barrett's Epithelium: Report of a Case. Surgery Today 37:12, 1096-1101
CrossRef251
Ahmad Faried, Leri S. Faried, Nurhayat Usman, Hiroyuki Kato, Hiroyuki Kuwano. (2007) Clinical and Prognostic Significance of RhoA and RhoC Gene Expression in Esophageal Squamous Cell Carcinoma. Annals of Surgical Oncology 14:12, 3593-3601
CrossRef252
Anna L Paterson, Rebecca C Fitzgerald. (2007) Biomarkers in Barrett's oesophagus and oesophageal adenocarcinoma. Expert Opinion on Medical Diagnostics 1:3, 363-376
CrossRef253
Laura A. Healy, Aoife M. Ryan, Bussa Gopinath, Suzanne Rowley, Patrick J. Byrne, John V. Reynolds. (2007) Impact of obesity on outcomes in the management of localized adenocarcinoma of the esophagus and esophagogastric junction. The Journal of Thoracic and Cardiovascular Surgery 134:5, 1284-1291
CrossRef254
Chris R. Kelsey, Junzo P. Chino, Christopher G. Willett, Robert W. Clough, Herbert I. Hurwitz, Michael A. Morse, Johanna C. Bendell, Thomas A. D'Amico, Brian G. Czito. (2007) Paclitaxel-Based Chemoradiotherapy in the Treatment of Patients With Operable Esophageal Cancer. International Journal of Radiation Oncology*Biology*Physics 69:3, 770-776
CrossRef255
Rebecca Kristeleit, Yujo Chua, David Cunningham. 2007. Multidisciplinary Team Management of Upper Gastrointestinal, Hepatic, Pancreatic, and Biliary Cancers. .
CrossRef256
Alberto Ruol, Giuseppe Portale, Carlo Castoro, Stefano Merigliano, Matteo Cagol, Francesco Cavallin, Vanna Chiarion Sileni, Luigi Corti, Sabrina Rampado, Mario Costantini, Ermanno Ancona. (2007) Effects of Neoadjuvant Therapy on Perioperative Morbidity in Elderly Patients Undergoing Esophagectomy for Esophageal Cancer. Annals of Surgical Oncology 14:11, 3243-3250
CrossRef257
Andrew P. Barbour, Nabil P. Rizk, Hans Gerdes, Manjit S. Bains, Valerie W. Rusch, Murray F. Brennan, Daniel G. Coit. (2007) Endoscopic Ultrasound Predicts Outcomes for Patients with Adenocarcinoma of the Gastroesophageal Junction. Journal of the American College of Surgeons 205:4, 593-601
CrossRef258
Aminah Jatoi, James A. Martenson, Nathan R. Foster, Howard L. McLeod, Bradley S. Lair, Frank Nichols, Loren K. Tschetter, Dennis F. Moore, Tom R. Fitch, Steven R. Alberts. (2007) Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiation for Locally Advanced Esophageal Cancer. American Journal of Clinical Oncology 30:5, 507-513
CrossRef259
Yi-Jen Chen, An Liu, Chunhui Han, Peter T. Tsai, Timothy E. Schultheiss, Richard D. Pezner, Nilesh Vora, Dean Lim, Stephen Shibata, Kemp H. Kernstine, Jeffrey Y.C. Wong. (2007) Helical Tomotherapy for Radiotherapy in Esophageal Cancer: A Preferred Plan With Better Conformal Target Coverage and More Homogeneous Dose Distribution. Medical Dosimetry 32:3, 166-171
CrossRef260
Mark B. Orringer, Becky Marshall, Andrew C. Chang, Julia Lee, Allan Pickens, Christine L. Lau. (2007) Two Thousand Transhiatal Esophagectomies. Annals of Surgery 246:3, 363-374
CrossRef261
Rahul A. Shimpi, Josh George, Paul Jowell, Frank G. Gress. (2007) Staging of esophageal cancer by EUS: staging accuracy revisited. Gastrointestinal Endoscopy 66:3, 475-482
CrossRef262
Ahmad Faried, Leri S. Faried, Takashi Nakagawa, Takahito Yamauchi, Mami Kitani, Hiroyuki Sasabe, Toyo Nishimura, Nurhayat Usman, Hiroyuki Kato, Takayuki Asao, Hiroyuki Kuwano, Shin Yazawa. (2007) Chemically synthesized sugar-cholestanols possess a preferential anticancer activity involving promising therapeutic potential against human esophageal cancer. Cancer Science 98:9, 1358-1367
CrossRef263
Marcelo Mamede, Paula Abreu-e-Lima, Maria Raquel Oliva, V??nia Nos??, Harvey Mamon, Victor H. Gerbaudo. (2007) FDG-PET/CT Tumor Segmentation-Derived Indices of Metabolic Activity to Assess Response to Neoadjuvant Therapy and Progression-Free Survival in Esophageal Cancer. American Journal of Clinical Oncology 30:4, 377-388
CrossRef264
S. Mesenas, C. Vu, M. McStay, M. Forshaw, L. Doig, R. Mason, N. Boyle, J. Meenan. (2007) A large series, resection controlled study to assess the value of radial EUS in restaging gastroesophageal cancer following neoadjuvant chemotherapy. Diseases of the Esophagus 0:0, 070723104350005-???
CrossRef265
Emmanuelle Samalin, Marc Ychou. (2007) Neoadjuvant treatment in upper gastrointestinal adenocarcinomas: new paradigms from old concepts?. Current Opinion in Oncology 19:4, 384-389
CrossRef266
Christopher J. Shearer, James J. Going, Lisa J. Neilson, Robert C. Stuart. (2007) MODIFIED CLASSIFICATION FOR ADENOCARCINOMA OF THE GASTRO-OESOPHAGEAL JUNCTION. ANZ Journal of Surgery 77:7, 544-549
CrossRef267
Yasuyuki Seto, Keisho Chin, Kotaro Gomi, Takuyo Kozuka, Takashi Fukuda, Kazuhiko Yamada, Toshiki Matsubara, Masanori Tokunaga, Yo Kato, Akifumi Yafune, Toshiharu Yamaguchi. (2007) Treatment of thoracic esophageal carcinoma invading adjacent structures. Cancer Science 98:7, 937-942
CrossRef268
J. C. Clifton, R. J. Finley, G. Gelfand, A. J. Graham, R. Inculet, R. Malthaner, L. Tan, J. Lim, J. Singer, C. Lovato. (2007) Development and validation of a disease-specific quality of life questionnaire (EQOL) for potentially curable patients with carcinoma of the esophagus. Diseases of the Esophagus 20:3, 191-201
CrossRef269
L. Walshe, S. Rowley, M. Coffey, D. Hollywood, M. J. Kennedy, C. Gillham, N. Ravi, J. V. Reynolds. (2007) Comparison of two fractionation regimens in the multimodal therapy of cancer of the esophagus. Diseases of the Esophagus 20:3, 217-224
CrossRef270
M. A. Morgan, W. G. Lewis, A. N. Hopper, X. Escofet, T. J. Havard, A. E. Brewster, T. D. L. Crosby, S. A. Roberts, G. W. B. Clark. (2007) Prospective comparison of transthoracic versus transhiatal esophagectomy following neoadjuvant therapy for esophageal cancer. Diseases of the Esophagus 20:3, 225-231
CrossRef271
Min Kyoung Kim, Jin-Sook Ryu, Sung-Bae Kim, Jin Hee Ahn, Soo Young Kim, Seung-II Park, Yong Hee Kim, Ho Yong Song, Ji Hoon Shin, Hwoon Yong Jung, Gin Hyug Lee, Kee Don Choi, Kyung-Ja Cho, Jong Hoon Kim. (2007) Value of complete metabolic response by 18F-fluorodeoxyglucose-positron emission tomography in oesophageal cancer for prediction of pathologic response and survival after preoperative chemoradiotherapy. European Journal of Cancer 43:9, 1385-1391
CrossRef272
Christophe Mariette, Guillaume Piessen, Jean-Pierre Triboulet. (2007) Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities. The Lancet Oncology 8:6, 545-553
CrossRef273
Zhongxing Liao, James D. Cox, Ritsuko Komaki. (2007) Radiochemotherapy of Esophageal Cancer. Journal of Thoracic Oncology 2:6, 553-568
CrossRef274
Geoffrey Y. Ku, David H. Ilson. (2007) Esophageal Cancer: Adjuvant Therapy. The Cancer Journal 13:3, 162-167
CrossRef275
Eugene Y. Chang, Christina A. Smith, Christopher L. Corless, Charles R. Thomas, John G. Hunter, Blair A. Jobe. (2007) Accuracy of pathologic examination in detection of complete response after chemoradiation for esophageal cancer. The American Journal of Surgery 193:5, 614-617
CrossRef276
John Vincent Reynolds, Cian Muldoon, Donal Hollywood, Narayanasamy Ravi, Suzanne Rowley, Ken O???Byrne, John Kennedy, Thomas J. Murphy. (2007) Long-term Outcomes Following Neoadjuvant Chemoradiotherapy for Esophageal Cancer. Annals of Surgery 245:5, 707-716
CrossRef277
Harry H. Yoon, Michael K. Gibson. (2007) Combined-modality therapy for esophageal and gastroesophageal junction cancers. Current Oncology Reports 9:3, 184-192
CrossRef278
Lawrence Kleinberg, Michael K Gibson, Arlene A Forastiere. (2007) Chemoradiotherapy for localized esophageal cancer: regimen selection and molecular mechanisms of radiosensitization. Nature Clinical Practice Oncology 4:5, 282-294
CrossRef279
James M. O’Riordan, Suzanne Rowley, James O. Murphy, Narayasami Ravi, Patrick J. Byrne, John V. Reynolds. (2007) Impact of Solitary Involved Lymph Node on Outcome in Localized Cancer of the Esophagus and Esophagogastric Junction. Journal of Gastrointestinal Surgery 11:4, 493-499
CrossRef280
David J. Adelstein, Thomas W. Rice, Lisa A. Rybicki, Jerrold P. Saxton, Gregory M. M. Videtic, Sudish C. Murthy, Gregory Zuccaro, John J. Vargo, John A. Dumot, Marjorie A. Carroll. (2007) A Phase II Trial of Accelerated Multimodality Therapy for Locoregionally Advanced Cancer of the Esophagus and Gastroesophageal Junction. American Journal of Clinical Oncology 30:2, 172-180
CrossRef281
Andrew J. Graham, Fiona M. Shrive, William A. Ghali, Braden J. Manns, Sean C. Grondin, Richard J. Finley, Joanne Clifton. (2007) Defining the Optimal Treatment of Locally Advanced Esophageal Cancer: A Systematic Review and Decision Analysis. The Annals of Thoracic Surgery 83:4, 1257-1264
CrossRef282
H. McKean, R. C. Miller, A. Jatoi. (2007) Non-traumatic vertebral fractures in patients with locally advanced esophageal cancer: a previously unreported, unrecognized problem. Diseases of the Esophagus 20:2, 102-106
CrossRef283
Luis F. Oñate-Ocaña, Gonzalo Milán-Revollo, Vincenzo Aiello-Crocifoglio, José F. Carrillo, Dolores Gallardo-Rincón, Rocío Brom-Valladares, Roberto Herrera-Goepfert, Alfonso Dueñas-González. (2007) Treatment of the Adenocarcinoma of the Esophagogastric Junction at a Single Institution in Mexico. Annals of Surgical Oncology 14:4, 1439-1448
CrossRef284
Grant R. Caddy, Robert Y. Chen. (2007) CURRENT CLINICAL APPLICATIONS OF ENDOSCOPIC ULTRASOUND. ANZ Journal of Surgery 77:3, 101-111
CrossRef285
Brigid M. OʼConnor, Manpreet Kaur Chadha, Amitkumar Pande, Jeffrey C. Lombardo, Chumy E. Nwogu, Hector R. Nava, Gary Yang, Milind M. Javle. (2007) Concurrent Oxaliplatin, 5-Fluorouracil, and Radiotherapy in the Treatment of Locally Advanced Esophageal Carcinoma. The Cancer Journal 13:2, 119-124
CrossRef286
Brian G. Czito, Chris R. Kelsey, Herbert I. Hurwitz, Chris G. Willett, Michael A. Morse, Gerard C. Blobe, Nishan H. Fernando, Thomas A. D’Amico, David H. Harpole, Wanda Honeycutt, Daohai Yu, Johanna C. Bendell. (2007) A Phase I study of capecitabine, carboplatin, and paclitaxel with external beam radiation therapy for esophageal carcinoma. International Journal of Radiation Oncology*Biology*Physics 67:4, 1002-1007
CrossRef287
Ali A. Siddiqui, David Loren, Robert Dudnick, Thomas Kowalski. (2007) Expandable Polyester Silicon-Covered Stent for Malignant Esophageal Structures before Neoadjuvant Chemoradiation: A Pilot Study. Digestive Diseases and Sciences 52:3, 823-829
CrossRef288
Andrew P. Barbour, Nabil P. Rizk, Mithat Gonen, Laura Tang, Manjit S. Bains, Valerie W. Rusch, Daniel G. Coit, Murray F. Brennan. (2007) Lymphadenectomy for Adenocarcinoma of the Gastroesophageal Junction (GEJ): Impact of Adequate Staging on Outcome. Annals of Surgical Oncology 14:2, 306-316
CrossRef289
Henry Wang, Janice Ryu, David Gandara, Richard J. Bold, Shiro Urayama, Michael Tanaka, Zelanna Goldberg, David Follette, Samir Narayan, Derick Lau. (2007) A Phase II Study of Paclitaxel, Carboplatin, and Radiation with or without Surgery for Esophageal Cancer. Journal of Thoracic Oncology153-157
CrossRef290
Dong W. Kim, Charles D. Blanke, Huiyun Wu, Yu Shyr, Jordan Berlin, R. Daniel Beauchamp, Bapsi Chakravarthy. (2007) Phase II study of preoperative paclitaxel/cisplatin with radiotherapy in locally advanced esophageal cancer. International Journal of Radiation Oncology*Biology*Physics 67:2, 397-404
CrossRef291
David J. Bowrey, Martyn D. Evans, Geoffrey W. B. Clark. (2007) Impact of Methicillin-resistant Staphylococcus aureus Infection on Outcome after Esophagectomy. World Journal of Surgery 31:2, 326-331
CrossRef292
Klaus L. Prenzel, Alexandra König, Paul M. Schneider, Christian Schnickmann, Stephan E. Baldus, Wolfgang Schröder, Elfriede Bollschweiler, Hans P. Dienes, Rolf P. Mueller, Jakob R. Izbicki, Arnulf H. Hölscher. (2007) Reduced Incidence of Nodal Micrometastasis after Major Response to Neoadjuvant Chemoradiation in Locally Advanced Esophageal Cancer. Annals of Surgical Oncology 14:2, 954-959
CrossRef293
D.P. Cronin-Fenton, L. Sharp, A.-E. Carsin, H. Comber. (2007) Patterns of care and effects on mortality for cancers of the oesophagus and gastric cardia: A population-based study. European Journal of Cancer 43:3, 565-575
CrossRef294
Mohan Suntharalingam. (2007) Definitive Chemoradiation in the Management of Locally Advanced Esophageal Cancer. Seminars in Radiation Oncology 17:1, 22-28
CrossRef295
Bryan J. Schneider, Susan G. Urba. (2007) Preoperative Chemoradiation for the Treatment of Locoregional Esophageal Cancer: The Standard of Care?. Seminars in Radiation Oncology 17:1, 45-52
CrossRef296
John F. Bruzzi, Stephen G. Swisher, Mylene T. Truong, Reginald F. Munden, Wayne L. Hofstetter, Homer A. Macapinlac, Arlene M. Correa, Osama Mawlawi, Jaffer A. Ajani, Ritsuko R. Komaki, Norio Fukami, Jeremy J. Erasmus. (2007) Detection of interval distant metastases. Cancer 109:1, 125-134
CrossRef297
Chilukuri Srinivas, Sarbani Ghosh Laskar, R.C. Mistry, C.S. Pramesh, K.A. Dinshaw. (2007) Systematic overview of preoperative chemoradiation trials in esophageal cancer: In response to article by Ian Geh et al.. Radiotherapy and Oncology 82:1, 106-107
CrossRef298
Christopher Jackson, Naureen Starling, Yu Jo Chua, David Cunningham. (2007) Pharmacotherapy for Oesophagogastric Cancer. Drugs 67:17, 2539-2556
CrossRef299
Thomas Höhler, Claus Rödel, Arnulf H. Hölscher, Salah-Eddin Al-Batran. (2007) Neoadjuvante und palliative Therapie des Ösophagus- und Magenkarzinoms. Onkologie 30:2, 23-26
CrossRef300
Theodore S. Hong, Elizabeth M. Crowley, Joseph Killoran, Harvey J. Mamon. (2007) Considerations in Treatment Planning for Esophageal Cancer. Seminars in Radiation Oncology 17:1, 53-61
CrossRef301
Takashi KOBAYASHI, Masanori TERUYA, Hozumi TANAKA, Kaoru KOBAYASHI, Koji MORITA. (2007) EVALUATION OF NEOADJUVANT CHEMORADIOTHERAPY IN CLINICAL STAGE II AND III ESOPHAGEAL SQUAMOUS CELL CARCINOMA IN A REGIONAL CENTER HOSPITAL. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association) 68:12, 2931-2939
CrossRef302
Tsung-Teh Wu, Lucian R. Chirieac, Susan C. Abraham, Alyssa M. Krasinskas, Huamin Wang, Asif Rashid, Arlene M. Correa, Wayne L. Hofstetter, Jaffer A. Ajani, Stephen G. Swisher. (2007) Excellent Interobserver Agreement on Grading the Extent of Residual Carcinoma After Preoperative Chemoradiation in Esophageal and Esophagogastric Junction Carcinoma: A Reliable Predictor for Patient Outcome. The American Journal of Surgical Pathology 31:1, 58-64
CrossRef303
Jeremy J. Erasmus, Reginald F. Munden. (2007) The Role of Integrated Computed Tomography Positron-Emission Tomography in Esophageal Cancer: Staging and Assessment of Therapeutic Response. Seminars in Radiation Oncology 17:1, 29-37
CrossRef304
Takashi Yoshioka, Masato Sakayori, Shunsuke Kato, Natsuko Chiba, Shukichi Miyazaki, Kenji Nemoto, Hiroyuki Shibata, Hideki Shimodaira, Kazunori Ohtsuka, Yuichi Kakudo, Yuh Sakata, Chikashi Ishioka. (2006) Dose escalation study of docetaxel and nedaplatin in patients with relapsed or refractory squamous cell carcinoma of the esophagus pretreated using cisplatin, 5-fluorouracil, and radiation. International Journal of Clinical Oncology 11:6, 454-460
CrossRef305
S. J. Dawson, M. Michael, J. Biagi, K. F. Foo, M. Jefford, S. Y. Ngan, T. Leong, A. Hui, A. D. Milner, R. J. S. Thomas, J. R. Zalcberg. (2006) A phase I/II trial of celecoxib with chemotherapy and radiotherapy in the treatment of patients with locally advanced oesophageal cancer. Investigational New Drugs 25:2, 123-129
CrossRef306
Andrew M. Lowy, Irfan Firdaus, Debasish Roychowdhury, Kevin Redmond, John A. Howington, Jeffrey J. Sussman, Malek Safa, Syed A. Ahmad, Michael F. Reed, Patricia Rose, Laura James, Abdul Rahman Jazieh. (2006) A Phase II Study of Sequential Neoadjuvant Gemcitabine and Paclitaxel, Radiation Therapy With Cisplatin and 5-Fluorouracil and Surgery in Locally Advanced Esophageal Carcinoma. American Journal of Clinical Oncology 29:6, 555-561
CrossRef307
K. P. McKian, R. C. Miller, S. D. Cassivi, A. Jatoi. (2006) Curing patients with locally advanced esophageal cancer: an update on multimodality therapy. Diseases of the Esophagus 19:6, 448-453
CrossRef308
R. C. Miller, M. G. Haddock, L. L. Gunderson, J. H. Donohue, V. F. Trastek, S. R. Alberts, C. Deschamps. (2006) Intraoperative radiotherapy for treatment of locally advanced and recurrent esophageal and gastric adenocarcinomas. Diseases of the Esophagus 19:6, 487-495
CrossRef309
Ioannis Rouvelas, Wenyi Zeng, Mats Lindblad, Pernilla Viklund, Weimin Ye, Jesper Lagergren. (2006) Survival After Neoadjuvant Therapy Compared with Surgery Alone for Resectable Esophageal Cancer in a Population-based Study. World Journal of Surgery 30:12, 2182-2190
CrossRef310
K. Ott, W. Weber, J.-R. Siewert. (2006) The importance of PET in the diagnosis and response evaluation of esophageal cancer. Diseases of the Esophagus 19:6, 433-442
CrossRef311
C M Gillham, J A Lucey, M Keogan, G J Duffy, V Malik, A A Raouf, K O'Byrne, D Hollywood, C Muldoon, J V Reynolds. (2006) 18FDG uptake during induction chemoradiation for oesophageal cancer fails to predict histomorphological tumour response. British Journal of Cancer 95:9, 1174-1179
CrossRef312
Matsuo Nagata, Hiroshi Yamamoto, Nobuhiro Takiguchi, Osamu Kainuma, Akihiro Cho, Mikito Mori, Sohichi Narumoto, Takehide Asano, Kazuo Hatano. (2006) Neoadjuvant chemoradiotherapy followed by esophagectomy versus definitive chemoradiotherapy in resectable stage II/III (T1-3N0, 1M0) esophageal squamous cell carcinoma. Esophagus 3:3, 105-111
CrossRef313
David H. Ilson. (2006) Cancer of the gastroesophageal junction: Current therapy options. Current Treatment Options in Oncology 7:5, 410-423
CrossRef314
R. M. Hermann, O. Horstmann, F. Haller, C. Perske, H. Christiansen, A. Hille, H. Schmidberger, L. Füzesi. (2006) Histomorphological tumor regression grading of esophageal carcinoma after neoadjuvant radiochemotherapy: which score to use?. Diseases of the Esophagus 19:5, 329-334
CrossRef315
John V. Reynolds, Narayanasamy Ravi, Donal Hollywood, M. John Kennedy, Suzanne Rowley, Aoife Ryan, Niall Hughes, Michael Carey, Patrick Byrne. (2006) Neoadjuvant chemoradiation may increase the risk of respiratory complications and sepsis after transthoracic esophagectomy. The Journal of Thoracic and Cardiovascular Surgery 132:3, 549-555
CrossRef316
J. V. Reynolds, R. McLaughlin, J. Moore, S. Rowley, N. Ravi, P. J. Byrne. (2006) Prospective evaluation of quality of life in patients with localized oesophageal cancer treated by multimodality therapy or surgery alone. British Journal of Surgery 93:9, 1084-1090
CrossRef317
S. Chris Malaisrie, Wayne L. Hofstetter, Arlene M. Correa, Jaffer A. Ajani, Ritsuko R. Komaki, David C. Rice, Ara A. Vaporciyan, Garrett L. Walsh, Jack A. Roth, Tsung T. Wu, Stephen G. Swisher. (2006) The addition of induction chemotherapy to preoperative, concurrent chemoradiotherapy improves tumor response in patients with esophageal adenocarcinoma. Cancer 107:5, 967-974
CrossRef318
G. A. Ohnmacht, M. S. Allen, S. D. Cassivi, C. Deschamps, F. C. Nichols, P. C. Pairolero. (2006) Percutaneous endoscopic gastrostomy risks rendering the gastric conduit unusable for esophagectomy. Diseases of the Esophagus 19:4, 311-312
CrossRef319
M. MacGuill, E. Mulligan, N. Ravi, S. Rowley, P. J. Byrne, D. Hollywood, J. Kennedy, P. N. Keeling, J. V. Reynolds. (2006) Clinicopathologic factors predicting complete pathological response to neoadjuvant chemoradiotherapy in esophageal cancer. Diseases of the Esophagus 19:4, 273-276
CrossRef320
Ichinosuke Hyodo. (2006) Promise of definitive chemoradiotherapy for esophageal cancer balanced with late radiation toxicity: an old but new issue. Journal of Gastroenterology 41:5, 504-506
CrossRef321
Afonso Ribeiro, Dido Franceschi, Javier Parra, Alan Livingstone, Mayra Lima, Kara Hamilton-Nelson, Bach Ardalan. (2006) Endoscopic Ultrasound Restaging After Neoadjuvant Chemotherapy in Esophageal Cancer. The American Journal of Gastroenterology 101:6, 1216-1221
CrossRef322
James P. Hamilton, Fumiaki Sato, Bruce D. Greenwald, Mohan Suntharalingam, Mark J. Krasna, Martin J. Edelman, Austin Doyle, Agnes T. Berki, John M. Abraham, Yuriko Mori, Takatsugu Kan, Carmit Mantzur, Bogdan Paun, Suna Wang, Tetsuo Ito, Zhe Jin, Stephen J. Meltzer. (2006) Promoter Methylation and Response to Chemotherapy and Radiation in Esophageal Cancer. Clinical Gastroenterology and Hepatology 4:6, 701-708
CrossRef323
Jeremy J. Erasmus, Reginald F. Munden, Mylene T. Truong, Jeremy J. Ho, Wayne L. Hofstetter, Homer A. Macapinlac, Arlene M. Correa, Tsung-Teh Wu, John F. Bruzzi, Edith M. Marom, Bradley S. Sabloff, Jaffer A. Ajani, Ritsuko Komaki, Zhongxing Liao, Jeffrey H. Lee, Norio Fukami, Robert Bresalier, Stephen G. Swisher. (2006) Preoperative Chemo-Radiation-Induced Ulceration in Patients with Esophageal Cancer: A Confounding Factor in Tumor Response Assessment in Integrated Computed Tomographic-Positron Emission Tomographic Imaging. Journal of Thoracic Oncology 1:5, 478-486
CrossRef324
M. R. Stephens, W. G. Lewis, A. E. Brewster, I. Lord, G. R. J. C. Blackshaw, I. Hodzovic, G. V. Thomas, S. A. Roberts, T. D. L. Crosby, C. Gent, M. C. Allison, K. Shute. (2006) Multidisciplinary team management is associated with improved outcomes after surgery for esophageal cancer. Diseases of the Esophagus 19:3, 164-171
CrossRef325
E van Meerten, K Muller, H W Tilanus, P D Siersema, W M H Eijkenboom, H van Dekken, T C K Tran, A van der Gaast. (2006) Neoadjuvant concurrent chemoradiation with weekly paclitaxel and carboplatin for patients with oesophageal cancer: a phase II study. British Journal of Cancer 94:10, 1389-1394
CrossRef326
M.J. Forshaw, J.A. Gossage, K. Chrystal, K. Cheong, P.G. Harper, R.C. Mason. (2006) Symptomatic Responses to Neoadjuvant Chemotherapy for Carcinoma of the Oesophagus and Oesophagogastric Junction: Are They Worth Measuring?. Clinical Oncology 18:4, 345-350
CrossRef327
Thomas Ng, Thomas Dipetrillo, John Purviance, Howard Safran. (2006) Multimodality treatment of esophageal cancer: A review of the current status and future directions. Current Oncology Reports 8:3, 174-182
CrossRef328
Reginald F. Munden, Homer A. Macapinlac, Jeremy J. Erasmus. (2006) Esophageal Cancer: The Role of Integrated CT-PET in Initial Staging and Response Assessment After Preoperative Therapy. Journal of Thoracic Imaging 21:2, 137-145
CrossRef329
S. Mukherjee, J. Abraham, A. Brewster, R. Hardwick, T. Havard, W. Lewis, C. Askill, J. Manson, G.T. Williams, S.A. Roberts, J. Court, T. Crosby. (2006) Pilot Study of Preoperative Combined Modality Treatment for Locally Advanced Operable Oesophageal Carcinoma: Toxicities and Long-term Outcome. Clinical Oncology 18:4, 338-344
CrossRef330
Edward A. Levine, Michael R. Farmer, Paige Clark, Girish Mishra, Coty Ho, Kim R. Geisinger, Susan A. Melin, James Lovato, Tim Oaks, A William Blackstock. (2006) Predictive Value of 18-Fluoro-Deoxy-Glucose-Positron Emission Tomography (18F-FDG-PET) in the Identification of Responders to Chemoradiation Therapy for the Treatment of Locally Advanced Esophageal Cancer. Annals of Surgery 243:4, 472-478
CrossRef331
W. Hohenberger, T. Bartscher, H. Golcher. (2006) Studien der chirurgischen Onkologie. Der Onkologe 12:4, 356-361
CrossRef332
Christophe Mariette, Jean-Pierre Triboulet. (2006) Should Resectable Esophageal Cancer Be Resected?. Annals of Surgical Oncology 13:4, 447-449
CrossRef333
Arthur Y. Hung, Christopher A. Canning, Kamal M. Patel, John M. Holland, Lisa A. Kachnic. (2006) Radiation Therapy for Gastrointestinal Cancer. Hematology/Oncology Clinics of North America 20:2, 287-320
CrossRef334
Feng-Ming (Spring) Kong, Lujun Zhao, James A. Hayman. (2006) The Role of Radiation Therapy in Thoracic Tumors. Hematology/Oncology Clinics of North America 20:2, 363-400
CrossRef335
Christoph Oehler, I. Frank Ciernik. (2006) Radiation therapy and combined modality treatment of gastrointestinal carcinomas. Cancer Treatment Reviews 32:2, 119-138
CrossRef336
Yan Gu, Stephen G. Swisher, Jaffer A. Ajani, Arlene M. Correa, Wayne L. Hofstetter, Zhongxing Liao, Ritsuko R. Komaki, Asif Rashid, Stanley R. Hamilton, Tsung-Teh Wu. (2006) The number of lymph nodes with metastasis predicts survival in patients with esophageal or esophagogastric junction adenocarcinoma who receive preoperative chemoradiation. Cancer 106:5, 1017-1025
CrossRef337
Ahmad Faried, Leri S. Faried, Hitoshi Kimura, Makoto Sohda, Masanobu Nakajima, Tatsuya Miyazaki, Hiroyuki Kato, Tatsuya Kanuma, Hiroyuki Kuwano. (2006) Differential sensitivity of paclitaxel-induced apoptosis in human esophageal squamous cell carcinoma cell lines. Cancer Chemotherapy and Pharmacology 57:3, 301-308
CrossRef338
Jeffrey G. Gaca, Rebecca P. Petersen, Bercedis L. Peterson, David H. Harpole, Thomas A. D’Amico, Theodore N. Pappas, Hilliard F. Seigler, Walter G. Wolfe, Douglas S. Tyler. (2006) Pathologic Nodal Status Predicts Disease-Free Survival After Neoadjuvant Chemoradiation for Gastroesophageal Junction Carcinoma. Annals of Surgical Oncology 13:3, 340-346
CrossRef339
Leonard R. Henry, Melvyn Goldberg, Walter Scott, Andre Konski, Neal J. Meropol, Gary Freedman, Louis M. Weiner, Perry Watts, Mary Beard, Susan McLaughlin, Jonathan D. Cheng. (2006) Induction Cisplatin and Paclitaxel Followed by Combination Chemoradiotherapy with 5-Fluorouracil, Cisplatin, and Paclitaxel Before Resection in Localized Esophageal Cancer: A Phase II Report. Annals of Surgical Oncology 13:2, 214-220
CrossRef340
Robert G. Wadleigh, Salah Abbasi, Louis Korman. (2006) Palliative Ethanol Injections of Unresectable Advanced Esophageal Carcinoma Combined with Chemoradiation. The American Journal of the Medical Sciences 331:2, 110-112
CrossRef341
Hideomi Yamashita, Keiichi Nakagawa, Masao Tago, Naoki Nakamura, Kenshiro Shiraishi, Ken-ichi Mafune, Michio Kaminishi, Kuni Ohtomo. (2006) Treatment results of preoperative concurrent chemoradiotherapy followed by surgery for stage III or IV esophageal squamous cell carcinoma. Radiation Medicine 24:1, 65-71
CrossRef342
Javier Valencia Julve, Vicente Alonso Orduña, Ricardo Escó Barón, Miriam López-Mata, Agustina Méndez Villamón. (2006) Influence of hemoglobin levels on survival after radical treatment of esophageal carcinoma with radiotherapy. Clinical and Translational Oncology 8:1, 22-30
CrossRef343
Steven R. DeMeester. (2006) Adenocarcinoma of the Esophagus and Cardia: A Review of the Disease and Its Treatment. Annals of Surgical Oncology 13:1, 12-30
CrossRef344
Jason L Hornick, Francis A Farraye, Robert D Odze. (2006) Prevalence and Significance of Prominent Mucin Pools in the Esophagus Post Neoadjuvant Chemoradiotherapy for Barrett??s-Associated Adenocarcinoma. The American Journal of Surgical Pathology 30:1, 28-35
CrossRef345
J.Th.M. Plukker, H.L. van Westreenen. (2006) Staging in oesophageal cancer. Best Practice & Research Clinical Gastroenterology 20:5, 877-891
CrossRef346
Michael C. Dobelbower, Suzanne M. Russo, Kevin P. Raisch, Leisa L. Seay, Lisa K. Clemons, Susan Suter, James Posey, James A. Bonner. (2006) Epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib, and concurrent 5-fluorouracil, cisplatin and radiotherapy for patients with esophageal cancer: a phase I study. Anti-Cancer Drugs 17:1, 95-102
CrossRef347
P. Tripp, H. K. Malhotra, M. Javle, A. Shaukat, R. Russo, S. Boer, M. Podgorsak, H. Nava, G. Y. Yang. (2005) Cardiac function after chemoradiation for esophageal cancer: comparison of heart dose-volume histogram parameters to multiple gated acquisition scan changes. Diseases of the Esophagus 18:6, 400-405
CrossRef348
Y. Nabeya, T. Ochiai, H. Matsubara, S. Okazumi, T. Shiratori, K. Shuto, T. Aoki, S. Miyazaki, Y. Gunji, T. Uno, H. Ito, H. Shimada. (2005) Neoadjuvant chemoradiotherapy followed by esophagectomy for initially resectable squamous cell carcinoma of the esophagus with multiple lymph node metastasis. Diseases of the Esophagus 18:6, 388-397
CrossRef349
Frédéric Mal, Thierry Perniceni, Hugues Levard, Christine Denet, Pierre Validire, Brice Gayet. (2005) Pre-operative predictive factors of early recurrence after resection of adenocarcinoma of the esophagus and cardia. Gastroentérologie Clinique et Biologique 29:12, 1275-1278
CrossRef350
Côme Lepage, Anne-Marie Bouvier, Sylvain Manfredi, Olivier Coatmeur, Nicolas Cheynel, Jean Faivre. (2005) Trends in incidence and management of esophageal adenocarcinoma in a well-defined population. Gastroentérologie Clinique et Biologique 29:12, 1258-1263
CrossRef351
Jean-Franois Bosset, F. Lorchel, G. Mantion, J. Buffet, G. Créhange, M. Bosset, L. Chaigneau, S. Servagi. (2005) Radiation and chemoradiation therapy for esophageal adenocarcinoma. Journal of Surgical Oncology 92:3, 239-245
CrossRef352
Pooja Rohatgi, Stephen G. Swisher, Arlene M. Correa, Tsung-T. Wu, Zhongxing Liao, Ritsuko Komaki, Garrett L. Walsh, Ara A. Vaporciyan, David C. Rice, Jack A. Roth, Jaffer A. Ajani. (2005) Characterization of pathologic complete response after preoperative chemoradiotherapy in carcinoma of the esophagus and outcome after pathologic complete response. Cancer 104:11, 2365-2372
CrossRef353
M.M. Mooney. (2005) Neoadjuvant and adjuvant chemotherapy for esophageal adenocarcinoma. Journal of Surgical Oncology 92:3, 230-238
CrossRef354
Jason J. Schrager, John L. Tarpley, Walter E. Smalley, Mary T. Austin, A. Scott Pearson. (2005) Endoscopic ultrasound: impact on survival in patients with esophageal cancer. The American Journal of Surgery 190:5, 682-686
CrossRef355
Paul M. Schneider, Stephan E. Baldus, Ralf Metzger, Martin Kocher, Rudolf Bongartz, Elfriede Bollschweiler, Hartmut Schaefer, Juergen Thiele, Hans P. Dienes, Rolf P. Mueller, Arnulf H. Hoelscher. (2005) Histomorphologic Tumor Regression and Lymph Node Metastases Determine Prognosis Following Neoadjuvant Radiochemotherapy for Esophageal Cancer. Annals of Surgery 242:5, 684-692
CrossRef356
Jeeyun Lee, Kyoung-Eun Lee, Young-Hyuck Im, Won Ki Kang, Keunchil Park, Kwhanmien Kim, Young Mog Shim. (2005) Adjuvant Chemotherapy with 5-Fluorouracil and Cisplatin in Lymph Node-Positive Thoracic Esophageal Squamous Cell Carcinoma. The Annals of Thoracic Surgery 80:4, 1170-1175
CrossRef357
H. Igaki, H. Kato, Y. Tachimori, Y. Nakanishi, T. Shimoda. (2005) Surgery for clinical T3 carcinomas of the upper thoracic oesophagus and the need for new strategies. British Journal of Surgery 92:10, 1235-1240
CrossRef358
Giovanni de Manzoni, Corrado Pedrazzani, Ernesto Laterza, Felice Pasini, Antonio Grandinetti, Marco Bernini, Andrea Ruzzenente, Germana Zerman, Anna Tomezzoli, Claudio Cordiano. (2005) Induction Chemoradiotherapy for Squamous Cell Carcinoma of the Thoracic Esophagus: Impact of Increased Dosage on Long-Term Results. The Annals of Thoracic Surgery 80:4, 1176-1183
CrossRef359
Hiroyuki Kato, Minoru Fukuchi, Tatsuya Miyazaki, Masanobu Nakajima, Hitoshi Kimura, Ahmad Faried, Makoto Sohda, Yasuyuki Fukai, Norihiro Masuda, Ryokuhei Manda, Hitoshi Ojima, Katsuhiko Tsukada, Noboru Oriuchi, Keigo Endo, Hiroyuki Kuwano. (2005) Positron emission tomography in esophageal cancer. Esophagus 2:3, 111-121
CrossRef360
Corrado Pedrazzani, Marco Bernini, Simone Giacopuzzi, Raffaele Pugliese, Filippo Catalano, Mara Festini, Luca Rodella, Giovanni de Manzoni. (2005) Evaluation of Siewert classification in gastro-esophageal junction adenocarcinoma: What is the role of endoscopic ultrasonography?. Journal of Surgical Oncology 91:4, 226-231
CrossRef361
C. R. Thomas. (2005) Current and ongoing progress in the therapy for resectable esophageal cancer. Diseases of the Esophagus 18:4, 211-214
CrossRef362
M. M. M. Abdel-Latif, J. M. O'Riordan, N. Ravi, D. Kelleher, J. V. Reynolds. (2005) Activated nuclear factor-kappa B and cytokine profiles in the esophagus parallel tumor regression following neoadjuvant chemoradiotherapy. Diseases of the Esophagus 18:4, 246-252
CrossRef363
Alain Sauvanet, Christophe Mariette, Pascal Thomas, Patrick Lozac’h, Philippe Segol, Emmanuel Tiret, Jean-Robert Delpero, Denis Collet, Joël Leborgne, Bernard Pradère, André Bourgeon, Jean-Pierre Triboulet. (2005) Mortality and Morbidity after Resection for Adenocarcinoma of the Gastroesophageal Junction: Predictive Factors. Journal of the American College of Surgeons 201:2, 253-262
CrossRef364
Hubert J. Stein, Burkhard H. A. Rahden, J. Rüdiger Siewert. (2005) Survival after oesophagectomy for cancer of the oesophagus. Langenbeck's Archives of Surgery 390:4, 280-285
CrossRef365
Gauri Varadhachary, Jaffer A Ajani. (2005) Preoperative and adjuvant therapies for upper gastrointestinal cancers. Expert Review of Anticancer Therapy 5:4, 719-725
CrossRef366
Joseph B. Zwischenberger, Brannon R. Hyde, Juan C. Escalon. (2005) What’s New in General Thoracic Surgery. Journal of the American College of Surgeons 201:1, 90-99
CrossRef367
X. Zhang, D. I. Watson, G. G. Jamieson, J. R. Bessell, P. G. Devitt. (2005) Neoadjuvant chemoradiotherapy for esophageal carcinoma. Diseases of the Esophagus 18:2, 104-108
CrossRef368
Robert James Cerfolio, Ayesha S. Bryant, Buddhiwardhan Ohja, Alfred A. Bartolucci, Mohamad A. Eloubeidi. (2005) The accuracy of endoscopic ultrasonography with fine-needle aspiration, integrated positron emission tomography with computed tomography, and computed tomography in restaging patients with esophageal cancer after neoadjuvant chemoradiotherapy. The Journal of Thoracic and Cardiovascular Surgery 129:6, 1232-1241
CrossRef369
Ziv Gamliel, Mark J. Krasna. (2005) Multimodality Treatment of Esophageal Cancer. Surgical Clinics of North America 85:3, 621-630
CrossRef370
Nasser Altorki. (2005) En-bloc Esophagectomy—The Three-Field Dissection. Surgical Clinics of North America 85:3, 611-619
CrossRef371
Stephen G. Swisher, Wayne Hofstetter, Tsung T. Wu, Arlene M. Correa, Jaffer A. Ajani, Ritsuko R. Komaki, Lucian Chirieac, Kelly K. Hunt, Zhongxing Liao, Alexandria Phan, David C. Rice, Ara A. Vaporciyan, Garrett L. Walsh, Jack A. Roth. (2005) Proposed Revision of the Esophageal Cancer Staging System to Accommodate Pathologic Response (pP) Following Preoperative Chemoradiation (CRT). Annals of Surgery 241:5, 810-820
CrossRef372
Kenneth K. Wang, Michel Wongkeesong, Navtej S. Buttar. (2005) American Gastroenterological Association Technical Review on the Role of the Gastroenterologist in the Management of Esophageal Carcinoma. Gastroenterology 128:5, 1471-1505
CrossRef373
Banke Agarwal, Stephen G. Swisher, Jaffer Ajani, Kaitlyn Kelly, Ritsuko R. Komaki, Emad Abu-Hamda, Arlene M. Correa, Jack A. Roth. (2005) Differential Response to Preoperative Chemoradiation and Surgery in Esophageal Adenocarcinomas Based on Presence of Barrett's Esophagus and Symptomatic Gastroesophageal Reflux. The Annals of Thoracic Surgery 79:5, 1716-1723
CrossRef374
Nicholas J. Shaheen. (2005) Advances in Barrett’s Esophagus and Esophageal Adenocarcinoma. Gastroenterology 128:6, 1554-1566
CrossRef375
Jane M. Blazeby, Emma Sanford, Stephen J. Falk, Derek Alderson, Jenny L. Donovan. (2005) Health-related quality of life during neoadjuvant treatment and surgery for localized esophageal carcinoma. Cancer 103:9, 1791-1799
CrossRef376
Jang-Ming Lee, An-Chi Lo, Shi-Yi Yang, Huei-Shian Tsau, Robert J. Chen, Yung-Chie Lee. (2005) Association of Angiotensin-Converting Enzyme Insertion/Deletion Polymorphism With Serum Level and Development of Pulmonary Complications Following Esophagectomy. Annals of Surgery 241:4, 659-665
CrossRef377
Lucian R. Chirieac, Stephen G. Swisher, Jaffer A. Ajani, Ritsuko R. Komaki, Arlene M. Correa, Jeffrey S. Morris, Jack A. Roth, Asif Rashid, Stanley R. Hamilton, Tsung-Teh Wu. (2005) Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer 103:7, 1347-1355
CrossRef378
James R. Rigas, Konstantin H. Dragnev, Jeffrey A. Bubis. (2005) Docetaxel in the Treatment of Esophageal Cancer. Seminars in Oncology 32, 39-51
CrossRef379
Masahiko Yano, Takushi Yasuda, Hiroshi Miyata, Yoshiyuki Fujiwara, Shuji Takiguchi, Morito Monden. (2005) Correlation between histological effects on the main tumors and nodal status after chemoradiotherapy for squamous cell carcinoma of the esophagus. Journal of Surgical Oncology 89:4, 244-250
CrossRef380
J. DeWitt, K. Kesler, J. A. Brooks, J. LeBlanc, L. McHenry, K. McGreevy, S. Sherman. (2005) Endoscopic ultrasound for esophageal and gastroesophageal junction cancer: Impact of increased use of primary neoadjuvant therapy on preoperative locoregional staging accuracy. Diseases of the Esophagus 18:1, 21-27
CrossRef381
Tawee Tanvetyanon, Joseph I. Clark, Steve C. Campbell, Simon S. Lo. (2005) Neoadjuvant Therapy: An Emerging Concept in Oncology. Southern Medical Journal 98:3, 338-344
CrossRef382
A. Gómez España, R. Serrano Blanch, E. Aranda Aguilar. (2005) Cáncer de esófago. Medicine - Programa de Formación Médica Continuada Acreditado 9:25, 1605-1612
CrossRef383
Rose B. Ganim, Alden H. Harken. (2005) Invited commentary: Looking beyond bare survival. Surgery 137:2, 178-179
CrossRef384
Sarah E. Greer, Philip P. Goodney, John E. Sutton, John D. Birkmeyer. (2005) Neoadjuvant chemoradiotherapy for esophageal carcinoma: A meta-analysis. Surgery 137:2, 172-177
CrossRef385
David C. Rice, Arlene M. Correa, Ara A. Vaporciyan, Nidhi Sodhi, W. Roy Smythe, Stephen G. Swisher, Garrett L. Walsh, Joe B. Putnam, Ritsuko Komaki, Jaffer A. Ajani, Jack A. Roth. (2005) Preoperative Chemoradiotherapy Prior to Esophagectomy in Elderly Patients is Not Associated With Increased Morbidity. The Annals of Thoracic Surgery 79:2, 391-397
CrossRef386
E. Vazquez-Sequeiros, D. Boixeda Miquel. (2005) Indications de la ponctionbiopsie à l’aiguille fine sous échoendoscopie (EUS-FNA) dans la pathologie ganglionnaire. Acta Endoscopica 35:1, 25-33
CrossRef387
Nicolas Plaisant, Pierre Senesse, David Azria, Claire Lemanski, Marc Ychou, Francois Quenet, Bernard Saint-Aubert, Philippe Rouanet. (2005) Surgery for Esophageal Cancer after Concomitant Radiochemotherapy: Oncologic and Functional Results. World Journal of Surgery 29:1, 32-38
CrossRef388
Takahiro MORI, Shukichi MIYAZAKI, Go MIYATA, Ko SUGAWARA, Ko ONODERA, Hirofumi ICHIKAWA, Takashi KAMEI, Hiroshi KIKUCHI, Rikiya KANBA, Susumu SATOMI, Tatsuya TAKAHASHI. (2005) Preoperative Radiation Therapy is an Independent and Strong Risk Factor for Late Non-cancer Death after Esophagectomy. Interdisciplinary Information Sciences 11:2, 141-147
CrossRef389
Young S. Oh, Dayna S. Early, Riad R. Azar. (2005) Clinical Applications of Endoscopic Ultrasound to Oncology. Oncology 68:4-6, 526-537
CrossRef390
Sang-Hee Cho, Ik-Joo Chung, Sang-Yun Song, Deok-Hwan Yang, Jeong-Rae Byun, Yeo-Kyeoung Kim, Je-Jung Lee, Kook-Joo Na, Hyeoung-Joon Kim. (2005) Bi-weekly Chemotherapy of Paclitaxel and Cisplatin in Patients with Metastatic or Recurrent Esophageal Cancer. Journal of Korean Medical Science 20:4, 618
CrossRef391
Michael Stahl, Hansjochen Wilke, Martin Stuschke, Martin K. Walz, Ulrich Fink, Michael Molls, J. R
diger Siewert, Michael Schroeder, Hans-Bruno Makoski, Ulrich Schmidt, Siegfried Seeber, Udo Vanhoefer. (2005) Clinical response to induction chemotherapy predicts local control and long-term survival in multimodal treatment of patients with locally advanced esophageal cancer. Journal of Cancer Research and Clinical Oncology 131:1, 67-72
CrossRef392
Axel Kleespie, Christiane J. Bruns, Karl-Walter Jauch. (2005) Clinical Significance of VEGF-A, -C and -D Expression in Esophageal Malignancies. Onkologie 28:5, 281-288
CrossRef393
Steven K. Seung, John W. Smith, John Molendyk, Stephen B. Bader, Michael Phillips, James Regan, Jeannie Louie, Edward Soo, Mark Seligman, Janet Ruzich, Laurie Skokan, Helen J. Ross. (2004) Selective dose escalation of chemoradiotherapy for esophageal cancer: Role of treatment intensification. Seminars in Oncology 31, 13-19
CrossRef394
A. Genio, G. Rossetti, V. Napolitano, V. Maffettone, A. Renzi, L. Brusciano, G. Russo, G. Genio. (2004) Laparoscopic esophagectomy in the palliative treatment of advanced esophageal cancer after radiochemotherapy. Surgical Endoscopy 18:12, 1789-1794
CrossRef395
S. E. Baldus, S. P. M
CrossRef396
Frank C.-F. Lin, Amy E. Durkin, Mark K. Ferguson. (2004) Induction Therapy Does Not Increase Surgical Morbidity After Esophagectomy for Cancer. The Annals of Thoracic Surgery 78:5, 1783-1789
CrossRef397
C. Mariette, G. Piessen, J.M. Balon, I. Van Seuningen, J.P. Triboulet. (2004) Surgery alone in the curative treatment of localised oesophageal carcinoma. European Journal of Surgical Oncology (EJSO) 30:8, 869-876
CrossRef398
Stephen G. Swisher, Mary Maish, Jeremy J. Erasmus, Arlene M. Correa, Jaffer A. Ajani, Robert Bresalier, Ritsuko Komaki, Homer Macapinlac, Reginald F. Munden, Joe B. Putnam, David Rice, W.Roy Smythe, Ara A. Vaporciyan, Garrett L. Walsh, Tsung T. Wu, Jack A. Roth. (2004) Utility of PET, CT, and EUS to Identify Pathologic Responders in Esophageal Cancer. The Annals of Thoracic Surgery 78:4, 1152-1160
CrossRef399
J. A. Harvey, J. R. Bessell, E. Beller, J. Thomas, D. C. Gotley, B. H. Burmeister, E. T. Walpole, D. B. Thomson, I. Martin, L. Doyle, E. Burmeister, B. M. Smithers. (2004) Chemoradiation therapy is effective for the palliative treatment of malignant dysphagia. Diseases of the Esophagus 17:3, 260-265
CrossRef400
Zenia L Martin, Karl J Sweeney, Thomas F Gorey. (2004) Peroral and Transgastric Esophageal Anastomosis With Flexible Shaft Remote-Control Stapler (SurgASSIST). Surgical Laparoscopy, Endoscopy & Percutaneous Techniques 14:4, 230-233
CrossRef401
Axel Kleespies, Markus Guba, Karl-Walter Jauch, Christiane J. Bruns. (2004) Vascular endothelial growth factor in esophageal cancer. Journal of Surgical Oncology 87:2, 95-104
CrossRef402
CrossRef403
R. Iyer, N. Wilkinson, T. Demmy, M. Javle. (2004) Controversies in the Multimodality Management of Locally Advanced Esophageal Cancer: Evidence-Based Review of Surgery Alone and Combined-Modality Therapy. Annals of Surgical Oncology 11:7, 665-673
CrossRef404
Banke Agarwal, Stephen Swisher, Jaffer Ajani, Kaitlyn Kelly, Christina Fanning, Ritsuko R. Komaki, Joe B. Putnam, Emad Abu-Hamda, Kimber L. Molke, Garrett L. Walsh, Arlene M. Correa, Linus Ho, Zhongxing Liao, Patrick M. Lynch, David C. Rice, W. Roy Smythe, Craig W. Stevens, Ara A. Vaporciyan, James Yao, Jack A. Roth. (2004) Endoscopic Ultrasound after Preoperative Chemoradiation Can Help Identify Patients Who Benefit Maximally after Surgical Esophageal Resection. The American Journal of Gastroenterology 99:7, 1258-1266
CrossRef405
F Miyazono, R Metzger, U Warnecke-Eberz, S E Baldus, J Brabender, E Bollschweiler, W Doerfler, R P Mueller, H P Dienes, T Aikou, A H Hoelscher, P M Schneider. (2004) Quantitative c-erbB-2 but not c-erbB-1 mRNA expression is a promising marker to predict minor histopathologic response to neoadjuvant radiochemotherapy in oesophageal cancer. British Journal of Cancer
CrossRef406
I Brink, M Hentschel, T.A Bley, A Walch, M Mix, M Kleimaier, E Moser, A Imdahl. (2004) Effects of neoadjuvant radio-chemotherapy on 18F-FDG-PET in esophageal carcinoma. European Journal of Surgical Oncology (EJSO) 30:5, 544-550
CrossRef407
A. Shaukat, A. Mortazavi, T. Demmy, H. Nava, N. Wilkinson, G. Yang, J. Kepner, M. Javle. (2004) Should preoperative, post-chemoradiotherapy endoscopy be routine for esophageal cancer patients?. Diseases of the Esophagus 17:2, 129-135
CrossRef408
Jaffer A. Ajani, Garrett Walsh, Ritsuko Komaki, Jeff Morris, Stephen G. Swisher, Joe B. Putnam, Patrick M. Lynch, Tsung-Teh Wu, Roy Smythe, Ara Vaporciyan, Josephine Faust, Deborah S. Cohen, Rebecca Nivers, Jack A. Roth. (2004) Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction. Cancer 100:11, 2347-2354
CrossRef409
P. M. Lawlor, J. A. McCullough, P. J. Byrne, J. V. Reynolds. (2004) Gastric myoelectrical activity post-chemoradiotherapy and esophagectomy: a prospective study using subscapular surface recording. Diseases of the Esophagus 17:1, 76-80
CrossRef410
G. N. J. Tytgat, H. Bartelink, R. Bernards, G. Giaccone, J. J. B. van Lanschot, G. J. A. Offerhaus, G. J. Peters. (2004) Cancer of the esophagus and gastric cardia: recent advances*. Diseases of the Esophagus 17:1, 10-26
CrossRef411
Q. Yang, K. R. Cleary, J. C. Yao, S. G. Swisher, J. A. Roth, P. M. Lynch, R. Komaki, J. A. Ajani, A. Rashid, S. R. Hamilton, T.-T. Wu. (2004) Significance of post-chemoradiation biopsy in predicting residual esophageal carcinoma in the surgical specimen. Diseases of the Esophagus 17:1, 38-43
CrossRef412
Mohamed M. M. Abdel-Latif, James O??Riordan, Henry J. Windle, Eleanor Carton, Nagunivan Ravi, Dermot Kelleher, John V. Reynolds. (2004) NF-??B Activation in Esophageal Adenocarcinoma. Annals of Surgery 239:4, 491-500
CrossRef413
E.D Mulligan, B Dunne, M Griffin, N Keeling, J.V Reynolds. (2004) Margin involvement and outcome in oesophageal carcinoma: a 10-year experience in a specialist unit. European Journal of Surgical Oncology (EJSO) 30:3, 313-317
CrossRef414
GAVIN C HAREWOOD, K SHIVA KUMAR. (2004) Assessment of clinical impact of endoscopic ultrasound on esophageal cancer. Journal of Gastroenterology and Hepatology 19:4, 433-439
CrossRef415
Jessica S Donington, Daniel L Miller, Mark S Allen, Claude Deschamps, Francis C Nichols, Peter C Pairolero. (2004) Preoperative chemoradiation therapy does not improve early survival after esophagectomy for patients with clinical stage III adenocarcinoma of the esophagus. The Annals of Thoracic Surgery 77:4, 1193-1199
CrossRef416
Paul Ryan, Seán McCarthy, Jacquie Kelly, J.Kevin Collins, Colum Dunne, Liam Grogan, Oscar Breathnach, Fergus Shanahan, P.Declan Carey, Thomas N. Walsh, Gerald C. O’Sullivan. (2004) Prevalence of bone marrow micrometastases in esophagogastric cancer patients with and without neoadjuvant chemoradiotherapy. Journal of Surgical Research 117:1, 121-126
CrossRef417
Dora Kwong, Alfred Lam, Xy Guan, Simon Law, Amy Tai, John Wong, Jonathan Sham. (2004) Chromosomal aberrations in esophageal squamous cell carcinoma among chinese: gain of 12p predicts poor prognosis after surgery. Human Pathology 35:3, 309-316
CrossRef418
Eero I.T. Sihvo, Markku E Luostarinen, Jarmo A Salo. (2004) Fate of Patients with Adenocarcinoma of the Esophagus and the Esophagogastric Junction: A Population-Based Analysis. The American Journal of Gastroenterology 99:3, 419-424
CrossRef419
Vinay M Tak, Keith S Naunheim. (2004) Current status of multimodality therapy for esophageal carcinoma. Journal of Surgical Research 117:1, 22-29
CrossRef420
Peter Naughton, Thomas N Walsh. (2004) Multimodality therapy for cancers of the esophagus and gastric cardia. Expert Review of Anticancer Therapy 4:1, 141-150
CrossRef421
P. H. Deprez, I. Borbath. (2004) Comment et pourquoi j’explore le médiastin?. Acta Endoscopica 34:1, 13-21
CrossRef422
J.M. O'Riordan, O.N. Tucker, P.J. Byrne, G.S.A. McDonald, N. Ravi, P.W.N. Keeling, J.V. Reynolds. (2004) Factors Influencing The Development of Barrett's Epithelium in The Esophageal Remnant Postesophagectomy. The American Journal of Gastroenterology 99:2, 205-211
CrossRef423
E. Quintero Carrión, D. Nicolás Pérez. (2004) Adenocarcinoma gástrico y de la unión esófago-gástrica. Medicine - Programa de Formación Médica Continuada Acreditado 9:2, 100-111
CrossRef424
Markus Moehler, Carl C. Schimanski, Ines Gockel, Theodor Junginger, Peter R. Galle. (2004) (Neo)adjuvant Strategies of Advanced Gastric Carcinoma: Time for a Change?. Digestive Diseases 22:4, 345-350
CrossRef425
Sanjay Sharma. (2004) Radical Esophagectomy for Carcinoma Esophagus-Is It Essential?. Nihon Kikan Shokudoka Gakkai Kaiho 55:2, 92-103
CrossRef426
Paul M Harari, Mark A Ritter, Daniel G Petereit, Minesh P Mehta. (2004) Chemoradiation for upper aerodigestive tract cancer: balancing evidence from clinical trials with individual patient recommendations. Current Problems in Cancer 28:1, 7-40
CrossRef427
C.O McDonnell, G Holden, M.E Sheridan, D Foley, M Moriarty, T.N Walsh, D.J Bouchier-Hayes. (2004) Improvement in efficacy of chemoradiotherapy by addition of an antiangiogenic agent in a murine tumor model. Journal of Surgical Research 116:1, 19-23
CrossRef428
SIMON LAW, JOHN WONG. (2004) Therapeutic options for esophageal cancer. Journal of Gastroenterology and Hepatology 19:1, 4-12
CrossRef429
Andreas Imdahl, Ulrich Schöffel, Günther Ruf. (2004) Impact of neoadjuvant therapy of perioperative morbidity in patients with esophageal cancer. The American Journal of Surgery 187:1, 64-68
CrossRef430
Hideki Bo, Mohammad Ghazizadeh, Hajime Shimizu, Yuji Kurihara, Seiko Egawa, Yukichi Moriyama, Takashi Tajiri, Oichi Kawanami. (2004) Effect of Ionizing Irradiation on Human Esophageal Cancer Cell Lines by cDNA Microarray Gene Expression Analysis. Journal of Nippon Medical School 71:3, 172-180
CrossRef431
Enzinger, Peter C., Mayer, Robert J., . (2003) Esophageal Cancer. New England Journal of Medicine 349:23, 2241-2252
Full Text432
Michael D. Kelly, Thomas N. Walsh. (2003) Adjuvant treatment for resectable adenocarcinoma of the oesophagus. ANZ Journal of Surgery 73:12, 976-978
CrossRef433
Enrique Vazquez-Sequeiros, Maurits J Wiersema, Jonathan E Clain, Ian D Norton, Michael J Levy, Yvonne Romero, Diva Salomao, Ross Dierkhising, Alan R Zinsmeister. (2003) Impact of lymph node staging on therapy of esophageal carcinoma. Gastroenterology 125:6, 1626-1635
CrossRef434
J Balart, J Balmaña, X Rius, R Salazar, M Gallen, S Navarro, A Arcusa, E Gallardo, J Brunet. (2003) Treatment of oesophageal cancer with preoperative chemoradiotherapy may increase operative mortality. European Journal of Surgical Oncology (EJSO) 29:10, 884-889
CrossRef435
Aminah Jatoi. (2003) Aggressive multimodality therapy for patients with locally advanced esophageal cancer: is there a role for amifostine?. Seminars in Oncology 30, 72-75
CrossRef436
David H Ilson. (2003) Oesophageal cancer: new developments in systemic therapy. Cancer Treatment Reviews 29:6, 525-532
CrossRef437
Susan G. Urba, Mark B. Orringer, Mark Ianettonni, James A. Hayman, Hayasaka Satoru. (2003) Concurrent cisplatin, paclitaxel, and radiotherapy as preoperative treatment for patients with locoregional esophageal carcinoma. Cancer 98:10, 2177-2183
CrossRef438
R.S Keresztes, J.L Port, M.W Pasmantier, R.J Korst, N.K Altorki. (2003) Preoperative chemotherapy for esophageal cancer with paclitaxel and carboplatin: results of a phase II trial. The Journal of Thoracic and Cardiovascular Surgery 126:5, 1603-1608
CrossRef439
Sibyl E. Anderson, Bruce D. Minsky, Manjit Bains, David P. Kelsen, David H. Ilson. (2003) Combined modality therapy in esophageal cancer: The Memorial experience. Seminars in Surgical Oncology 21:4, 228-232
CrossRef440
Thomas W Rice, David J Adelstein, Mark A Chidel, Lisa A Rybicki, Malcolm M DeCamp, Sudish C Murthy, Eugene H Blackstone. (2003) Benefit of postoperative adjuvant chemoradiotherapy in locoregionally advanced esophageal carcinoma. The Journal of Thoracic and Cardiovascular Surgery 126:5, 1590-1596
CrossRef441
C. O. McDonnell, D. J. Bouchier-Hayes, D. Toomey, D. Foley, E. W. Kay, E. Leen, T. N. Walsh. (2003) Effect of neoadjuvant chemoradiotherapy on angiogenesis in oesophageal cancer. British Journal of Surgery 90:11, 1373-1378
CrossRef442
Samira Syed, Tony Y Eng, Charles R Thomas, Ian M Thompson, Geoffrey R Weiss. (2003) Current issues in the management of advanced squamous cell carcinoma of the penis. Urologic Oncology: Seminars and Original Investigations 21:6, 431-438
CrossRef443
P.F. Rice, T.L.D. Crosby, S.A. Roberts. (2003) Variability of the Carina–Incisor Distance as assessed by Endoscopic Ultrasound. Clinical Oncology 15:7, 383-385
CrossRef444
Melvyn Goldberg, Jeffrey Farma, Craig Lampert, Patrick Colarusso, Lawrence Coia, Harold Frucht, Eric Goosenberg, Mary Beard, Louis M Weiner. (2003) Survival following intensive preoperative combined modality therapy with paclitaxel, cisplatin, 5-fluorouracil, and radiation in resectable esophageal carcinoma: A phase I report. The Journal of Thoracic and Cardiovascular Surgery 126:4, 1168-1173
CrossRef445
M Tachibana, H Yoshimura, S Kinugasa, M Shibakita, D.K Dhar, S Ueda, T Fujii, N Nagasue. (2003) Postoperative chemotherapy vs. chemoradiotherapy for thoracic esophageal cancer: a prospective randomized clinical trial. European Journal of Surgical Oncology (EJSO) 29:7, 580-587
CrossRef446
William E Burak. (2003) Is neoadjuvant therapy the answer to adenocarcinoma of the esophagus?. The American Journal of Surgery 186:3, 296-300
CrossRef447
Mikihito Nakamori, Makoto Iwahashi, Masaki Nakamura, Hiroki Yamaue. (2003) Clinical benefit of chemosensitivity test for patients with regional lymph node-positive esophageal squamous cell carcinoma. Journal of Surgical Oncology 84:1, 10-16
CrossRef448
G. de Manzoni, C. Pedrazzani, F. Pasini, E. Durante, M. Gabbani, A. Grandinetti, A. Guglielmi, C. Griso, C. Cordiano. (2003) Pattern of recurrence after surgery in adenocarcinoma of the gastro-oesophageal junction. European Journal of Surgical Oncology (EJSO) 29:6, 506-510
CrossRef449
Peter C Wu, Mitchell C Posner. (2003) The role of surgery in the management of oesophageal cancer. The Lancet Oncology 4:8, 481-488
CrossRef450
Gregory D Leonard, John A McCaffrey, Michael Maher. (2003) Optimal therapy for oesophageal cancer. Cancer Treatment Reviews 29:4, 275-282
CrossRef451
Michael K. Gibson, Arlene A. Forastiere. (2003) Combined-Modality Therapy for Esophageal Cancer. The Cancer Journal 9:4, 238-240
CrossRef452
Anthony Watson. (2003) Diagnosis and therapy for advanced esophageal cancer. Current Opinion in Gastroenterology 19:4, 400-405
CrossRef453
Mohamad A. Eloubeidi, Andrew C. Mason, Renee A. Desmond, Hashem B. El-Serag. (2003) Temporal trends (1973-1997) in survival of patients with esophageal adenocarcinoma in the United States: a glimmer of hope?. The American Journal of Gastroenterology 98:7, 1627-1633
CrossRef454
Anthony A. Meluch, F. Anthony Greco, James R. Gray, Melodie Thomas, Valerie M. Sutton, J. Lucian Davis, Leonard A. Kalman, Don W. Shaffer, Kathleen Yost, David A. Rinaldi, John D. Hainsworth. (2003) Preoperative Therapy with Concurrent Paclitaxel/Carboplatin/Infusional 5-FU and Radiation Therapy in Locoregional Esophageal Cancer. The Cancer Journal 9:4, 251-260
CrossRef455
B Visser. (2003) Adjuvant and neoadjuvant therapy for esophageal cancer: a critical reappraisal. Surgical Oncology 12:1, 1-7
CrossRef456
J. D. Urschel, S. Ashiku, R. Thurer, F. W. Sellke. (2003) Salvage or planned esophagectomy after chemoradiation therapy for locally advanced esophageal cancer - a review. Diseases of the Esophagus 16:2, 60-65
CrossRef457
John D Urschel, Hari Vasan. (2003) A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. The American Journal of Surgery 185:6, 538-543
CrossRef458
Dennis Blom. (2003) Surgical management of esophageal malignancy. Current Gastroenterology Reports 5:3, 192-197
CrossRef459
S Mukherjee, D Aston, M Minett, A.E Brewster, T.D.L Crosby. (2003) The Significance of Cardiac Doses Received During Chemoradiation of Oesophageal and Gastro–oesophageal Junctional Cancers. Clinical Oncology 15:3, 115-120
CrossRef460
J Harney, K Goodchild, H Phillips, R Glynne-Jones, P.J Hoskin, M.I Saunders. (2003) A Phase I/II Study of CHARTWEL with Concurrent Chemotherapy in Locally Advanced, Inoperable Carcinoma of the Oesophagus. Clinical Oncology 15:3, 109-114
CrossRef461
J.W Denham, A Steigler, J Kilmurray, C Wratten, B Burmeister, D.S Lamb, D Joseph, G Delaney, D Christie, G Jamieson, B.M Smithers, S Ackland, E Walpole. (2003) Relapse Patterns after Chemo-radiation for Carcinoma of the Oesophagus. Clinical Oncology 15:3, 98-108
CrossRef462
Arnaud D. Roth. (2003) Curative treatment of gastric cancer: towards a multidisciplinary approach?. Critical Reviews in Oncology/Hematology 46:1, 59-100
CrossRef463
Christophe Mariette, Jean-Michel Balon, Guillaune Piessen, Sylvain Fabre, Isabelle Van Seuningen, Jean-Pierre Triboulet. (2003) Pattern of recurrence following complete resection of esophageal carcinoma and factors predictive of recurrent disease. Cancer 97:7, 1616-1623
CrossRef464
(2003) Surgical Treatment of Esophageal Cancer. New England Journal of Medicine 348:12, 1177-1179
Full Text465
S Tormey, A Nasyr, DA McNamara, PJ Byrne, TN Walsh. (2003) Effect of tumour and chemoradiotherapy on oesophageal motility. Irish Journal of Medical Science 172:1, 9-12
CrossRef466
John Wong, Simon Law. (2003) Esophageal cancer: what price swallowing?. Journal of the American College of Surgeons 196:3, 347-353
CrossRef467
G. Terrosu, C. Cedolini, V. Bresadola, U. Baccarani, A. Uzzau, M. Signor, S. Fongione, A. Buffoli, A. Iop, E. Vigevani, C. Sacco, G. Cartei, F. Bresadola. (2003) Preoperative chemoradiotherapy in cancer of the thoracic esophagus. Diseases of the Esophagus 16:1, 9-16
CrossRef468
A. A. Raouf, D. A. Evoy, E. Carton, E. Mulligan, M. M. Griffin, J. V. Reynolds. (2003) Loss of Bcl-2 expression in Barrett's dysplasia and adenocarcinoma is associated with tumor progression and worse survival but not with response to neoadjuvant chemoradiation. Diseases of the Esophagus 16:1, 17-23
CrossRef469
Jari V. R
CrossRef470
Simon Law, Dora L.W. Kwong, Ka-Fai Kwok, Kam-Ho Wong, Kent-Man Chu, Jonathan S. T. Sham, John Wong. (2003) Improvement in Treatment Results and Long-Term Survival of Patients With Esophageal Cancer. Transactions of the ... Meeting of the American Surgical Association 121, 33-42
CrossRef471
Stephen H Bailey, David A Bull, David H Harpole, Jeffrey J Rentz, Leigh A Neumayer, Theodore N Pappas, Jennifer Daley, William G Henderson, Barbara Krasnicka, Shukri F Khuri. (2003) Outcomes after esophagectomy: a ten-year prospective cohort. The Annals of Thoracic Surgery 75:1, 217-222
CrossRef472
Jo Ann Brooks, Kenneth A. Kesler, Cynthia S. Johnson, Donato Ciaccia, John W. Brown. (2002) Prospective analysis of quality of life after surgical resection for esophageal cancer: Preliminary results. Journal of Surgical Oncology 81:4, 185-194
CrossRef473
Carol A. Sherman, Andrew T. Turrisi, Michael B. Wallace, Carolyn E. Reed. (2002) Locally advanced esophageal cancer. Current Treatment Options in Oncology 3:6, 475-485
CrossRef474
Mark R Anderson, Janusz AZ Jankowski. (2002) Curing oesophageal cancer. European Journal of Gastroenterology & Hepatology 14:11, 1173-1175
CrossRef475
Wayne Hofstetter, Stephen G. Swisher, Arlene M. Correa, Kenneth Hess, Joe B. Putnam, Jaffer A. Ajani, Marcelo Dolormente, Rhodette Francisco, Ritsuko R. Komaki, Axbal Lara, Faye Martin, David C. Rice, Arcenio J. Sarabia, W. Roy Smythe, Ara A. Vaporciyan, Garrett L. Walsh, Jack A. Roth. (2002) Treatment Outcomes of Resected Esophageal Cancer. Annals of Surgery 236:3, 376-385
CrossRef476
W. Uhl, O. Strobel, H. Friess, M. Schilling, M. W. Buchler. (2002) Fundus rotation gastroplasty: rationale, technique and results*. Diseases of the Esophagus 15:2, 101-105
CrossRef477
T. N. Walsh, M. Grennell, S. Mansoor, A. Kelly. (2002) Neoadjuvant treatment of advanced stage esophageal adenocarcinoma increases survival*. Diseases of the Esophagus 15:2, 121-124
CrossRef478
Nam P. Nguyen, James M. Leonardo, Ulf Karlsson, Mohammad Salehpour, Paul Vos, Cristian Robiou, Jon F. Moran, Pat Thomas, Laurie Bullock, Adir Ludin, Gordon Jendrasiak, Sabah Sallah. (2002) Preoperative Chemotherapy and Radiation for Advanced Esophageal Carcinoma. American Journal of Clinical Oncology 25:4, 358-364
CrossRef479
Yael Refaely, Mark J Krasna. (2002) Multimodality therapy for esophageal cancer. Surgical Clinics of North America 82:4, 729-746
CrossRef480
Dennis Blom, Jeffrey H. Peters, Tom R. DeMeester. (2002) Controversies in the current therapy of carcinoma of the esophagus1 1No competing interests declared.. Journal of the American College of Surgeons 195:2, 241-250
CrossRef481
John R Doty, Jorge D Salazar, Arlene A Forastiere, Elisabeth I Heath, Lawrence Kleinberg, Richard F Heitmiller. (2002) Postesophagectomy morbidity, mortality, and length of hospital stay after preoperative chemoradiation therapy. The Annals of Thoracic Surgery 74:1, 227-231
CrossRef482
David H. Ilson. (2002) New developments in the treatment of esophageal cancer. Current Oncology Reports 4:3, 213-221
CrossRef483
Vinay K. Gupta, James O. Park, Nora T. Jackowiak, Helena J. Mauceri, Saraswathy Seetharam, Ralph R. Weichselbaum, Mitchell C. Posner. (2002) Combined gene therapy and ionizing radiation is a novel approach to treat human esophageal adenocarcinoma. Annals of Surgical Oncology 9:5, 500-504
CrossRef484
M. Churn, B. Jones, A. Sun Myint. (2002) Radical Radiotherapy Incorporating a Brachytherapy Boost for the Treatment of Carcinoma of the Thoracic Oesophagus: Results from a Cohort of Patients and Review of the Literature. Clinical Oncology 14:2, 117-122
CrossRef485
Taofeek Owonikoko, MD, Martin Rees, MD, Helmut E. Gabbert, MD, Mario Sarbia, MD. (2002) Intratumoral Genetic Heterogeneity in Barrett Adenocarcinoma. American Journal of Clinical Pathology 117:4, 558-566
CrossRef486
Simon Law, John Wong. (2002) Changing disease burden and management issues for esophageal cancer in the Asia-Pacific region. Journal of Gastroenterology and Hepatology 17:4, 374-381
CrossRef487
John W.C Entwistle, Melvyn Goldberg. (2002) Multimodality therapy for resectable cancer of the thoracic esophagus. The Annals of Thoracic Surgery 73:3, 1009-1015
CrossRef488
Christopher E Avendano, Patrick A Flume, Gerard A Silvestri, Lydia B King, Carolyn E Reed. (2002) Pulmonary complications after esophagectomy. The Annals of Thoracic Surgery 73:3, 922-926
CrossRef489
S.Michael Griffin, Ian H Shaw, Samuel M Dresner. (2002) Early complications after Ivor Lewis subtotal esophagectomy with two-field lymphadenectomy: risk factors and management1 1No competing interests declared.. Journal of the American College of Surgeons 194:3, 285-297
CrossRef490
John D Urschel, Hari Vasan, Chris J Blewett. (2002) A meta-analysis of randomized controlled trials that compared neoadjuvant chemotherapy and surgery to surgery alone for resectable esophageal cancer. The American Journal of Surgery 183:3, 274-279
CrossRef491
P. H. Lukas, U. Fink. (2002) Multimodality Treatment for Oesophageal Cancer. European Surgery-Acta Chirurgica Austriaca 34:1, 27-28
CrossRef492
T. R. DeMeester. (2002) Surgery for Esophageal Cancer: State of the Art and Future Perspectives. European Surgery-Acta Chirurgica Austriaca 34:1, 5-8
CrossRef493
Stephen G Swisher, Paula Wynn, Joe B Putnam, Melinda B Mosheim, Arlene M Correa, Ritsuko R Komaki, Jaffer A Ajani, W.Roy Smythe, Ara A Vaporciyan, Jack A Roth, Garrett L Walsh. (2002) Salvage esophagectomy for recurrent tumors after definitive chemotherapy and radiotherapy. The Journal of Thoracic and Cardiovascular Surgery 123:1, 175-183
CrossRef494
Richard M. Gore, Vahid Yaghmai. 2002. Esophageal Cancer. , 359-390.
CrossRef495
David H. Ilson, David Kelsen. 2002. Esophageal Cancer: Treatment. , 169-177.
CrossRef496
Janusz A Jankowski, Mark R Anderson. (2001) The treatment, management and prevention of oesophageal cancer. Expert Opinion on Biological Therapy 1:6, 1017-1028
CrossRef497
T Lerut. (2001) Cancer of the esophagus and gastro-esophageal junction: potentially curative therapies. Surgical Oncology 10:3, 113-122
CrossRef498
Jeffrey A. Hagen, Steven R. DeMeester, Jeffrey H. Peters, Para Chandrasoma, Tom R. DeMeester. (2001) Curative Resection for Esophageal Adenocarcinoma. Annals of Surgery 234:4, 520-531
CrossRef499
M. E. Flett, M. N. Lim, D. Bruce, S. H. Campbell, K. G. M. Park. (2001) Prognostic value of laparoscopic ultrasound in patients with gastro-esophageal cancer. Diseases of the Esophagus 14:3-4, 223-226
CrossRef500
A. Melcher. (2001) Chemoradiation: From the Laboratory to the Clinic*. Clinical Oncology 13:5, 356-360
CrossRef501
R. Chan, S. Morrill, D. Freeman, M. Colman, J. Zwischenberger. (2001) Bi-modality (chemo-radiation) versus tri-modality (chemo-radiation followed by surgery) treatment for carcinoma of the esophagus. Diseases of the Esophagus 14:3-4, 202-207
CrossRef502
Jeffrey A. Hagen, Tom R. DeMeester. (2001) Esophageal adenocarcinoma. The Annals of Thoracic Surgery 72:4, 1430-1432
CrossRef503
Kevin G. Billingsley, Charles Maynard, David L. Schwartz, Jason A. Dominitz. (2001) The use of trimodality therapy for the treatment of operable esophageal carcinoma in the veteran population. Cancer 92:5, 1272-1280
CrossRef504
J. Ruediger Siewert, Hubert J. Stein, Marcus Feith, Björn L.D.M. Bruecher, Holger Bartels, Ulrich Fink. (2001) Histologic Tumor Type Is an Independent Prognostic Parameter in Esophageal Cancer: Lessons From More Than 1,000 Consecutive Resections at a Single Center in the Western World. Annals of Surgery 234:3, 360-369
CrossRef505
John D. Hainsworth, Howard A. Burris, Anthony A. Meluch, Margaret N. Baker, Lisa H. Morrissey, F. Anthony Greco. (2001) Paclitaxel, carboplatin, and long-term continuous infusion of 5-fluorouracil in the treatment of advanced squamous and other selected carcinomas. Cancer 92:3, 642-649
CrossRef506
Anne L Thomas, William P Steward. (2001) Recent advances in the nonsurgical treatment of upper gastrointestinal tract tumors. Expert Review of Anticancer Therapy 1:2, 258-268
CrossRef507
Jaffer A. Ajani, Ritsuko Komaki, Joe B. Putnam, Garrett Walsh, Jon Nesbitt, Peter W. Pisters, Patrick M. Lynch, Ara Vaporciyan, Roy Smythe, Sandeep Lahoti, Issac Raijman, Stephen Swisher, Faye D. Martin, Jack A. Roth. (2001) A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction. Cancer 92:2, 279-286
CrossRef508
Andrew M. Lowy, Barry W. Feig, Nora Janjan, Tyvin A. Rich, Peter W. T. Pisters, Jaffer A. Ajani, Paul F. Mansfield. (2001) A Pilot Study of Preoperative Chemoradiotherapy for Resectable Gastric Cancer. Annals of Surgical Oncology 8:6, 519-524
CrossRef509
Simon Law, John Wong. (2001) Esophageal cancer. Current Opinion in Gastroenterology 17:4, 393-399
CrossRef510
Eric L. R. B
CrossRef511
V.R Archer, P.J Mulholland, D.D Stocken, S.J Darnton, D.R Ferry. (2001) Combined Results from Three Phase II Trials of Neoadjuvant Chemotherapy in Operable Adenocarcinoma of the Oesophagus. Clinical Oncology 13:3, 164-169
CrossRef512
Ermanno Ancona, Alberto Ruol, Stefano Santi, Stefano Merigliano, Vanna Chiarion Sileni, Haralabos Koussis, Giovanni Zaninotto, Luigi Bonavina, Alberto Peracchia. (2001) Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma. Cancer 91:11, 2165-2174
CrossRef513
Antonio L Visbal, Mark S Allen, Daniel L Miller, Claude Deschamps, Victor F Trastek, Peter C Pairolero. (2001) Ivor Lewis esophagogastrectomy for esophageal cancer. The Annals of Thoracic Surgery 71:6, 1803-1808
CrossRef514
Matthew S Slater, John Holland, Douglas O Faigel, Brett C Sheppard, Clifford W Deveney. (2001) Does neoadjuvant chemoradiation downstage esophageal carcinoma?. The American Journal of Surgery 181:5, 440-444
CrossRef515
B. K. Oelschlager, C. A. Pellegrini. (2001) Role of laparoscopy and thoracoscopy in the treatment of esophageal adenocarcinoma *. Diseases of the Esophagus 14:2, 91-94
CrossRef516
Adam S. Garden. (2001) ORGAN PRESERVATION FOR CARCINOMA OF THE LARYNX AND HYPOPHARYNX. Hematology/Oncology Clinics of North America 15:2, 243-260
CrossRef517
Mark J Krasna, Carolyn E Reed, Donna Nedzwiecki, Donna R Hollis, James D Luketich, Malcolm M DeCamp, Robert J Mayer, David J Sugarbaker. (2001) CALGB 9380: a prospective trial of the feasibility of thoracoscopy/laparoscopy in staging esophageal cancer. The Annals of Thoracic Surgery 71:4, 1073-1079
CrossRef518
Jean-Marie Collard. (2001) Exclusive radical surgery for esophageal adenocarcinoma. Cancer 91:6, 1098-1104
CrossRef519
Brian P. Whooley, Simon Law, Sudish C. Murthy, Andreas Alexandrou, John Wong. (2001) Analysis of Reduced Death and Complication Rates After Esophageal Resection. Annals of Surgery 233:3, 338-344
CrossRef520
M. K. Schilling, M. Eichenberger, C. A. Maurer, G. Sigurdsson, M. W. Buchler. (2001) Ketoconazole and pulmonary failure after esophagectomy: a prospective clinical trial. Diseases of the Esophagus 14:1, 37-40
CrossRef521
S. Saha, T. C. B. Dehn. (2001) Ratio of invaded to removed lymph nodes as a prognostic factor in adenocarcinoma of the distal esophagus and esophagogastric junction. Diseases of the Esophagus 14:1, 32-36
CrossRef522
Bruce D. Minsky. (2001) UFT
CrossRef523
Isac I. Schnirer, Ritsuko Komaki, James C. Yao, Stephen Swisher, Joe Putnam, Peter W. T. Pisters, Jack A. Roth, Jaffer A. Ajani. (2001) Pilot Study of Concurrent 5-Fluorouracil/Paclitaxel Plus Radiotherapy in Patients With Carcinoma of the Esophagus and Gastroesophageal Junction. American Journal of Clinical Oncology: Cancer Clinical Trials 24:1, 91-95
CrossRef524
Luigi Bonavina, Davide Soligo, Nadia Quirici, Patrizia Bossolasco, Bruno Cesana, Giorgio Lambertenghi Deliliers, Alberto Peracchia. (2001) Bone marrow—disseminated tumor cells in patients with carcinoma of the esophagus or cardia. Surgery 129:1, 15-22
CrossRef525
Shizuo Nakano, Masamichi Baba, Shoji Natsugoe, Chikara Kusano, Mario Shimada, Toshitaka Fukumoto, Takashi Aikou. (2001) The role of neoadjuvant radiochemotherapy using low-dose fraction cisplatin and 5-fluorouracil in patients with carcinoma of the esophagus. The Japanese Journal of Thoracic and Cardiovascular Surgery 49:1, 11-16
CrossRef526
Frederik Wenz, Harvey Mamon. (2001) Perioperative radiotherapy for cancer of the esophagus. Seminars in Surgical Oncology 20:1, 33-39
CrossRef527
Thomas Lehnert, Martina Treiber, Uta Tiefenbacher, Christian Herfarth, Michael Wannenmacher. (2001) Intraoperative radiotherapy for gastrointestinal cancer. Seminars in Surgical Oncology 20:1, 40-49
CrossRef528
Masahiko Yano, Hitoshi Shiozaki, Toshimasa Tsujinaka, Masatoshi Inoue, Yuichiro Doki, Yoshiyuki Fujiwara, Morito Monden. (2000) Squamous cell carcinoma of the esophagus infiltrating the respiratory tract is less sensitive to preoperative concurrent radiation and chemotherapy11No competing interests declared.. Journal of the American College of Surgeons 191:6, 626-634
CrossRef529
Lawrence E. Harrison. (2000) Is esophageal cancer a surgical disease?. Journal of Surgical Oncology 75:4, 227-231
CrossRef530
Ashesh B. Jani, Philip P. Connell, Valerie J. Vesich, Katherine M. O’Brien, Luci M. Chen. (2000) Analysis of the Role of Adjuvant Chemotherapy for Invasive Carcinoma of the Esophagus. American Journal of Clinical Oncology: Cancer Clinical Trials 23:6, 554-558
CrossRef531
Rebecca Wong, Richard Malthaner. (2000) Esophageal cancer: A systematic review. Current Problems in Cancer 24:6, 293-373
CrossRef532
Stephen G. Swisher, Peter W. T. Pisters, Ritsuko Komaki, Sandeep Lahoti, Jaffer A. Ajani. (2000) Gastroesophageal junction adenocarcinoma. Current Treatment Options in Oncology 1:5, 387-398
CrossRef533
Brian P. Whooley, John Wong. (2000) Intrathoracic Oesophageal Anastomosis: Is it Worth the Risk?. ANZ Journal of Surgery 70:9, 677-680
CrossRef534
Mustapha Adham, J. Baulieux, F. Mornex, E. de la Roche de Bransat, C. Ducerf, J. C. Souquet, J. P. Gerard. (2000) Combined chemotherapy and radiotherapy followed by surgery in the treatment of patients with squamous cell carcinoma of the esophagus. Cancer 89:5, 946-954
CrossRef535
J. R??diger Siewert, Marcus Feith, M. Werner, Hubert J. Stein. (2000) Adenocarcinoma of the Esophagogastric Junction. Annals of Surgery 232:3, 353-361
CrossRef536
CG Manshanden, JBF Hulscher, M Hovius, P Fockens, JJB van Lanschot, H Obertop. (2000) Limited resection for carcinoma of the upper thoracic oesophagus is not a realistic option. European Journal of Surgical Oncology (EJSO) 26:6, 561-566
CrossRef537
Gerald C. O'Sullivan, Fergus Shanahan. (2000) Esophagogastric cancer-time to change the paradigm. The American Journal of Gastroenterology 95:9, 2153-2154
CrossRef538
Satdarshan P. S. Monga, Robert Wadleigh, A. Sharma, Houtan Adib, Doris Strader, Gurinder Singh, John W. Harmon, Marlene Berlin, Dulabh K. Monga, Lopa Mishra. (2000) Intratumoral Therapy of Cisplatin/Epinephrine Injectable Gel for Palliation in Patients With Obstructive Esophageal Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials 23:4, 386-392
CrossRef539
Dennis Blom, Jeffrey H. Peters. (2000) Surgery, radiotherapy, and chemotherapy in carcinoma of the esophagus. Current Opinion in Gastroenterology 16:4, 392-399
CrossRef540
J Tschmelitsch. (2000) Modern staging in gastric cancer. Surgical Oncology 9:1, 23-30
CrossRef541
H Stein. (2000) Cancer of the esophagogastric junction. Surgical Oncology 9:1, 35-41
CrossRef542
J.I. Geh, R. Glynne-Jones, Q.S.K. Kwok, U. Banerji, J.I. Livingstone, E.R. Townsend, R.A. Harrison, I.C. Mitchell. (2000) Preoperative ECF Chemotherapy in Gastro-Oesophageal Adenocarcinoma. Clinical Oncology 12:3, 182-187
CrossRef543
Andreas Imdahl, Jost Jenkner, Christian Ihling, Klaus-Dieter Rückauer, Eduard Heinrich Farthmann. (2000) Is MIB-1 proliferation index a predictor for response to neoadjuvant therapy in patients with esophageal cancer?. The American Journal of Surgery 179:6, 514-520
CrossRef544
Juan C Meneu-Diaz, Luis A Blazquez, Emilio Vicente, Javier Nuño, Yolanda Quijano, Pedro Lopez-Hervás, Manuel Devesa, Virgilio Fresneda. (2000) The role of multimodality therapy for resectable esophageal cancer. The American Journal of Surgery 179:6, 508-513
CrossRef545
Richard C. Karl, Robert Schreiber, David Boulware, Scott Baker, Domenico Coppola. (2000) Factors Affecting Morbidity, Mortality, and Survival in Patients Undergoing Ivor Lewis Esophagogastrectomy. Annals of Surgery 231:5, 635-643
CrossRef546
John M Daly, Willard A Fry, Alex G Little, David P Winchester, Rosemary F McKee, Andrew K Stewart, Amy M Fremgen. (2000) Esophageal cancer: results of an American College of Surgeons patient care evaluation study11No competing interests declared.. Journal of the American College of Surgeons 190:5, 562-572
CrossRef547
Amitabh Chak, Marcia I. Canto, Gregory S. Cooper, Gerard Isenberg, Joseph Willis, Nathan Levitan, Julie Clayman, Arlene Forastiere, Elisabeth Heath, Michael V. Sivak. (2000) Endosonographic assessment of multimodality therapy predicts survival of esophageal carcinoma patients. Cancer 88:8, 1788-1795
CrossRef548
Hubert J. Stein, Andreas Sendler, Ulrich Fink, J.R. Siewert. (2000) MULTIDISCIPLINARY APPROACH TO ESOPHAGEAL AND GASTRIC CANCER. Surgical Clinics of North America 80:2, 659-682
CrossRef549
L. P. S. Stassen, F. T. Bosman, P. D. Siersema, W. C. J. Hop, J. G. A. M. Blomjous, H. W. Tilanus, . (2000) Recurrence and survival after resection of adenocarcinoma of the gastric cardia. Diseases of the Esophagus 13:1, 32-38
CrossRef550
E.Pendleton Alexander, Timothy Lipman, John Harmon, Robert Wadleigh. (2000) Aggressive multimodality therapy for stage III esophageal cancer: a phase I/II study. The Annals of Thoracic Surgery 69:2, 363-368
CrossRef551
T. Conroy, M.C. Kaminsky, D. Peiffert, P. Wolff. (2000) Traitements non chirurgicaux des cancers de l'œsophage. La Revue de Médecine Interne 21:1, 58-73
CrossRef552
Mark J Krasna, You Sheng Mao, Joshua R Sonett, Gen Tamura, Ray Jones, Mohan Suntharalingam, Stephen J Meltzer. (1999) P53 gene protein overexpression predicts results of trimodality therapy in esophageal cancer patients. The Annals of Thoracic Surgery 68:6, 2021-2024
CrossRef553
Ernesto Laterza, Giovanni de’ Manzoni, Pietro Tedesco, Alfredo Guglielmi, Giuseppe Verlato, Claudio Cordiano. (1999) Induction Chemo-Radiotherapy for Squamous Cell Carcinoma of the Thoracic Esophagus: Long-Term Results of a Phase II Study. Annals of Surgical Oncology 6:8, 777-784
CrossRef554
P. Soontrapornchai, H. Elsaleh, D. Joseph, J.M. Hamdorf, A.K. House, B. Iacopetta. (1999) TP53 gene mutation status in pretreatment biopsies of oesophageal adenocarcinoma has no prognostic value. European Journal of Cancer 35:12, 1683-1687
CrossRef555
Manabu Muto, Atsushi Ohtsu, Shin-ichi Miyamoto, Kei Muro, Narikazu Boku, Satoshi Ishikura, Mitsuo Satake, Takashi Ogino, Hisao Tajiri, Shigeaki Yoshida. (1999) Concurrent chemoradiotherapy for esophageal carcinoma patients with malignant fistulae. Cancer 86:8, 1406-1413
CrossRef556
Ziv Gamliel, Mark J. Krasna. (1999) Combined modality therapy for esophageal cancer. Current Oncology Reports 1:2, 149-154
CrossRef557
(1999) Esophageal Cancer Preoperative Chemotherapy?Can We Justify What We Do?. The American Journal of Gastroenterology 94:9, 2562-2563
CrossRef558
Shawn Mallery, Malcolm DeCamp, Raphael Bueno, Steven J. Mentzer, David J. Sugarbaker, Scott J. Swanson, Jacques Van Dam. (1999) Pretreatment staging by endoscopic ultrasonography does not predict complete response to neoadjuvant chemoradiation in patients with esophageal carcinoma. Cancer 86:5, 764-769
CrossRef559
M KRASNA. (1999) The role of thoracoscopic staging of esophageal cancer patients*1. European Journal of Cardio-Thoracic Surgery 16, S31-S33
CrossRef560
Mark B. Orringer, Becky Marshall, Mark D. Iannettoni. (1999) Transhiatal Esophagectomy: Clinical Experience and Refinements. Annals of Surgery 230:3, 392
CrossRef561
J.R. Siewert, H.J. Stein, A. Sendler, U. Fink. (1999) Surgical resection for cancer of the cardia. Seminars in Surgical Oncology 17:2, 125-131
CrossRef562
Naiel Hafez, Saleh Ayache, Mohammed A. Hussain, Beverly D. Jones, Robert G. Wadleigh. (1999) Simultaneous Chemotherapy and Radiotherapy With Escalating Doses of Chemotherapy in Patients With Advanced Esophageal Carcinoma. American Journal of Clinical Oncology 22:4, 352-354
CrossRef563
Snehal Damle, Jonathan J. Beitler, Hilda Haynes, Margarita Camacho, Ellen Wolf, Scott Wadler. (1999) Phase I-II Study of 5-Fluorouracil, Recombinant Interferon α2a, and Cisplatin in Combination With External Beam Radiation Therapy Followed by Surgery in Patients With Locally Advanced Carcinoma of the Esophagus. American Journal of Clinical Oncology 22:4, 391-395
CrossRef564
Masao Hosokawa, Hiroki Shirato, Masanori Ohara, Kenji Kagei, Seiko Hashimoto, Shigeo Nishino, Akio Takamura, Takuro Arimoto. (1999) Intraoperative radiation therapy to the upper mediastinum and nerve-sparing three-field lymphadenectomy followed by external beam radiotherapy for patients with thoracic esophageal carcinoma. Cancer 86:1, 6-13
CrossRef565
Carlos Torres, Helen Wang, Jerold Turner, Ali Shahsafaei, Robert D Odze. (1999) Prognostic significance and effect of chemoradiotherapy on microvessel density (angiogenesis) in esophageal Barrett's esophagus-associated adenocarcinoma and squamous cell carcinoma. Human Pathology 30:7, 753-758
CrossRef566
William R. Brugge. (1999) Endoscopic Ultrasound Staging of Esophageal Cancer: Assuming Responsibility. The American Journal of Gastroenterology 94:7, 1724-1727
CrossRef567
Lawrence R. Coia, Bruce D. Minsky, Madhu J. John, Daniel G. Haller, Jerome Landry, Thomas M. Pisansky, Christopher G. Willett, John P. Hoffman, Brian A. Berkey, Jean B. Owen, Gerald E. Hanks. (1999) The evaluation and treatment of patients receiving radiation therapy for carcinoma of the esophagus. Cancer 85:12, 2499-2505
CrossRef568
Baek-Yeol Ryoo, Yoon-Koo Kang, Young-Hyuck Im, Yong-Jo Kim, Bong-Seog Kim, Tae You Kim, Sook-Hyang Jung, Jong Ho Park, Hee Jong Baek, You-Cheoul Kim, Young Mog Shim, Chang-Min Kim, Jae Ill Zo. (1999) Adjuvant (Cisplatin, Etoposide, and 5-Fluorouracil) Chemotherapy After Curative Resection of Gastric Adenocarcinomas Involving the Esophagogastric Junction. American Journal of Clinical Oncology 22:3, 253-257
CrossRef569
Toshimasa Tsujinaka, Hitoshi Shiozaki, Makoto Yamamoto, Masatoshi Inoue, Masahiko Yano, Yuichiro Doki, Morito Monden. (1999) Role of preoperative chemoradiation in the management of upper third thoracic esophageal squamous cell carcinoma. The American Journal of Surgery 177:6, 503-506
CrossRef570
Jonker, Mehran, Maroun, Crepeau. (1999) Neoadjuvant chemotherapy before surgery for resectable carcinoma of the lower esophagus. Diseases of the Esophagus 12:2, 144-148
CrossRef571
Andrew M. Lowy, Paul F. Mansfield, Steven D. Leach, Richard Pazdur, Pamela Dumas, Jaffer A. Ajani. (1999) Response to Neoadjuvant Chemotherapy Best Predicts Survival After Curative Resection of Gastric Cancer. Annals of Surgery 229:3, 303-308
CrossRef572
Gerald C. O'Sullivan, Dyan Sheehan, Andrew Clarke, Robert Stuart, Jacqui Kelly, M.David Kiely, Tom Walsh, J.Kevin Collins, Fergus Shanahan. (1999) Micrometastases in esophagogastric cancer: High detection rate in resected rib segments. Gastroenterology 116:3, 543-548
CrossRef573
David R. Jones, Leonard A. Parker, Frank C. Detterbeck, Thomas M. Egan. (1999) Inadequacy of computed tomography in assessing patients with esophageal carcinoma after induction chemoradiotherapy. Cancer 85:5, 1026-1032
CrossRef574
P. Deprez. (1999) Comparaison de l'échoendoscopie avec les nouvelles méthodes d'imagerie médicale. Acta Endoscopica 29:1, 15-23
CrossRef575
Carlos Torres, Jerrold R. Turner, Helen H. Wang, William Richards, David Sugarbaker, Ali Shahsafaei, Robert D. Odze. (1999) Pathologic prognostic factors in Barrett's-associated adenocarcinoma. Cancer 85:3, 520-528
CrossRef576
S. Vincent Rajkumar, Jan C. Buckner, Paula J. Schomberg, Henry C. Pitot, James N. Ingle, Terrence L. Cascino. (1999) Phase I Evaluation of Preirradiation Chemotherapy with Carmustine and Cisplatin and Accelerated Radiation Therapy in Patients with High-grade Gliomas. Neurosurgery 44:1, 67-73
CrossRef577
Charles J. Lightdale. (1999) Esophageal cancer. The American Journal of Gastroenterology 94:1, 20-29
CrossRef578
Kelsen, David P., Ginsberg, Robert, Pajak, Thomas F., Sheahan, Daniel G., Gunderson, Leonard, Mortimer, Joanne, Estes, Norman, Haller, Daniel G., Ajani, Jaffer, Kocha, Walter, Minsky, Bruce D., Roth, Jack A., . (1998) Chemotherapy Followed by Surgery Compared with Surgery Alone for Localized Esophageal Cancer. New England Journal of Medicine 339:27, 1979-1984
Full Text579
Rainer Fietkau, Torsten Libera. (1998) Präoperative Radiochemotherapie des Ösophaguskarzinoms: Segen oder Fluch?. Strahlentherapie und Onkologie 174:11, 598-599
CrossRef580
Steven M. Keller, Louise M. Ryan, Lawrence R. Coia, Phuong Dang, David J. Vaught, Charles Diggs, Louis M. Weiner, Al B. Benson. (1998) High dose chemoradiotherapy followed by esophagectomy for adenocarcinoma of the esophagus and gastroesophageal junction. Cancer 83:9, 1908-1916
CrossRef581
Douglas O. Faigel, Clifford Deveney, Daniel Phillips, M. Brian Fennerty. (1998) Biopsy-negative malignant esophageal stricture: diagnosis by endoscopic ultrasound. The American Journal of Gastroenterology 93:11, 2257-2260
CrossRef582
Anna Maria Gevers, Elisabeth Macken, Martin Hiele, Paul Rutgeerts. (1998) A comparison of laser therapy, plastic stents, and expandable metal stents for palliation of malignant dysphagia in patients without a fistula. Gastrointestinal Endoscopy 48:4, 383-388
CrossRef583
John S. Bolton, George M. Fuhrman, William S. Richardson. (1998) ESOPHAGEAL RESECTION FOR CANCER. Surgical Clinics of North America 78:5, 773-794
CrossRef584
Larry L. Shears, Ulysses Ribeiro, John Kane, Adriana Safatle-Ribeiro, Simon Watkins, Mitchell Posner. (1998) Apoptosis In Esophageal Cancer Following Induction Chemoradiotherapy. Journal of Surgical Research 79:1, 20-24
CrossRef585
J. Izibicki, S. Hosch, U. Pichlmeier. (1998) FOR WHOM THE BELL TOLLS. The American Journal of Gastroenterology 93:9, 1585-1586
CrossRef586
Michael Maher, Thomas F. Gorey. (1998) Editorial. Irish Journal of Medical Science 167:3, 130-131
CrossRef587
T. Lerut. (1998) Esophageal surgery at the end of the millennium. The Journal of Thoracic and Cardiovascular Surgery 116:1, 1-20
CrossRef588
Paul J Ross, Sheela Rao, David Cunningham. (1998) Chemotherapy of oesophago-gastric cancer. Pathology & Oncology Research 4:2, 87-95
CrossRef589
Andrew J. Graham, Richard J. Finley, Joanne C. Clifton, Ken G. Evans, Guy Fradet. (1998) Surgical management of adenocarcinoma of the cardia. The American Journal of Surgery 175:5, 418-421
CrossRef590
M Stahl. (1998) Pre-operative sequential chemo- and radiochemotherapy in locally advanced carcinomas of the lower oesophagus and gastro-oesophageal junction. European Journal of Cancer 34:5, 668-673
CrossRef591
Wolfgang Fischbach, Volker Groß, Jürgen Schölmerich, Christian Ell, Peter Layer, Wolfgang E. Fleig, Hubert Zirngibl. (1998) Update gastroenterologie 1997 — Teil I. Medizinische Klinik 93:2, 70-80
CrossRef592
Steven J Hoff, John L Sawyers, Charles D Blanke, Hak Choy, James R Stewart. (1998) Prognosis of Adenocarcinoma Arising in Barrett’s Esophagus. The Annals of Thoracic Surgery 65:1, 176-181
CrossRef593
T.S. Maughan, T.D.L. Crosby. (1998) Combined modality treatment in oesophageal carcinoma. Clinical Oncology 10:6, 354-355
CrossRef594
S.J. Darnton, D.R. Ferry, M.H. Cullen, A.G. Casson. (1998) A phase II trial of preoperative mitomycin, cisplatin and 5-fluorouracil in adenocarcinoma of the oesophagus. Clinical Oncology 10:6, 372-376
CrossRef595
Ashley R. Poynton, Thomas N. Walsh, Alan Kelly, Michael Harney, Robert Stuart, Peter A. Daly, Thomas P.J. Hennessy. (1997) Small cell carcinoma of the oesophagus. European Journal of Surgical Oncology (EJSO) 23:6, 509-512
CrossRef596
A Mahadevan. (1997) The role of radiotherapy in the surgical management of gastrointestinal cancer. Surgical Oncology 6:4, 201-208
CrossRef597
Cameron D. Wright, John C. Wain, Thomas J. Lynch, Noah C. Choi, Michael L. Grossbard, Robert W. Carey, Ashby C. Moncure, Hermes C. Grillo, Douglas J. Mathisen. (1997) Induction therapy for esophageal cancer with paclitaxel and hyperfractionated radiotherapy: A phase I and II study. The Journal of Thoracic and Cardiovascular Surgery 114:5, 811-816
CrossRef598
E. D. Mulligan, M. G. O’Riordain, M. Duggan, J. Crowe, J. Lennon, P. MacMathuna, J. M. Fitzpatrick, T. F. Gorey. (1997) The role of surgery and laser ablation in oesophageal carcinoma. Irish Journal of Medical Science 166:4, 203-205
CrossRef599
Charles R. Thomas. (1997) BIOLOGY OF ESOPHAGEAL CANCER AND THE ROLE OF COMBINED MODALITY THERAPY. Surgical Clinics of North America 77:5, 1139-1167
CrossRef600
David J. Adelstein, Thomas W. Rice, Mark Becker, Marjorie A. Larto, Thomas J. Kirby, Anuradha Koka, Melvin Tefft, Gregory Zuccaro. (1997) Use of concurrent chemotherapy, accelerated fractionation radiation, and surgery for patients with esophageal carcinoma. Cancer 80:6, 1011-1020
CrossRef601
G. Mathew, G. G. Jamieson. (1997) Neoadjuvant therapy for oesophageal cancer. British Journal of Surgery 84:9, 1185-1187
CrossRef602
David Kelsen. (1997) MULTIMODALITY THERAPY FOR ADENOCARCINOMA OF THE ESOPHAGUS. Gastroenterology Clinics of North America 26:3, 635-645
CrossRef603
Tom R. DeMeester. (1997) SURGICAL TREATMENT OF DYSPLASIA AND ADENOCARCINOMA. Gastroenterology Clinics of North America 26:3, 669-684
CrossRef604
Martin Stuschke, Rolf Sauer. (1997) Multimodale Therapie oder alleinige chirurgie beim adenokarzinom des Ösophagus?. Strahlentherapie und Onkologie 173:9, 486-487
CrossRef605
Simon Law, Manson Fok, Selwyn Chow, Kent-Man Chu, John Wong. (1997) Preoperative chemotherapy versus surgical therapy alone for squamous cell carcinoma of the esophagus: A prospective randomized trial. The Journal of Thoracic and Cardiovascular Surgery 114:2, 210-217
CrossRef606
Daniel J. Blezek, Richard A. Robb. (1997) Evaluating virtual endoscopy for clinical use. Journal of Digital Imaging 10:S1, 51-55
CrossRef607
JANE M BLAZEBY, DEREK ALDERSON. (1997) Review: Chemotherapy, irradiation and their roles in the management of oesophageal cancer. Journal of Gastroenterology and Hepatology 12:8, 612-619
CrossRef608
Bosset, Jean-François, Gignoux, Marc, Triboulet, Jean-Pierre, Tiret, Emmanuel, Mantion, Georges, Elias, Dominique, Lozach, Patrick, Ollier, Jean-Claude, Pavy, Jean-Jacques, Mercier, Mariette, Sahmoud, Tarek, Ségol, PhilippeFlamant, Jean-BernardArnaud, Jean-PierrePlachot, Jean-PierreMandard, Anne-MarieChaillard, Gaelle. (1997) Chemoradiotherapy Followed by Surgery Compared with Surgery Alone in Squamous-Cell Cancer of the Esophagus. New England Journal of Medicine 337:3, 161-167
Full Text609
Luigi Bonavina, Raffaello Incarbone, Ezio Lattuada, Andrea Segalin, Bruno Cesana, Alberto Peracchia. (1997) Preoperative laparoscopy in management of patients with carcinoma of the esophagus and of the esophagogastric junction. Journal of Surgical Oncology 65:3, 171-174
CrossRef610
David R Jones, Frank C Detterbeck, Thomas M Egan, Leonard A Parker, Stephen A Bernard, Joel E Tepper. (1997) Induction Chemoradiotherapy Followed by Esophagectomy in Patients With Carcinoma of the Esophagus. The Annals of Thoracic Surgery 64:1, 185-192
CrossRef611
J. R. Siewert, H. J. Stein. (1997) Barrett's cancer: Indications, extent, and results of surgical resection. Seminars in Surgical Oncology 13:4, 245-252
CrossRef612
Tom R. DeMeester. (1997) Esophageal carcinoma: Current controversies. Seminars in Surgical Oncology 13:4, 217-233
CrossRef613
Simon Y. Law, John Wong. (1997) Esophageal cancer surgery: The value of controlled clinical trials. Seminars in Surgical Oncology 13:4, 281-287
CrossRef614
B. Mark Smithers, Peter Devitt, Glyn G. Jamieson, Justin Bessell, David Gotley, P. Grantley Gill, Mervyn Neely, David J. Joseph, Eric K. Yeoh, Bryan Burmeister, James W. Denham. (1997) A combined modality approach to the management of oesophageal cancer. European Journal of Surgical Oncology (EJSO) 23:3, 219-223
CrossRef615
Everett E Vokes. (1997) Combined modality therapy of solid tumours. The Lancet 349, S4-S6
CrossRef616
Cyrus R. Kapadia. (1997) Oxides, Onions, and Other Matters Gastrointestinal-1996-A Perspective. Journal of Clinical Gastroenterology 24:3, 133-139
CrossRef617
Frank Hartmann, Michael Pfreundschuh. (1997) Onkologie ’96. Medizinische Klinik 92:2, 83-100
CrossRef618
(1997) Multimodal Therapy for Esophageal Adenocarcinoma. New England Journal of Medicine 336:5, 374-376
Full Text619
Wilke, Hansjochen, , Fink, Ulrich, . (1996) Multimodal Therapy for Adenocarcinoma of the Esophagus and Esophagogastric Junction. New England Journal of Medicine 335:7, 509-510
Full Text
- Letters
